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Abstract
Effects of a low protein (LP) diet during gestation on the metabolism of rat offspring have
been well characterized and leads to glucose intolerance in adulthood. It is unknown how LP
impacts endocrine pancreas development in the mouse, or whether this affects future β-cell
plasticity. Streptozotocin (STZ) – induced β-cell injury has been demonstrated to be followed by
β-cell regeneration in young animals, but the mechanism(s) of regeneration are not clear. Our
objective was to characterize a mouse model of maternal LP, in addition to identifying factors
that contribute to the long term development of glucose intolerance and the mechanism of βcell regeneration.
We hypothesized that protein restriction during gestation in mice will alter development,
leading to long term glucose impairments and a failure to regenerate β-cell mass after STZ.
Pregnant Balb/c mice were placed on a control (C; 20% protein) or an isocaloric LP (8%
protein) diet throughout gestation and C thereafter. Offspring were injected with multiple low
doses of STZ or vehicle at postnatal day 1 for each dietary treatment. The offspring were
examined to assess β-cell mass, glucose homeostasis and potential sources of regenerated βcells. Additionally, differential gene expression was analyzed by cDNA microarray to identify
candidate genes involved in β-cell regeneration.
LP-fed offspring had a reduced birth weight, and females developed glucose intolerance at
d130, confirming previous studies in rats. LP offspring had a reduced capacity for β-cell
regeneration following STZ compared to C-fed offspring. LP+STZ mice were observed to have an
increased presence of putative precursor β-cells within islets, assessed by the frequency of cells
containing the transcription factor Pdx-1, but not insulin. This suggests that such cells may fail to
differentiate and contribute to new β-cell formation following exposure to LP. Additionally,
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female LP+STZ mice had a reduced presence of the trophic islet peptide, regenerating isletderived 1 (Reg1), when compared to the C+STZ animals.
In conclusion, these studies have developed a mouse model of nutrition-induced fetal
programming of metabolism, have shown that prior LP exposure compromised future β-cell
plasticity, and have identified key genes relevant to β-cell regeneration whose expression is
altered in LP-treated animals.

Keywords
low protein diet, development, pancreatic β-cell, streptozotocin induced regeneration, glucagonlike peptide-1, regenerating islet-derived 1
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CHAPTER 1:
General Introduction

1

1.1.Diabetes
Diabetes mellitus affects people of all ages and ethnic backgrounds, with serious
health risks to the individual and a tremendous cost to the healthcare system. Diabetes
is an epidemic with more than 285 million people worldwide affected by this disease (1).
More specifically, in Canada over 9 million people have pre-diabetes or diabetes (1). The
personal cost of diabetes is a reduced quality of life and the increased risk of
complications such as blindness, kidney disease, and heart disease. The cost of diabetes
and its complications to the Canadian Healthcare system is an estimated $13.2 billion a
year (1). Therefore it is imperative that appropriate treatments are found to improve the
quality and quantity of life of diabetic individuals and to also reduce the cost to the
health care system.
In general, diabetes mellitus is a disruption in glucose regulation. There are two
main types of diabetes, with 10% affected by type 1 diabetes and 90% affected by type 2
(2; 3). In individuals with type 1 diabetes, insulin deficiency is the result of substantial
loss of pancreatic insulin – producing β-cells due to autoimmune destruction (4).
Consequently, individuals are placed on insulin therapy to restore glucose homeostasis.
Individuals with type 2 diabetes are characterized by having several metabolic defects
including peripheral insulin resistance and β-cell deficiency in insulin secretion (5; 6).
Obesity puts additional stress on the β-cells due to increased tissue requirements for
insulin. High insulin demands and continuous imbalances in glucose homeostasis cause
gluco- and lipo-toxicity, which contribute to a progressive decrease in β-cell mass (2; 712) and increasing the likelihood of disease complications. This demonstrates the critical
2

importance of maintaining β-cell mass to compensate for increased insulin demands due
to obesity and/or insulin resistance. Understanding the dynamics of β-cell growth,
survival and dysfunction are crucial to manipulate the development or regeneration of
β-cells for replacement therapy in diabetes.
1.1.2. Current Therapies
Individuals with type 1 diabetes require insulin daily to help maintain blood glucose
values. Insulin supplementation is oral or by injection using either a syringe or an insulinadministering pump. Whole pancreas transplantation has been accepted as an
alternative therapy for individuals with type 1 diabetes who are undergoing
simultaneous kidney transplant (13). Although there is still a significant cost and
morbidity risk associated with this surgery, there is an 84-88% graft survival rate after
one year (13; 14). Islet transplantation is a much less invasive procedure and may
provide the best option for excellent glycemic control (13). Early attempts to transplant
islets into type 1 individuals resulted in only 8% remaining insulin independent after 1
year (15). With advancements in immunosuppressive agents, the Edmonton Protocol
was developed in the late 1990’s with the aim to reduce toxicity and avoid the harmful
effects of some immunosuppressants on the β-cells (16). The Edmonton Protocol
consisted of a glucocorticoid – free immunosuppressive protocol that included sirolimus,
low dose tacrolimus and a monoclonal antibody against the interleukin-2 receptor
(daclizumab) (16). Insulin independence was achieved in ~30% and 10% of patients after
2 and 5 years, respectively, demonstrating a marked improvement in the effectiveness
of islet transplantation (17). However, there still remains a need to refine the islet
3

isolation technique and the immunosuppressive regime to better maximize graft survival
and function while limiting toxicity. Additionally, 2-3 cadaveric donors are required per
islet transplant with some individuals requiring multiple transplants over time.
Lifestyle changes are recommended for individuals with type 2 diabetes, including
diet and exercise, as well as weight loss for obese individuals. Additionally oral
medications may be given, such as Metformin to reduce hepatic glucose production
(18), Thiazolidinediones to improve peripheral tissue insulin sensitivity, or Sulfonylureas
to stimulate insulin secretion (19). Glucagon-like peptide-1 (GLP-1) receptor agonists or
inhibitors of the GLP-1 inactivating enzyme dipeptidyl peptidase-4 are used to enhance
glucose-stimulated insulin secretion (GSIS) (19). Insulin therapy may be required in
addition to one of the above agents with progression of the disease.
1.2. Pancreas Anatomy and Development
The pancreas is situated in the abdomen, attached at the initial curvature of the
duodenum and also the stomach and extends to where the tail of the pancreas attaches
to the spleen (Figure 1.1). There are two main compartments of the pancreas serving
endocrine and exocrine functions. The endocrine pancreas plays a role in glucose
metabolism and accounts for 1-2% of the total pancreas. The remaining portion is the
exocrine pancreas, which is made up of acinar cells and ducts that produce and deliver
digestive enzymes and bicarbonate to the small intestine. The Islets of Langerhans
compose the endocrine pancreas and are made up primarily by β-cells (~80%) in the
core and the remaining cells forming the mantle of the islet; α (~14%), δ (~6%) (20) and
few epsilon and PP cells. In contrast, human islets do not display the core/mantle
4

Figure 1.1. Anatomical location of the pancreas.
The head of the pancreas is attached at the initial curve of the duodenum and stretches
across the abdomen where the tail attaches to the spleen. Inset, shows the organization
of the five different cell types of the islet of Langerhans; the β (green), α (red), δ (blue),
PP (yellow) and epsilon (purple) cells. Adapted from McKinley, M. and O’Loughlin V.D.
Human Anatomy, 2nd Edition, 2003 (21).
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architecture described in rodents, as all cell types are dispersed throughout the islet
(22). Human islet composition varies widely, but contains approximately 54% β-cells,
34% α-cells, and 10% δ-cells (22). Insulin secreting β-cells act to decrease blood glucose
concentrations by stimulating glucose uptake in the liver, muscle and adipose tissues.
Glucagon, which is secreted by the α-cells, is the counter regulatory hormone that acts
to increase blood glucose levels in times of fasting. Glucagon stimulates liver and muscle
cells to convert stored glycogen into glucose. Together, insulin and glucagon are the
major pancreatic endocrine hormones that function in maintaining glucose homeostasis.
The δ-cells produce somatostatin which acts to inhibit insulin and glucagon secretion
and also controls gastric emptying. Epsilon cells produce ghrelin which stimulates
appetite. The function of pancreatic polypeptide released by PP cells is unknown.
At embryonic day (e) 8.5 in the mouse, the endodermal foregut expresses the
transcription factor pancreatic duodenal homoebox-1 (PDX-1) defining the region for the
pancreas, stomach, duodenum and common bile duct (23; 24). Pancreatic development
begins with the appearance of the dorsal and ventral pancreatic buds at about e8.5 to
e9.5 from the mid-gut endoderm (25). Each bud develops into highly branched
structures, with endocrine cells visible in the early stages of bud development, while the
acini and ducts are distinguishable by e14.5 (26). Endocrine cells develop from the
pancreatic ductal epithelial cells and initially exist as individual cells or small clusters.
Development of endocrine cells from the pancreatic ductal epithelium is initiated by
expression of the basic helix-loop-helix transcription factor neurogenin 3 (NGN3) (27).
Gradual expression of the transcription factors NGN3, ISL-1, NKX2.2, ΒETA2 and PAX6 in
6

immature endocrine cells is accompanied by a decrease in PDX-1 expression (28).
Mature β-cell differentiation requires the return of PDX-1 expression, as well as
expression of NKX6.1 and PAX4, with a loss of expression of NGN3 and ΒETA2 (26; 28;
29). A few days before birth, mature islets form and there is a rapid 2-fold increase in βcell numbers due to β-cell replication and maturation of β-cell precursors (30-32). This
rapid neogenesis of islets continues throughout neonatal life, but progressively declines
at weaning (32). By adulthood the mitotic rate of β-cells is very low, about 0.5% of βcells (33). A remodelling of the pancreas occurs in the neonatal rat, which is marked by a
decrease in insulin-like growth factor (IGF) -II expression, which acts as a survival factor
for β-cells (34). This corresponds to a transient wave of β-cell apoptosis, peaking at
postnatal day 14, however β-cell mass is maintained during the first few weeks in the
neonatal rat, indicating the generation of new islets to replace β-cell loss (34-36). This
transition period in the neonatal rodent may suggest a change in β-cell population, from
cells with slow glucose responsiveness for insulin release, to cells with acute glucosestimulated insulin release that are better adapted to metabolic control in adult life (28).
A similar wave of β-cell apoptosis has been described in the human fetal pancreas in the
third trimester (34). Islet development complete and beta cell responsiveness acquired
by birth in humans, while in rodents islet development is completed postnatally during
lactation(34; 36).
1.3. Pancreatic duodenal homeobox-1 in Development
The most important transcription factor in pancreas development is PDX-1. It is the
first molecular marker that temporally correlates with pancreatic commitment for
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epithelial cells located in the primordial gut (23; 30; 37). PDX-1 is initially detected at
e8.5 in the region of the gut epithelium that later develops into the pancreas, stomach,
duodenum and common bile duct (23; 24). A high expression of PDX-1 is maintained in
most epithelial cells of the pancreatic bud until e10.5 (37). Between e11.5 and e13.5
PDX-1 is essential for the subsequent differentiation of endocrine and exocrine cells
(38). By late gestation, PDX-1 is selectively maintained at high levels in β-cells, with low
levels of expression in acinar cells (23; 39). In the adult, PDX-1 expression is largely
limited to the β-cells and to a few δ-cells (37). In the mature β-cell, PDX-1 functions as an
essential mediator of the glucose – induced effect on insulin gene transcription (40; 41).
In addition to being the major regulator of the insulin gene, PDX-1 also regulates the
expression of glucose transporter (GLUT) 2 (42), glucokinase (GCK) (43), and islet
amyloid polypeptide (44) and represses glucagon expression (25).
1.4. Islet Vasculature
The dense capillary network that forms in pancreatic islets allows for nutrient and
growth factor delivery, as well as accurate glucose sensing and dispersion of islet
hormones into systemic circulation (45). Blood vessels also play an important role in
pancreas development and differentiation. At e8.5-9.5 pancreatic growth is initiated
where the endodermal epithelium contacts the endothelium of the dorsal aorta (46; 47).
These sites of pancreatic growth are marked by expression of PDX-1 (48; 49) after which
endocrine cell differentiation is detectable by the expression of insulin in the dorsal
pancreatic endothelium adjacent to the portal vein (46). When isolated endoderm was
cultured with dorsal aortae, PDX-1 and insulin expression were induced, suggesting a
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strong signalling relationship between them during development (46; 47). It was further
shown that development of islet vasculature and establishment of islet blood flow
occurs concomitantly with islet formation by the observation that coalescing endocrine
cells were adjacent to blood perfused lectin+ capillaries (50). The signalling mechanism
between the vasculature and islet cells was shown to involve vascular endothelial
growth factor-A (VEGF) (50). β-cell specific loss of VEGF expression caused an islet
deficiency in vessel number, as well as reduced size/branching (50). Abnormal islet
vasculature resulted in decreased insulin secretion and glucose intolerance (50). While
β-cells signal to endothelial cells through VEGF, the islet vasculature responds with the
production of hepatocyte growth factor (HGF) which acts as a potent stimulator of β-cell
growth (45; 51; 52). When HGF was overexpressed in the islet, β-cell proliferation
significantly increased leading to an increase in β-cell mass and insulin production (52).
1.5. β-Cell Function
The glucose transporter, GLUT2, is responsible for the insulin-dependent uptake of
glucose into the β-cell (53; 54). Following transport into the cell, glucose is
phosphorylated by GCK in the rate limiting step for glucose metabolism (55; 56). The
resulting change in the ATP : ADP ratio leads to closure of the ATP-sensitive K+ channels
and depolarization of the cell membrane (56; 57). Depolarization triggers opening of the
voltage gated Ca2+ channels and rapid influx of Ca2+ (56; 57). The readily releasable pool
of insulin secretory granules are located close to the plasma membrane in the vicinity of
the rise in intracellular Ca2+, which stimulates exocytosis of insulin (56; 57). This first
phase response occurs within 5-10 min of stimulation and accounts for about 10% of
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secretory granules (58; 59). The second phase of insulin secretion is independent of the
KATP channel and mainly involves the recruitment of granules from the intracellular
storage pool (58; 60). Second messengers such as protein kinase C, cyclic AMP, inositol
triphosphate, and diacylglycerol may all contribute to further increasing intracellular
Ca2+ levels, however the exact signalling mechanism and transport of the secretory
vesicles to the membrane remains unknown (57; 58; 61). Insulin released into circulation
can then act on peripheral tissues to stimulate glucose uptake.
1.6. β-Cell Plasticity
An adequate source of proper functioning β-cells is necessary to improve the health
of diabetic individuals. β-cell mass is a dynamic balance between β-cell growth and β-cell
loss. β-cell growth occurs through replication of pre-existing β-cells, neogenesis of βcells via stem/precursor cells and also through β-cell hypertrophy, while β-cell death
occurs by apoptosis or necrosis (62-64). In rodents, there is an enhanced rate of
replication and neogenesis that is interrupted by a brief episode of increased apoptosis
during the neonatal period (34; 36). These changes early in life lead to an increase in βcell mass soon after weaning (36). However, the rates of β-cell growth and death are
dramatically decreased as the young rodent matures into adulthood. In adult rodents
there is very slow turnover of β-cells, with about 0.5% of β-cells self-replicating (33) and
a corresponding rate of apoptosis of 0.5% of β-cells (65; 66). This would suggest a
limited ability for β-cell growth in adult rodents under normal physiologic conditions.
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1.6.1. Expansion of β-Cell Mass
Despite low replication rates, pregnancy and obesity are two physiologic situations
in which β-cell expansion in the adult is possible. During pregnancy, prolactin and
placental lactogen drive β-cell hyperplasia and hypertrophy (67). This allows for
compensation of the increasing metabolic demands of the developing fetus (35). Insulin
resistance is a main feature of obesity, but two-thirds of obese individuals do not
develop diabetes (68). A study showed that glucose homeostasis was maintained
through endocrine tissue hyperplasia in non-diabetic obese subjects (2; 69). In animal
models, there was a significant increase in β-cell mass in the obese non-diabetic Zucker
fa/fa rat compared to the lean Fa rat due to hyperplasia, hypertrophy or by neogenesis
(70). Therefore plasticity of β-cell mass can exist in the adult under particular physiologic
conditions. However, in the pathological setting of diabetes, the plasticity of β-cells from
type 2 diabetic individuals was reduced when examined in vitro compared to nondiabetic β-cells (71).
1.7. Alternative Sources of β-Cells
Given the demand for β-cell replacement therapy in diabetes and the current
limitations to pancreas and islet transplantation, alternative approaches to generate βcells are being pursued. Three areas of focus include differentiation of stem cells,
expansion of primary β-cells ex vivo and transdifferentiation. The embryonic stem (ES)
cells are pluripotent cells capable of differentiation into β-like cells. Several groups have
demonstrated the ability to produce β-cells from mouse ES cells or human ES cell lines
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(72-76). These studies provided evidence that the ES-derived cells expressed key
markers of β-cells such as PDX-1, insulin, GLUT2, GCK, NKX2.2, NKX6.1; they released
insulin in response to glucose and improved glycemia following transplants into diabetic
mice (72-76). As techniques and culture conditions improve, ES-derived cells more
closely resemble β-cells phenotypically, based on electron microscopy, and expressing
genes characteristic of mature β-cells (75; 76). Additionally, following transplant into
immune compromised mice, measurements of serum C-peptide levels, an indication of
insulin production, were similar to that of 3,000-5,000 transplanted islets (75). While
advancements are being made, ES-derived β-cells must express the full complement of
mature β-cell markers and be capable of tightly regulating blood glucose levels to be
useful clinically.
Isolation of β-cells and their subsequent expansion and transplantation back into
the individual is a promising approach. Isolated islets placed into culture will
dedifferentiate into a mesenchymal-like phenotype, losing expression of islet hormones
and key β-cell transcription factors (77; 78). These more primitive cells can be expanded
and then directed to redifferentiate back to a β-cell phenotype, however, like efforts to
differentiate stem cells, these newly formed β-cells have very low levels of insulin mRNA
(77-79).
There are many political and ethical issues associated with ES cell use and limited
success with the expansion of β-cells ex vivo, have forced researchers to look at other
cell types as possible sources for new β-cells. The process of converting one cell type
into another cell type is called transdifferentiation. A study in mice showed that liver
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cells transfected in vivo with an adenovirus expressing pdx-1 led to the expression of βcell markers and considerable amounts of serum insulin, as well as the reversal of
chemically induced diabetes (80). Acinar cells can be converted into β-cells through
adenoviral transfection of three key transcription factors: PDX-1, NGN3 and MAFA (81).
Recently α-cells were also converted into β-cells through the ectopic expression of Pax4
(82), while another group observed the spontaneous conversion of α-cells into β-cells
following near-total β-cell ablation using a lineage tracing model (83).
1.8. Mechanisms of β-Cell Regeneration
Stimulation of endogenous tissue regeneration is another avenue that is being
examined for β-cell replacement therapy. The capacity to repair tissue following an
insult has been demonstrated in many tissues, including the skin (84), liver (85) and
heart (86). This mechanistic tissue regeneration has also been demonstrated in many
animal models of pancreas injury such as partial duct ligation and partial
pancreatectomy or by β-cell specific injury with alloxan and streptozotocin. These
studies have attempted to identify the source of new β-cells following regeneration as a
means to generate an increased supply of β-cells. There are three main sources of new
β-cells: replication, islet ductal neogenesis and stem/precursor cell differentiation.
1.8.1. β-Cell Replication
The first source to consider for increasing β-cell numbers is through cell replication.
The cell cycle involves the initiation and completion of the DNA replication (S) phase, cell
division or mitosis and a number of gaps (G) between these phases (87). Previous
13

literature has made it clear that the cell cycle checkpoint at the G1/S phase transition
(Figure 1.2.) is central to the control of β-cell proliferation (88). Crossing this checkpoint
and successful completion of the S phase requires that genes important for cell cycle
progression be upregulated, while suppressors of cell cycle progression are repressed.
This is accomplished via a family of transcriptional activators and repressors called the
E2F proteins (88). The retinoblastoma protein (pRb) is regarded as the molecular brake
on cell cycle progression, resulting in G1/S arrest (88). pRb binds preferentially to
E2F1, -2, and -3 and serves to repress their transcriptional activity (88-91). As well, pRb
enforces cell cycle arrest by recruiting histone deacetylases to the promoters of cell
cycle progression genes, restricting chromatin remodeling and therefore repressing cell
cycle progression (92; 93).
Targeted phosphorylation of pRb by cyclin dependent kinase (CDK) -2, -4, -6 or PI3K
serves to inactivate the protein (88; 94; 95). The actions of CDK4 and -6 occur through
their association with cyclin D1 to phosphorylate and inactivate pRb (96). Adenoviral
overexpression of CDK4 and cyclin D1 in rodent and human islets resulted in marked
increased pRb phosphorylation and increased β-cell replication (97). Furthermore, CDK4
knockout mice develop diabetes due to a reduction in β-cells (98). Phosphorylation of
pRb interferes with its binding to E2F proteins, relieving inhibition of E2F responsive cell
cycle genes (88; 99; 100), allowing for the progression of the cell cycle. The levels of
control of activation and inhibition of cell cycle progression are quite extensive as
suggested by Figure 1.2 and are described in greater detail in the review by Cozar-
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Figure 1.2. The cell cycle check point at the G1/S phase transition.
A schematic representing the proteins involved in regulation of the G1/S phase
transition of the cell cycle. Cozar-Costellano et al. Endocrine Reviews, 27(4): 356-370,
2006 (88).
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Costellano (88). Understanding the mechanisms of control of the β-cell cycle are
important for targeted stimulation of β-cell replication in order to increase β-cell mass.
1.8.2. Ductal Islet Neogenesis
During embryonic development, the formation of new islets, or islet neogenesis, is
believed to originate from ductal epithelial cells. The growing epithelium forms
proliferating ductules that branch and ultimately differentiate giving rise to mature
ducts, acinar cells and islets (101). A recapitulation of this process has been observed
during regeneration following 90% partial pancreatectomy (Px) in the rat (101).
Increased proliferation of ductal epithelium is followed by expression of PDX-1 during
the differentiation stage, leading to the formation of new islets and acinar cells (101;
102). In less rigorous models of regeneration, evidence of islet neogenesis was observed
by immunohistochemical analysis showing islet hormone positive cells within ducts or as
small clusters budding from ducts (103-105). Further evidence for the ductal origin of
neogenic islets has been shown recently through lineage tracing of the ductal marker
carbonic anhydrase II (CA II) in the mouse Px model (106).
1.8.3. Stem/Precursor Cell Differentiation
Finally, new β-cells may also arise from the differentiation of stem or precursor cells
within the postnatal pancreas, or from an extra-pancreatic source such as the liver. A
colony forming assay using adult mouse pancreatic cells identified multipotent precursor
cells capable of producing pancreatic endocrine cells in vitro (107). In addition to mature
duct cells, another study suggests that the ductal structures contain NGN3 expressing
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endocrine precursor cells within the ductal lining and are responsible for giving rise to
new β-cells (108). Other studies have provided evidence of an early endocrine precursor
cell marked by PDX-1 expression in the absence of insulin expression (109; 110). Cohormone expression may represent differentiation of precursor cells. Expression of
somatostatin and insulin or glucagon and insulin has been observed by
immunohistochemistry during regeneration (111; 112). In contrast, strong evidence
using lineage cell tracking has shown that adult β-cells arise from replication rather than
stem cell differentiation (113), however, this does not exclude the contribution of stem
cells to β-cell formation during the neonatal period and during regeneration (79).
Hepatic oval stem cells have also been studied as a potential non-pancreatic source for
the generation of new β-cells (114), but in addition to all of these cellular sources, it
remains to be determined whether they can be a clinically useful supply of new β-cells.
1.9. Models of β-cell Regeneration
Several different experimental models have been developed to study β-cell
regeneration. These models range from pancreas injury to β-cell specific insults and
describe observations of β-cell replication, ductal islet neogenesis or stem/precursor cell
differentiation during regeneration.
1.9.1. Partial Duct Ligation
The partial pancreatic duct obstruction model was developed by Rosenberg and
colleagues by wrapping a narrow piece of cellophane tape around the head of the
pancreas of the adult Syrian golden hamster (115). This led to the formation of new
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islets through migration of cells out from the epithelium of small intralobular ductules
reiterating normal fetal ontogeny (115; 116). There was a significant increase in ductal
cell proliferation 2 weeks following surgery and at 8 weeks an increase in islet cell
proliferation culminating in a 2.5 fold increase in islet mass (115; 116). This phenomenon
of islet neogenesis from duct cells was also observed in the adult rat following
pancreatic partial duct ligation (PDL) (117). These findings were supported by lineage
tracing of the ductal marker CA II in the mouse (106). The results of this study showed
that β-cells were marked by the tracer, β-galactosidase, following PDL suggesting they
were derived from CA II expressing duct cells (106). However, a study by Solar et al.
found contrasting results by cell lineage tracking of the duct cell marker HNF1β (118). No
evidence that duct cells gave rise to new endocrine cells following PDL was observed
(118). Previous work from this group suggests that NGN3+ endocrine precursor cells are
responsible for giving rise to new β-cells following PDL (108).
1.9.2. Partial Pancreatectomy
Partial pancreatectomy (Px) is another method that has been used to study β-cell
regeneration and is typically performed in adult animals. Following 90% resection of the
rat pancreas there is substantial regeneration of the exocrine and endocrine pancreas
(119; 120). In this model, two pathways of regeneration were observed: 1) replication of
pre-existing, differentiated exocrine and endocrine cells, and 2) the proliferation and
differentiation of ductal epithelium to form new pancreatic lobules (101; 119). More
recently, lineage tracing was performed using RIP-CreER;Z/AP adult mice to label the βcells and look at regeneration after 70% Px (113). They determined that β-cell replication
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was the major source of new β-cells and not stem cell differentiation as previously
suggested (113).
1.9.3. Alloxan
In 1943, it was reported that alloxan could induce diabetes in the rat due to specific
necrosis of the β-cells (121; 122). Alloxan is a very unstable compound that is
structurally similar to glucose (Figure 1.3) allowing for its uptake into the β-cell through
the GLUT2 transporter (123-125). Once in the β-cell, alloxan selectively inhibits GSIS
through specific inhibition of the glucose sensor, GCK, and causes necrosis of β-cells
through its ability to induce reactive oxygen species (ROS) formation (126). Regeneration
of mouse β-cells was observed following selective perfusion of alloxan after clamping
the superior mesenteric artery (127). β-cell destruction occurred in perfused regions of
the pancreas, while non-perfused regions were spared (127). Histological evidence
suggested islet neogenesis from differentiation of duct cells in the alloxan perfused
region and a significantly increased islet area due to β-cell replication in the nonperfused region (127). In rats, a single intraperitoneal (i.p.) injection of alloxan led to
increased serum glucose levels followed by β-cell regeneration 12 days later (128). βcell replication rates were increased and neogenesis was observed as
transdifferentiation of acinar and duct cells to β-cells (128).
1.10. Streptozotocin
Streptozotocin (STZ) is an antimicrobial agent and has also been used as a
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Figure 1.3. Comparison of the molecular structures of streptozotocin, glucose and
alloxan.
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chemotherapeutic alkylating agent (129-131). In 1963, Rakieten et al. (132) reported
that STZ was diabetogenic. STZ has become the main choice for the chemical induction
of diabetes in animal models and for the study of β-cell regeneration (126). STZ is a
glucose analogue known as 2-dexoymethyl-nitrosurea-glycopyranose (Figure 1.3) (133).
Similar to alloxan, GLUT2 on the β-cell plasma membrane selectively recognizes STZ due
to its similar structure to glucose and transports it into the cell (134; 135). The toxic
effects of STZ mainly arise from the transfer of the methyl group to a DNA molecule
leading to DNA fragmentation (136). Overstimulation of poly(ADP-ribose) polymerase
occurs in an attempt to repair DNA, which leads to depletion of cellular NAD+ and ATP
stores (136-138). Accordingly, diabetes develops due to necrosis of β-cells (126) leading
to hypoinsulinemia and hyperglycemia (139-143).
1.10.1. Single Dose STZ Model
STZ is conventionally administered as a single injection (132). It has a serum half life
of 15 minutes (144). β-cell necrosis is apparent within 24 hours by ultrastructural
examination (145). Blood glucose values peak 1-2 days after STZ and remain elevated
depending on the dose given (146). In neonatal rats, there are a few different protocols
used. First, the n0-STZ model is generated by injecting 100 mg/kg STZ i.p. or
intravenously at birth. Rats exhibit insulin deficient acute diabetes 3-5 days after birth
(139; 147). At 3-4 weeks of age, body weight and basal plasma glucose values cannot be
distinguished from control values (139; 147). However, by 8 weeks of age, rats show a
mild basal hyperglycemia, an abnormal response to an i.p. glucose tolerance test (IPGTT)
and 50% decrease in pancreatic insulin stores (147). Other neonatal models involve the
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injection of STZ on day 2, 4, or 5 (112; 139; 147; 148) and the severity of diabetes and
the degree of recovery that follows depends on the timing of STZ, as rats injected on day
5 lacked re-accumulation of insulin in the pancreas 2 weeks following STZ (133). In the
n0-STZ model, the recovery of plasma glucose to normal values 1 week after birth was
related to recovery of pancreatic insulin content and β-cell mass (139; 147). From day 4
onward, signs of regeneration became apparent in the numerous insulin positive cells
found throughout the acinar parenchyma and within the ductal epithelium (104). The
appearance of islets budding from ducts was a common feature (149). Examining the
mitotic rate suggested that most β-cells were formed by mitosis of undifferentiated cells
(149). However, the long term impairment of the plasma glucose homeostasis (147) and
persistence of a reduced β-cell mass in 4 month old animals (133; 147) are proof that the
regeneration process was incomplete. It has also been suggested that there may be
strain differences in the regeneration potential in rats (133).
1.10.2. Multiple Low Dose STZ Model
The multiple low dose model, first described by Like and Rossini (140), used five
daily injections of a sub-diabetogenic dose of STZ in mice, as compared to one large
diabetes-inducing dose of STZ as used in the rat model. CD-1 mice were injected with 40
mg/kg STZ daily for 5 days (140). Plasma glucose levels were significantly elevated after
the 4th injection and increased further in the following days (140). Large numbers of
lymphocytes and moderate numbers of macrophages surrounded or permeated the
islets (140). β-cell necrosis was observed and remaining β-cells showed degranulation
(140). Five daily injections of STZ (40 mg/kg) in rats failed to produce similar islet
22

inflammatory lesions, despite the fact that an equivalent single large injection of STZ
(160 mg/kg) produced marked hyperglycemia (140). With the one injection technique,
necrosis occurs within 4 hours, hyperglycemia is achieved rapidly and all islets are free of
inflammatory lesions (140). In contrast, multiple sub-diabetogenic injections induced
gradual elevation of plasma glucose, with mononuclear inflammatory cells in and around
the islets (140). Multiple low doses of alloxan similarly altered islet morphology and
increased blood glucose levels, however, no inflammatory infiltration was observed
(150).
1.10.3. STZ-Induced Regeneration
It has been shown that young rodents have a large capacity to regenerate β-cell
mass after STZ-mediated destruction (112; 143). Subtotal destruction of β-cells with STZ
is followed by regeneration of β-cells and remission of hyperglycemia in young rodents
(112; 143). The capacity to regenerate decreases with age, as observed when STZ was
administered to adult rats, showing incomplete regeneration leading to diabetes later in
life (133; 151). However, it was found that transplantation of bone marrow-derived stem
cells were able to improve regeneration and survival rates (152), suggesting that
regeneration is possible even in the adult. The limitation of regeneration in the adult
may be a paucity of inductive signals from endothelial progenitor cells or a lack of β-cell
precursors.
In the PDL and pancreatectomy models, there has been much debate about the
source of regenerated β-cells. There is strong evidence to suggest that new β-cells
mainly arise from replication of pre-existing β-cells (113; 153) while others contest that
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differentiation of progenitor cells is the main source of β-cells during regeneration (106;
108). However, there is less known about the source of new β-cells in STZ induced
regeneration. A recent study using lineage tracing technology demonstrated an increase
in Pdx-1+/MafB+/insulin— cells following STZ treatment suggesting an increase in
differentiation of β-cell progenitors leading to regeneration of mature insulin expressing
cells (109). While endogenous (154) or transplanted (152) bone marrow cells have been
shown to home to the regenerating pancreas, they differentiate into supportive vascular
endothelium. Moreover, vascular growth in parallel to that of β-cell replication appears
to be important for regeneration and involves growth factor signalling and extracellular
matrix interactions (155). Together these results suggest that the intra-islet niche may
facilitate β-cell replication, in addition to the differentiation of precursor cells for
regeneration of β-cells following STZ. From Table 1.1 there is evidence to support the
generation of new β-cells from all three main sources (replication, neogenesis, and
differentiation), depending on the model. A key question is which mechanism can best
be utilized to generate a functional supply of new β-cells and how can we stimulate this
process?
1.11. Genes involved in β-cell Regeneration
Understanding the mechanism of β-cell regeneration will also require the
elucidation of the genes involved. Following β-cell loss, upregulation of some genes are

24

Table 1.1. Models of β-cell plasticity
Model
Regimen
STZ
multiple low dose
(50 mg/kg)
n0-STZ (100 mg/kg)

Alloxan

Partial
Pancreatectomy
Partial Duct
Obstruction
Partial Duct
Ligation
Glucose infusion
Pregnancy

Obesity

Species
Mouse

Mechanism
differentiation

Reference
(109)

Rat

replication,
neogenesis
replication,
differentiation
ND

(104; 143;
149)
(112; 155)

replication,
differentiation,
neogenesis
ND
replication,
neogenesis
replication,
neogenesis
neogenesis

(127)

n4-STZ (70 mg/kg)

Rat

multiple low dose
(40 mg/kg)
perfusion; adult

Rat
Mouse

multiple dose; adult
single injection;
adult
70, 90% resection;
adult
cellophane
wrapping; adult
adult

Mouse
Rat

adult
adult

Rat
Rat
Human
Rat

Rat
Hamster
Mouse

adult

Mouse
Human

adult

Mouse

adult

Rat

neogenesis,
differentiation
neogenesis
replication
neogenesis
replication,
hypertrophy
proliferation
replication,
neogenesis
replication,
neogenesis
replication,
neogenesis

(140)

(150)
(128)
(101; 113;
119)
(115; 116)
(106; 108;
118)
(117)
(156)
(157)
(67)
(158)
(2; 69)
(33)
(70)

Studies on β-cell plasticity following β-cell or pancreas insult and under physiologic
conditions in humans, mice, rats or hamsters have been described in both neonatal and
adult models. The method of β-cell regeneration is listed; β-cell replication, ductal islet
neogenesis or differentiation of stem/precursor cells. n0-STZ = STZ injection on neonatal
day 0 (day of birth); n4-STZ = STZ injection on neonatal day 4. ND = not determined.
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expected to initiate the process of regeneration, while other genes may play a role in
cell proliferation and/or precursor differentiation.
1.11.1. The Regenerating gene family
The regenerating islet-derived gene family (Reg) belongs to the calcium dependent
C-type lectin gene superfamily (159). The Reg gene family encodes for group of small
secreted proteins, which can function as acute phase reactants, lectins, anti-apoptotic
factors or growth factors for β-cells, neural cells and epithelial cells in the digestive
system (160). In 1984, administration of nicotinamide to 90% pancreatectomized rats
accelerated the regeneration of pancreatic islets (161). A rat regenerating islet-derived
cDNA library was then screened and a novel gene was isolated encoding a 165 amino
acid protein, which was called Reg gene (161). It was later named Reg1 and is also
known as pancreatic thread protein (PTP), pancreatic stone protein (PSP) or
lithostathine (162). Since then, several Reg and Reg-related genes have been isolated
from a number of species and they have been grouped into three subclasses (Table 1.2)
based on the primary structures of the encoded proteins (163). Reg genes have
previously been shown to be upregulated during β-cell regeneration (164-166).
Specifically, REG1 and islet neogenesis associated peptide (INGAP; mouse Reg3δ)
proteins are thought to be regeneration or growth factors for pancreatic β-cells (164;
167-169). Reg genes have been shown to stimulate β-cell replication and this likely
occurs through the upregulation of cell cycle genes such as cyclin D1 and Cdk4 (168; 170;
171). Additionally, Reg genes have been shown to act on the ducts to stimulate β-cell
neogenesis (116; 169; 172).
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Table 1.2. The Reg gene family
Species
Type Human
Rat
I
Reg1α
Reg1
(PSP/Lithostathine/PTP)
Reg1β
II
III
HIP/PAP
Reg3/PAP2
PAP1/Peptide 23
PAP3

Mouse
Reg1
Reg2
Reg3α
Reg3β
Reg3γ
Reg3δ

Hamster

Cow

INGAP

PTP

Reg, Regenerating gene; PSP, gene for pancreatic stone protein; HIP, gene expressed in
hepatocellular carcinoma, intestine, and pancreas; PAP, gene for pancreatitis-associated
protein; PTP, gene for pancreatic thread protein; INGAP, gene for islet neogenesisassociated protein. Adapted from Okamoto, J Hepatobiliary Pancreat Surg, 6: 254-262,
1999 (163).
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1.11.2. PDX-1 and β-cell Regeneration
In addition to its role in development, PDX-1 has also been shown to play a role in βcell maturation and differentiation in the adult. A population of PDX-1+ cells expressing
little or no insulin (insulinlow) were tracked in vitro and over time acquired insulin
expression (insulin+) without cell division (110). This suggested the existence of a
precursor pool of immature β-cells in the adult. These immature β-cells had increased
expression of MAFB and NKX2.2, markers of early β-cell development, and also had
higher replication rates than mature β-cells. Using a lineage tracing model in adult mice,
Liu et al. (109) similarly found an insulin— precursor population within the islet that
differentiated into insulin+ cells over time. Additionally, these precursor cells contributed
to β-cell regeneration following five daily injections of STZ (50 mg/kg) (109). These
precursor cells also had higher rates of replication and were marked by expression of
PDX-1 and MAFB, demonstrating their immature state. Furthermore, after 90% Px in
adult rats there was an increased proliferation of the pancreatic ducts followed by an
increased expression of PDX-1 in the ducts (102). These findings suggested that β-cell
regeneration following Px involved differentiation of ducts to β-cells through expression
of PDX-1 (102). Collectively these studies suggest the existence of a PDX-1 expressing
immature cell population, which could be a valuable source of new β-cells.
1.12. Environmental effects on β-cell development and plasticity
As illustrated thus far, β-cell growth and regeneration are complicated processes
involving multiple cell types, coordinated timing of gene expression and signalling
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cascades. Therefore it is expected that external factors, such as the environment, may
strongly influence β-cell development and plasticity. One important factor to consider is
the intrauterine environment. Gestation is a critical developmental window and
metabolic abnormalities at this time may permanently reset important homeostatic
processes that could predispose an individual to disease later in life (173). Hales et al.
(174) studied a cohort of adult men to determine if fetal and infant growth were
associated with type 2 diabetes and impaired glucose tolerance. They found that
individuals with lower birth weight and body weight at 1 year had a higher proportion of
glucose intolerance (174). Of these low birth weight individuals, 17% were diagnosed
with type 2 diabetes (174). The thrifty phenotype hypothesis was proposed to describe
the etiology of type 2 diabetes. The hypothesis states that poor nutrition in fetal and
early infant life is detrimental to the development and function of β-cells (175). These
deficits, which may include more complex features such as the islet vasculature and
innervation, predispose the individual to the later development of type 2 diabetes (175).
There is also evidence to support an increased risk for low birth weight individuals for
the development of hypertension and the metabolic syndrome (176).
Animal models of intrauterine growth restriction (IUGR) have been developed as a
method to understand the role of the intrauterine environment in the development of
the fetus and the predisposition to adult disease. IUGR can be achieved through
maternal dietary restriction of calories (177; 178) or nutrients (protein) (179; 180).
Additionally, pharmacological (181; 182) or surgical intervention through uterine artery
ligation (183) can be used to mimic IUGR. In all cases the fetus becomes growth
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restricted due to inadequate nutrient delivery (173).
1.12.1. Uterine Artery Ligation
A rat model of uteroplacental insufficiency was produced by bilateral uterine artery
ligation at 19 days of gestation, 3 days before term (183). Uteroplacental insufficiency
limits the supply of critical substrates, such as oxygen, glucose and amino acid to the
fetus and results in poor growth (184). IUGR offspring had lower birth weights than
controls until 7 weeks of age, when the growth rate was accelerated and by 26 weeks of
age they became obese (183). At 14 days postnatally, IUGR pups exhibited a reduced βcell proliferation but a normal apoptotic rate (185). Pdx-1 expression was dramatically
reduced at 14 days of age and the reduced expression persisted until 3 months (185).
Despite reductions in Pdx-1 expression, β-cell mass was normal at 14 days of age, before
dropping below control values by 15 weeks of age (183; 185). IUGR offspring are glucose
intolerant and insulin resistant early on and by 7 weeks of age they develop mild fasting
hyperglycemia and hyperinsulinemia and at 26 weeks they are markedly hyperglycemic
(183). It was shown that Exendin-4 (Ex-4), a long acting glucagon-like peptide-1 analog,
was able to reverse the adverse affects of uteroplacental insufficiency (185). Treatment
of IUGR newborns for the first 6 days of life with Ex-4 restored Pdx-1 expression to
normal levels, β-cell proliferation rates were normalized and the progressive loss of βcell mass was prevented (185). These effects of Ex-4 administration were attributed to
the restoration of islet vascularity and VEGF expression (186). This indicates the
plasticity of the neonatal pancreas, which with intervention has the ability to overcome
adverse events in fetal life.
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1.12.2. Pharmacological Induction of IUGR
Injection of 30 mg/kg body weight of STZ to a pregnant rat will induce mild diabetes
and macrosomic offspring (187; 188). These offspring become glucose intolerant in
adulthood due to decreased insulin secretion (189). On the other hand, injection of a
higher dose of STZ (50mg/kg) to a pregnant rat induces severe maternal hyperglycemia
with fetal growth restriction (190; 191). Development of the fetal endocrine pancreas is
enhanced by the elevated blood glucose concentrations with resulting hypertrophy and
hyperplasia of the islets from day 20 of gestation until birth (term is 23 days) (192). Fetal
pancreatic islets are overstimulated and consequently the fetal β-cells become
degranulated, disorganized and incapable of responding to any stimulus (192; 193).
Fetuses cannot benefit from the increased fuel supply from the maternal rat because of
fetal hypoinsulinemia (188). Hypoinsulinemia, a reduced number of insulin receptors on
target cells (191) and suppression of plasma membrane-associated GLUT1 in skeletal
muscle (194) of fetuses leads to a reduction in fetal glucose uptake. After birth, the
percentage of islet tissue decreased to values lower than normal during the suckling
period (188). The β-cells can partly restore their secretory capacity because of
normalization of β-cell granulation (188). Body weight in these offspring remains
significantly lower during the entire postnatal life, the suckling period and after weaning
(173). At adult age, there were an increased number of neogenic islets in the
morphologically normal endocrine pancreas (187), with normal or elevated plasma
insulin concentrations (195; 196). However, the adult offspring become insulin resistant
(195; 196).
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1.12.3. Calorie Restriction Model
In maternal food restriction models, the decreased availability of nutrients for
transplacental transport and decreased placental blood flow result in a decreased
nutrient supply to the fetus (197), whose growth is restricted (198; 199). In one study,
the food intake of pregnant rats was restricted by 50% on e15 for the last week of
gestation (199). Insulin content was decreased in the IUGR offspring at postnatal day 1,
along with a reduced β-cell mass which was attributed to a decreased islet number.
Body weight and pancreatic weight recovered by day 21 after being nursed by control
mothers from birth. However, β-cell mass and insulin content were still reduced at this
time. β-cell proliferation rates were normal at both 1 and 21 day time points. The
authors concluded from this study that in utero undernutrition impairs β-cell
development but does not affect postnatal β-cell growth (199). Another study looked at
maternal food restriction for the entire period of gestation until birth or until weaning
(198). Offspring of both groups were growth restricted, exhibited decreased plasma
insulin levels and similar to the first study, insulin resistance in adulthood. It was
determined that insulin resistance resulted from decreased sensitivity of the liver, while
insulin action in peripheral tissues remained normal (198; 200). Offspring of food
restricted rats for the fetal period alone or both the fetal and neonatal periods, only
showed slight differences in plasma glucose, but a more dramatic reduction in body
weight with the extended food restriction (173; 198). Otherwise, there were no
differences in plasma insulin levels or tissue insulin sensitivity (173; 198). However, βcell mass was not measured in this second study with a longer duration of caloric
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restriction, but similar reductions in β-cell mass could be expected. (180). While reduced
calorie intake may occur in times of famine, such as the Dutch Hunger Winter (201), a
more common nutritional insult would be an imbalance of particular nutrients, such as
reduced protein.
1.13. The Low Protein Model
Maternal protein restriction is a well established model that has been used to
examine the impact of the fetal environment on endocrine pancreas development and
long term glucose homeostasis. The model was initially established by Snoeck et al.
(180) through the administration of an isocaloric 8% protein diet (LP group; versus 20%
in the control diet (C)) to pregnant rats for the entire period of gestation. The
composition of the diets can be found in Table 1.3. LP fed rats had an increased food
intake with no change in weight gain during pregnancy. Placental weight was unchanged
and litter size was similar to controls, however, birth weight was significantly reduced in
the LP offspring (180). At birth, LP offspring had a decreased islet cell proliferation rate,
which corresponded to fewer large islets and a decreased mean islet size. Additionally,
islet vascularization was reduced by more than 50% in LP offspring due to a decrease in
blood vessel number. Other studies have also observed similar reductions in birth
weight, β-cell proliferation, mean islet size and islet vascularization in LP offspring (202204). Furthermore, isolated islets of LP offspring at birth secreted less insulin in response
to glucose and amino acids than control islets (179; 205).
Postnatally, when dams are maintained on a LP diet for the period of lactation, body
weight is reduced at all time points until the day of weaning (day 21) (179; 202).
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Table 1.3. Composition of the diets (g/100g of diet)
Control
LP
Cornstarch
40
40
Casein (88% protein)
22.3
8.6
Maltodextrin
13.2
13.2
Sucrose
10.0
23.6
Soybean oil
4.5
4.5
Cellulose
5.0
5.0
Mineral mix
3.5
3.5
Vitamin mix
1.0
1.0
L-Cystine
0.3
0.3
Choline Bitartrate
0.25
0.25
Tert-butyl hydroquinone
0.0014
0.0014
Bio-Serv, Frenchtown, NJ, USA.
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Offspring pancreatic weight was reduced between days 2 and 14 compared to controlfed animals (202). β-cell mass and mean islet area were decreased in LP offspring
throughout lactation (202; 204) with an observed decrease in proliferation due to a
prolonged G1 phase of the cell cycle (202). In addition there was an increase in the
incidence of apoptosis in LP offspring at this time. The increased apoptosis
corresponded with a decreased mRNA expression and immunoreactive staining in the
islets for the islet survival factor, IGF-II compared to control offspring. There was a
decrease in nestin and CD34 expressing cells in the islets and pancreatic ducts in LP
offspring from birth to day 14 (204). These cells are thought to represent either
endocrine or endothelial cell precursors, which may be related to the limitation in
endocrine cell development. Despite the changes in islet development, blood glucose
values did not change between groups (202).
In adulthood, the prominent observation in LP offspring is the development of
glucose intolerance (179; 206; 207). Glucose intolerance in LP offspring was observed at
70 days of age and this was associated with a reduced insulin secretory response to
glucose (179; 208). There was no difference in blood glucose values from weaning to
day 84 between control and LP offspring, despite lower blood insulin levels in the LP
offspring (179; 208). As well, the islet volume density was reduced in the LP group at
day 84 (179). In a related study, glucose intolerance was first observed in LP offspring at
130 days of age, specifically in females (206; 207). In contrast to the previous study, no
difference in plasma insulin levels was observed between female control and LP
offspring, but the islet number and β-cell mass were decreased in LP offspring (207).
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Moreover, male LP offspring did not exhibit reductions in β-cell mass, but were insulin
resistant. Insulin levels were increased by 2 fold in male LP offspring but there was a
reduction in Akt phosphorylation in adipose and skeletal muscle, an indication of
decreased insulin signaling in these tissues. Both of these studies noted reductions in
body weight after weaning in both male and female LP offspring throughout the time
period studied (179; 207).
Thus far the studies have examined the administration of a LP diet during gestation
and lactation and while both periods are critical times for endocrine pancreas
development, studies have tried to determine the specific window in which glucose
homeostasis is programmed. If LP is administered only for the period of gestation, and
dams are given control food at parturition, glucose intolerance in adulthood still occurs
(179). However, glucose tolerance was slightly improved over the group that received LP
until weaning and body weight was similar to controls if protein was returned to normal
at birth. After weaning, blood insulin levels were no different from controls at all time
points measured and at day 84, islet volume density was not significantly different.
Furthermore, varying the timing of LP administration within gestation demonstrated
that the impact of LP was most pronounced in females when LP was given for the 2nd
week of gestation only and in males when LP was given during the 3rd week of gestation
only (207).
1.13.1. The Low Protein Mouse Model
While the LP rat model is well established and has been extensively studied, the LP
mouse model would allow for the use of genetic tools such as transgenic mice.
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Additionally, the effects of LP in a mouse model on pancreas development have only
recently been investigated. In one study, LP was administered to pregnant C57BL/6
mice for the entire period of gestation until day 3 postnatally when pups were cross
fostered to control fed dams (209). Body weight in LP offspring was reduced at day 3,
but following cross fostering to control fed dams, there was rapid catch up growth at
day 7 and overgrowth by day 21 compared to offspring receiving the control diet
throughout. Pancreas weight was reduced in LP offspring at day 21 when normalized to
body weight. There was no difference in fasting blood glucose or insulin levels at day 21
in male LP offspring. However, protein expression of key insulin signaling molecules in
muscle tissue were decreased compared to controls at day 21. In a second study,
pregnant C57BL/6J mice were given an isocaloric 9% LP diet (versus 19% in control) for
the period of gestation only and the offspring were cross fostered to control fed dams
at birth (210). Birth weights were significantly reduced in LP offspring. Male offspring
showed catch up growth by 8 weeks of age and surpassed the weight of the controls by
week 32. In contrast, female LP offspring showed growth restriction from birth until 32
weeks of age. Male LP offspring were glucose intolerant with a higher adiposity at 32
weeks of age, while female LP offspring were not significantly different from controls.
Studies on the LP mouse offspring have yet to address the impact on endocrine cell
development, which is of interest to understand the development of glucose
intolerance in adulthood. The main findings of the LP mouse model are contrasted with
other species and models of IUGR in Table 1.4.
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Table 1.4. Models of Intrauterine Growth Restriction
Birth
Glucose
Insult
Species
Sex
Weight Tolerance Islet histology Reference
Low Protein
Mouse
male
ND
(209; 210)
↓
↓
gestation only
female
NS
↓
Rat
mixed
NS
NS
(179)
↓
Rat

mixed

↓

ND

Low Protein
Rat
gestation &
lactation

male

↓
↓

NS

female

Low Protein
Rat
all of life

mixed

NS

Calorie
Rat
Restriction
last 2 weeks
gestation
last week Rat
gestation

female

↓

mixed

gestation and/or Rat
lactation
Uterine Artery
Rat
Ligation
(e19)
Pharmacological

Rat

female

Rat

mixed

↓

↓replication
↓islet size
↓vasculature
↓replication
↓beta cell

↓

↓vasculature
↓islet

(180)

(202; 204;
206; 207)

mass

(179)

ND

volume
ND

(177; 178)

↓

ND

↓islet

(199)

female

↓

mixed

NS

number
ND

(198)

↓

↓

↓beta cell

(183)

↓
↓

ND

mass - 15 wks
ND

↓

↑fetal islet
mass

(177)
(173; 189;
191; 192)

↓postnatal
Hertfordshire
cohort

Human

male

↓

↓

islet mass
ND

(174)

Different models and timing of insults inducing fetal growth restriction in humans, mice
and rats comparing birth weight, glucose tolerance and changes to the islet mass or
structure based on histology. ND = not determined. NS = no significant change.
38

1.13.2. Relevance of the Low Protein Model
The calorie restriction rat model provides an adequate representation of the effects
of famine on fetal development. In humans, these effects were well documented in
studies on the Dutch famine (201). In North America famine is of lesser concern and
placental insufficiency is a major cause of IUGR, thus the uterine artery ligation model
may be most appropriate. However, given that placental insufficiency in humans can
produce a protein deficiency in the fetus (211), the LP model shares features in common
with the human placental insufficiency IUGR condition. Furthermore, the LP model will
be useful to differentiate the specific effects of amino acid deficiency from placental
insufficiency which results in both decreased oxygen and nutrient delivery.
1.13.3. Reversal Strategies
While the consequences of development in a poor intrauterine environment have
been well documented, it is important to determine whether or not intervention can
reverse these effects. The LP diet was shown to alter the plasma amino acid profile of
dams and fetuses and specifically the amino acid taurine (212). Taurine is a sulfur
containing amino acid that is involved in coordination of nerve function, stabilization of
the cell membrane, detoxification, antioxidant reactions and modulation of osmotic
pressure (213). In the pancreas, taurine is found in the islets and stimulates insulin
release by fetal β-cells in vitro (214; 215). Taurine (25 g/L) was added to the drinking
water of LP dams to see if supplementation could reverse the negative impact of the LP
diet on the offspring (203; 216). Taurine supplementation to LP fed dams had no effect
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on body weight and pancreas weight, however, β-cell mass returned to control levels at
day 30 (216). This corresponded with a recovery of proliferation rates and a reduction in
apoptosis. As well, the islet blood vessel volume and numerical density returned to
control values and VEGF immunoreactivity in the islet was recovered in LP offspring
with taurine supplementation (203). In a related study, IUGR rats were injected with Ex4 for 6 consecutive days from birth (185; 217). Ex-4 normalized blood glucose levels and
glucose tolerance in IUGR offspring (185). Additionally, neonatal Ex-4 treatment
restored Pdx-1 expression, β-cell proliferation rates and β-cell mass. Increased islet
vascularity and restoration of VEGF expression prior to reversal of diabetes suggested
the requirement for islet vascular growth before recovery of β-cell mass and glucose
homeostasis (217). These studies suggest a degree of plasticity remains despite the
influence of fetal nutrient deficiency and allows for the possibility of intervention.
1.14. Maternal Malnutrition and Tissue Plasticity
Based on intervention studies, a degree of tissue plasticity is evident in growth
restricted offspring, but whether this plasticity is capable of tissue regeneration
following damage or loss is currently being investigated. A study by Elmes et al. (218)
looked at cardiac dysfunction and myocardial damage following ischemia-reperfusion
(IR) in offspring exposed to low protein in utero. They found that a LP diet during
gestation significantly impairs recovery of male adult rats after IR. When considering
tissue regeneration in the pancreas, β-cell neogenesis was activated and β-cell
proliferation was unaffected following Px in undernourished adult rats (219). Pregnant
rats were 65% calorie restricted (R) for the last week of gestation through lactation and
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the offspring maintained on the restricted diet until day 70 at which point male
offspring were subjected to a 90% Px (219). Two days following surgery, RPx rats
showed a significant increase in neogenesis which was greater than in control fed
offspring receiving Px. Additionally, β-cell proliferation was observed in RPx rats, but
was not different than in CPx rats. This study suggests that undernourished rats
maintain a capacity for β-cell regeneration in adulthood. In contrast, when dams were
50% calorie restricted from day 15 of gestation until weaning and the offspring injected
with a single dose of STZ (100 mg/kg) at birth, β-cell regeneration was impaired (220). βcell mass regenerated rapidly by day 7 in STZ treated rats of C-fed dams, however,
despite an initial increase to 40% of non-injected rats, the R+STZ rats show poor
regeneration to day 21. The observed impairment in β-cell regeneration was attributed
to reduced neogenesis, while β-cell proliferation was preserved. Tissue plasticity is
important for adaptations to physiologic and pathological conditions, as well as for
tissue repair after damage or loss. Therefore there are serious implications for
reductions in tissue plasticity due to fetal programming by environmental insults.
1.15. Rationale
Type 1 diabetic and advanced stage type 2 diabetic individuals have reductions in βcell mass which contributes to uncontrolled glucose homeostasis. Stimulation of
endogenous β-cell regeneration could prove to be a very beneficial therapeutic
approach for these individuals. Rodent models of β-cell regeneration following STZ
induced β-cell loss have been extensively studied, but the mechanism of regeneration
and the signalling pathways involved remain widely debated. We will use multiple low
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doses of STZ to partially reduce β-cell mass to determine whether newly regenerated βcells were the result of increased β-cell replication, duct associated islet neogenesis,
and/or precursor cell differentiation.
Models of IUGR have been used to understand the role of the intrauterine
environment in fetal programming and susceptibility to adult diseases such as obesity,
cardiovascular disease and diabetes. Protein restriction in pregnant rats during the
period of gestation is a reproducible model of glucose intolerance, insulin resistance
and type 2 diabetes. However, the administration of a LP diet to a pregnant mouse has
not been extensively characterized, especially regarding pancreas development.
Additionally, replication of the LP rat findings in a mouse model would open up an
avenue for the use of genetic tools to further study the mechanism behind fetal
programming of adult diseases. Furthermore, alterations in pancreas development due
to LP exposure in utero may limit the capacity for β-cell regeneration. Specifically, fetal
programming may reduce the precursor population or the replicative capacity of the βcells following LP, as has been observed in the rat model (202; 204). Moreover, the
effects of prior LP-feeding may cause altered expression of critical genes involved in βcell regeneration.
Microarray technology can be a powerful tool to examine gene expression profiles
between groups, as well as to identify altered expression of novel genes. Performing
microarray experiments in the current study could allow for identification of signalling
pathways and genes involved in: 1) β-cell regeneration and 2) the development of adult
disease following LP exposure.
42

1.16. Hypothesis
We hypothesize that protein restriction during development in mice leads to IUGR
and impairment of long term glucose homeostasis. In C-fed offspring, β-cells will
regenerate following STZ treatment due to an increased expression of effector genes
leading to β-cell proliferation and/or precursor cell differentiation. However, LP
offspring treated with STZ will have a failure in β-cell regeneration with a lack of β-cell
proliferation and/or precursor cell differentiation and a corresponding decrease in
effector gene expression.
1.17. Objectives
1. To characterize a LP mouse model, in which a LP diet will be administered for the
period of gestation only, and the histology of the endocrine pancreas examined for
short and long term changes in β-cell mass, in addition to functional measurements of
glucose homeostasis.
2. Using a multiple low dose regimen of STZ administration, we will determine if newly
regenerated β-cells originate from ductal or intra-islet precursor cell differentiation,
and/or from self-replication of β-cells.
3. We will determine the capacity for β-cell regeneration in LP offspring, and if this
process is compromised, identify whether the precursor cell population or the ability to
self replicate was altered in LP offspring.
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4. Using microarray technology and real-time PCR experiments, we will elucidate genes
and signalling pathways that are critical for β-cell regeneration and might be altered
following LP diet.
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CHAPTER 2:
The Effects of Low Protein during Gestation on Mouse Pancreatic Development and
Beta Cell Regeneration.
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on mouse pancreatic development and beta cell regeneration. Pediatric Research, 68:
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2.1. Introduction
Poor fetal growth and low birth weight are associated with increased risk of
impaired glucose tolerance (1), type 2 diabetes (2), the metabolic syndrome (3) and
cardiovascular disease (4) in adult life. Animal models that have been developed to
understand the role of the intrauterine environment in susceptibility to postnatal
disease have included maternal dietary calorie restriction (5), nutritional imbalance (6),
and pharmacological (7) or surgical intervention (8). Administration of a low protein (LP)
diet to rats during pregnancy results in reduced birth weight (6), impaired islet cell
development, deficient insulin release (9), an increased islet apoptotic rate (10; 11) and
decreased β-cell mass in the offspring (9-11). Offspring of LP-fed dams were glucose
intolerant at 130 days of age (12). Our first objective was to characterize an LP model in
mice, to facilitate future exploration into the mechanisms whereby nutritional insult can
predispose to adult disease by using genetically manipulated transgenic mice.
Pancreatic β-cells have a significant capacity to regenerate after injury in early life.
Subtotal deletion of β-cells with streptozotocin (STZ) is followed by their partial
regeneration and remission of hyperglycemia in young rodents (13; 14). However, this
regenerative ability decreases with age (15). New β-cells have been postulated to be
generated through 3 possible mechanisms: 1) β-cell replication (16), 2) ductal islet
neogenesis (17) and 3) stem/precursor cell differentiation (18). It remains to be
determined which mechanism is most important for β-cell regeneration, and could be
exploited for β-cell therapy. It is not known if administration of a LP diet to a pregnant
mouse will alter β-cell plasticity in the offspring following an STZ insult, or by which
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mechanism regeneration occurs, which constitutes our second objective in this study.
Understanding how the intrauterine environment alters plasticity of β-cell mass in the
offspring could lead to strategies to intervene before the onset of type 2 diabetes.
To investigate these objectives, the Balb/c mouse will be used over the more
common C57BL/6 mouse strains. Previous studies demonstrated that adult C57BL/6
mice were less glucose tolerant than other mouse strains, including Balb/c (19; 20).
Development of glucose intolerance in adult mice could potentially confound the results
obtained with the LP model. Furthermore, C57BL/6 mouse strains develop significant
insulitis following multiple low doses of STZ, while the Balb/c strain is resistant to
immune cell infiltration (21). Thus, the Balb/c mouse will provide an ideal model to
examine the current objectives without confounding factors such as glucose intolerance
and insulitis.
2.2. Materials and Methods
2.2.1. Animals
Balb/c mice (Charles River Ltd, Montreal, QC, Canada) were housed in a
temperature controlled room with 12 h light : dark cycle. Water and food (Bio-Serv,
Frenchtown, NJ, USA) were given ad libitum. The low protein (LP) diet (similar to Snoeck
et al. (6)) was isocaloric with 8% protein versus 20% in the control (C) diet. Pregnancy
was confirmed by a vaginal plug and mothers were randomly assigned to C or LP diet for
the duration of gestation. A total of 61 C litters and 52 LP litters were used, with 15
litters/diet followed for maternal weight and food intake measurements every 5th day
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until weaning. All dams were maintained on the C diet after parturition. On days 1
through 5 the offspring received injections of either 35 mg/kg dose of STZ (Sigma
Chemical, St.Louis, MO, USA) in sodium citrate buffer (0.1 mol/L, pH 4.5), or equal
volume of the vehicle (sham). The offspring were divided into four groups: C = control
diet, sham injected; C+STZ = control diet, STZ injected; LP = low protein diet, sham
injected; LP+STZ = low protein diet, STZ injected. On day (d) 1, 7, 14, 30 and 130 the
weights of the offspring were recorded and blood glucose levels were measured after a
24 h fast using an Ascencia Breeze glucometer (Bayer Inc., Toronto, ON, Canada). Mice
were then killed and the pancreata were removed and fixed in 10% formalin for
morphological analysis. Three mice from independent litters were included per group
for each gender. On d42 and 130 an intraperitoneal glucose tolerance test (IPGTT) was
performed for 90 min after a 4 h fast as described previously (22). At d130 the total
abdominal adipose tissue was removed and weighed. All animal procedures were
approved by the Animal Care Committee of the University of Western Ontario in
accordance with the guidelines of the Canadian Council for Animal Care (Appendix 1).
2.2.2. Immunohistochemistry
Simultaneous immunohistochemistry was performed on sections for glucagon and
insulin as described previously (23). Briefly, tissue sections were incubated with a mouse
anti-glucagon antibody (1:2000; Sigma) and a horse anti-mouse secondary antibody
(1:50 Vector Laboratories, Burlingame, CA, USA) and localized using ExtrAvidinPeroxidase (Sigma) and a liquid DAB substrate kit (BioGenex, Fremont, CA, USA).
Subsequently, sections were incubated with a rabbit anti-insulin antibody (1:200; Santa
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Cruz, Biotechnology, Santa Cruz, CA, USA) and a goat anti-rabbit secondary antibody
(Vector) and localized using the Vectastain ABC-AP kit (Vector) with the Vector Red
Alkaline Phosphatase substrate kit I (Vector). Sections were mounted under glass
coverslips with Permount (Fisher Scientific, Toronto, ON, Canada). A triple stain was
performed to determine co-localization of proliferating cell nuclear antigen (PCNA) with
insulin and glucagon. Glucagon was localized as above, using a rabbit anti-glucagon
antibody (1:300; Santa Cruz) with a goat anti-rabbit secondary antibody (1:50; Vector).
PCNA was localized using a mouse anti-PCNA antibody (1:50; Dako Cytomation,
Mississauga, ON, Canada) with a horse anti-mouse secondary antibody (1:50; Vector)
followed by Vectastain ABC-AP kit (Vector) and visualized using Vector Blue Alkaline
Phosphatase substrate kit III (Vector). Tween-20 1X Tris buffered saline was used as a
wash, with phosphate buffered saline (PBS) used for the insulin staining portion. Insulin
was localized as above with a guinea pig anti-insulin antibody (1:300; Abcam,
Cambridge, MA, USA) with a goat anti-guinea pig secondary antibody (1:50; Vector).
Apoptag Plus Peroxidase In Situ Apoptosis Dectection Kit (Millipore, Etobicoke, ON,
Canada) was used to visualize apoptotic cells. This was followed by staining for glucagon
(1:200) and insulin (1:200), as described in the above triple stain, and visualized with
Vector Red and Blue Alkaline Phosphatase substrate kits I and III (Vector), respectively.
Pancreatic duodenal homeobox-1 (PDX-1) and insulin dual immunofluorescent
staining was performed using a rabbit anti-PDX-1 primary antibody (1:200; generous gift
from Dr. Chris Wright, Vanderbilt University, Nashville, TN, USA) with donkey Cy3 antirabbit secondary antibody (1:50; Jackson ImmunoResearch Laboratories Inc., West
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Grove, PA, USA), mouse anti-insulin primary antibody (1:200; Sigma) and Alexafluor 488
goat anti-mouse secondary antibody (1:50; Invitrogen Canada Inc., Burlington, ON,
Canada) with 4’,6-diamidino-2-phenlindole (DAPI) nuclear counterstain (Invitrogen).
Sections were mounted under glass coverslips with Fluorescent mounting medium
(Dako). PDX-1+ cells were counted for every islet/section and the PDX1+/insulin— cell
population was expressed as percentage of total PDX1+ cells.
Appropriate controls were performed for all antibodies used as described in
Appendix 2.
2.2.3. Morphometric analysis
Three representative pancreatic sections (sections were 20 μm (d1) up to 60 μm
(d130) apart; coefficient of variation = 10.45%) from each of 3 animals/group were
imaged and analyzed using Northern Eclipse software (version 7.0; Empix Imaging,
Mississauga, ON, Canada). Total pancreas area for each section and the area of insulin
and glucagon immunoreactivity for each islet were measured. Islets with an area <300
µm2 (≤3 cells) were excluded from analysis to distinguish islets from scattered single cells
in the parenchyma and to avoid the bias of sampling of islets that were sectioned at the
tops. β- (and α-) cell mass was calculated as previously described (11) by determining
the β-cell fractional area of the total tissue section area multiplied by the pancreas
weight. Individual β- and α-cell size were determined by averaging the individual cell
area measured from 10-15 random islets for each of 3 sections per pancreas and 3
pancreata per group. Islet neogenesis from pancreatic ducts was identified by endocrine
cell clusters associated with a pancreatic duct as previously described (24-26).
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Neogenesis was quantified by the number of small clusters (between 3-10 cells) per
mm2 pancreas area.
2.2.4. Serum and Pancreatic Insulin
On d7, 14 and 30 at least 20 µL of serum was collected and stored at -80°C. Insulin
was measured using an Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc.,
Downers Grove, IL, USA) according to the manufacturer’s instructions with sensitivity 0.1
ng/mL (intra- and inter-assay coefficient of variance ≤ 8% and ≤ 10% respectively).
Insulin was extracted from d14 whole pancreata (~50 mg) by mechanical
homogenization in 500 µL acid ethanol (165mM HCl in 75% ethanol). After overnight
incubation at 4°C, samples were centrifuged (2000g) for 5 min at 4°C. Insulin was
quantified in the supernatant by rat insulin radioimmunoassay (Linco Research Inc, St.
Charles, MO, USA; 100% reactivity to mouse insulin) and normalized to pancreatic DNA
content. Assay sensitivity was 0.1 ng/mL, with an intra- and inter-assay coefficient of
variance of 4.6% and 9.4%, respectively. Representative standard curves are shown in
Appendix 3.
2.2.5. Statistical Analysis
Three-way ANOVA was performed using SPSS revealing significant differences with
respect to gender. The genders were separated to examine the effects of diet and
treatment using a two-way ANOVA with a Bonferroni post-test to look at main effects
and group differences. An unpaired t-test was used for d1 comparisons. GraphPad Prism
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v5 software (GraphPad Software, La Jolla, CA, USA) was used. All values are means ±
SEM and with a significance level of p < 0.05.
2.3. Results
2.3.1. Body, Organ Weights and Diabetes Onset
No difference in weight gain or food intake (g consumed/d) was observed between
the C and LP fed dams at any time during pregnancy or lactation (n = 15 dams per
group). The mean litter size for the C (5.1 ± 0.3 pups; n = 61) and the LP (5.8 ± 0.3 pups;
n = 52) groups was not significantly different. On d1, male and female LP offspring had
significantly reduced (p < 0.05) weights and at d7 the LP diet significantly reduced (p <
0.01) body weight in both genders, although all mice recovered weight by d14 (Table
2.1). Pancreas weight (% body weight) was significantly decreased (p < 0.05) in both
male C+STZ and LP mice on d7 compared to controls, while the effect of LP treatment
continued to significantly reduce (p < 0.05) pancreas weight (%) in male offspring at d 14
(Table 2.1).
All female mice survived to d130 and showed no difference in weight between
groups (Table 2.1). Male C+STZ and LP+STZ mice became overtly diabetic between d6080 as defined by a qualitative observation of increased urination, water consumption
and blood glucose measurements of ≥25 mmol/L on consecutive days, at which point
they were killed. The survival rates at 130 days for male C+STZ and LP+STZ mice were
67% and 33%, respectively (n = 6). Therefore only male C and LP mice were examined at
d130, where no difference in weight was observed (Table 2.1). At d130, previous STZ
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Table 2.1. Body weight, relative pancreas weight and blood glucose measurements.
Pancreas Weight/
Blood Glucose
Body Weight (g)
Body Weight (%)
(mmol/L)
Male
Female
Male
Female
Male
Female
Day 1
Control
1.67 ± 0.08
1.55 ± 0.04
0.35 ± 0.07
0.32 ± 0.06
3.8 ± 0.4
4.4 ± 0.3
*
*
LP
1.40 ± 0.04
1.42 ± 0.03
0.30 ± 0.04
0.42 ± 0.05
4.4 ± 0.2
3.8 ± 0.3
Day 7
Control
5.58 ± 0.54
4.71 ± 0.22
0.23 ± 0.04
0.15 ± 0.04
5.7 ± 0.4
6.0 ± 0.4
*
**
C+STZ
6.24 ± 0.68
4.89 ± 0.21
0.10 ± 0.03
0.17 ± 0.01
6.6 ± 0.4
5.9 ± 0.5
†
†
*
LP
4.73 ± 0.22
4.22 ± 0.13
0.09 ± 0.01
0.14 ± 0.06
5.2 ± 0.3
5.7 ± 0.3
†
†
*
**
LP+STZ
4.30 ± 0.17
4.25 ± 0.13
0.09 ± 0.01
0.16 ± 0.05
6.0 ± 0.3
6.3 ± 0.5
Day 14
Control
8.34 ± 0.49
8.81 ± 0.46
0.39 ± 0.01
0.21 ± 0.08
8.2 ± 0.6
8.6 ± 0.7
**
C+STZ
8.57 ± 0.63
8.36 ± 0.57
0.40 ± 0.03
0.24 ± 0.07
11.8 ± 1.3
9.6 ± 0.6
LP
8.95 ± 0.27
8.82 ± 0.31
0.29 ± 0.03‡ 0.45 ± 0.15
8.4 ± 0.8
8.5 ± 0.9
**
LP+STZ
8.81 ± 0.28
8.38 ± 0.27
0.25 ± 0.06‡ 0.18 ± 0.07
13.3 ± 2.7
9.4 ± 1.2
Day 30
Control
15.8 ± 0.9
15.0 ± 0.6
0.76 ± 0.02
0.86 ± 0.06
8.1 ± 0.5
8.1 ± 0.8
C+STZ
16.2 ± 1.0
13.9 ± 0.3
0.78 ± 0.11
0.79 ± 0.01
10.7 ± 1.1§ 9.6 ± 1.6
LP
15.2 ± 0.6
13.6 ± 0.7
0.76 ± 0.09
1.04 ± 0.20
8.4 ± 0.8
8.0 ± 1.4
LP+STZ
15.0 ± 0.7
13.7 ± 0.4
0.87 ± 0.02
1.07 ± 0.37
15.2 ± 2.8§ 9.9 ± 1.0
Day 130
Control
28.4 ± 0.9
22.8 ± 0.5
0.81 ± 0.04
0.99 ± 0.16
6.9 ± 0.3
6.9 ± 0.4
**
C+STZ
N/A
22.6 ± 0.7
N/A
1.00 ± 0.03
N/A
8.4 ± 0.7
LP
27.3 ± 0.7
22.9 ± 0.3
0.92 ± 0.02
0.94 ± 0.08
6.3 ± 0.5
7.3 ± 0.5
**
LP+STZ
N/A
22.5 ± 0.4
N/A
1.07 ± 0.08
N/A
8.2 ± 0.4

The body weight (g ± SEM; n = 7-17 per group), pancreas weight relative to body weight
(% ± SEM; n = 3 per group) and blood glucose values (mmol/L ± SEM; n = 6-13) are given
for male and female mouse offspring receiving C or LP with or without subsequent STZ
administration over the time points studied. Data was analyzed using an unpaired t-test
for d1 comparisons and a 2-way ANOVA with Bonferroni’s post-test for all other time
points. * p < 0.05 vs Control; † p < 0.01 effect of LP diet; ‡ p < 0.05 effect of LP diet;
** p < 0.05 effect of STZ; § p < 0.01 effect of STZ.
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treatment caused a decrease in mean abdominal adipose weight (% body weight), but
the LP diet had no effect in either gender (Female: C = 2.5 ± 0.3, C+STZ = 1.8 ± 0.4, LP =
2.9 ± 0.4, LP+STZ = 1.6 ± 0.4; Male: C = 2.0 ± 0.4, LP = 1.9 ± 0.3; n = 4-5).
2.3.2. β-Cell Mass
β-cell mass was significantly decreased (p < 0.05) in male LP offspring at d7 and was
unchanged throughout the remaining period studied. Female LP mice similarly had a
significantly decreased (p < 0.01) β-cell mass at d7, however, by d14 showed a significant
increase (p < 0.001) compared to C animals (Figure 2.1b). At d30 and 130, the β-cell
mass in LP females was comparable to C values (Figure 2.1b). Therefore, LP exposure
alone had no long term effects on β-cell mass of either gender.
β-cell loss occurred following STZ treatment for both control and LP-treated mice as
shown on d7, two days after the final STZ injection (Figure 2.1 & 2.2a,b; p < 0.05). No
histological evidence of insulitis was observed in animals receiving STZ. STZ
administration decreased β-cell mass by 51% and 45% in female C+STZ and LP+STZ mice
compared to the respective sham-treated groups on d7. In the male C+STZ and LP+STZ
groups there was a 64% and 52% decrease respectively. On d14 in males given STZ, with
or without LP exposure, there was a partial recovery of β-cell mass (Figure 2.1a). By d30,
male C+STZ mice fully recovered β-cell mass versus controls. In contrast LP+STZ mice
showed a significant deficit (p < 0.05) compared to LP sham treated mice (Figure 2.1a).
This indicates that the initial increase in β-cell mass in male LP+STZ mice was not
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Figure 2.1. Changes in β-cell mass with diet and STZ treatment.
β-cell mass (mg) for C (white bars), C+STZ (grey bars), LP (black bars) and LP+STZ
(hatched bars) offspring over time for male (a) and female (b) mice. Mean ± SEM; n = 3
animals per group, and 3 sections per pancreas. Data was analyzed using a 2-way
ANOVA with Bonferroni’s post-test. (a) ** p < 0.05 vs sham; § p < 0.001 vs sham; ││ p <
0.05 vs C+sham; (b) ** p < 0.05 vs sham; § p < 0.001 vs sham; # p < 0.001 vs C+sham; * p
< 0.01 effect of LP diet; † p < 0.01 effect of STZ; ‡ p < 0.001 effect of STZ.
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Figure 2.2. Representative immunohistochemical and -fluorescent images.
Localization of insulin (red) and glucagon (brown) in an islet from a female (a) C and (b)
C+STZ mouse showing a decrease in insulin immunoreactive positive β-cells on d7. No
histological evidence of lymphocyte infiltration was observed, or any gender differences
in islet architecture. (c-f) Identification of Pdx-1+/insulin— progenitor cells (arrows) from
a female LP+STZ islet. (c) Insulin; (d) Pdx-1; (e) insulin and Pdx-1; (f) merged image with
nuclear DAPI stain (blue). Magnification bars represent 100 µm.
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sustained. Due to poor survival rates in the STZ treated male mice, the data set for β-cell
mass at d130 was incomplete (C+STZ = 0.60 ± 0.07 mg, n = 3; LP+STZ = 0.54 ± 0.15 mg, n
= 2) but suggests a decreased β-cell mass without development of overt diabetes. In
female mice, LP+STZ animals had a significantly lower (p < 0.01) β-cell mass compared to
LP sham injected mice on d 7 (Figure 2.1b). Subsequently, female LP mice showed a
significant increase (p < 0.001) in β-cell mass by d14 compared to C animals which was
not seen following STZ treatment (Figure 2.1b). β-cell mass was completely recovered by
d30 in C+STZ but not LP+STZ mice. However, β-cell mass was not maintained over the
long term as measured at d130 in the C+STZ group, which was significantly lower (p <
0.001) than in C mice, while LP+STZ mice continued to show a reduced (p < 0.001) β-cell
mass compared to LP animals (Figure 2.1b).
2.3.3. α-Cell Mass
To determine if the effects of the LP diet were specific to β-cells, the α-cell mass was
also examined by histology (Figure 2.3). α-cell mass in male LP mice was significantly
reduced (p < 0.01) at d7, but was comparable to C mice for the remaining period of
study (Figure 2.3a). In female mice, initially there was a significant effect (p < 0.05) of the
LP diet in reducing α-cell mass at d7, however, LP mice significantly increased (p < 0.01)
α-cell mass at d14 and 30 when compared to C mice (Figure 2.3b). In male C+STZ mice
there was a transient decrease (p < 0.001) in α-cell mass on d7 compared to C (Figure
2.3a). In female mice, STZ treatment under LP conditions significantly reduced α-cell
mass at d14 and 30 (p < 0.05; Figure 2.3b).
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Figure 2.3. Changes in α-cell mass with diet and STZ treatment.
α-cell mass (mg) for C (black bars), C+STZ (white bars), LP (grey bars) and LP+STZ
(hatched bars) offspring over time for male (a) and female (b) mice. Mean ± SEM; n = 3
animals per group, and 3 sections per pancreas. Data was analyzed using a 2-way
ANOVA with Bonferroni’s post-test. (a) § p < 0.001 vs sham; ││ p < 0.05 vs C+sham; (b)
** p < 0.05 vs sham; § p < 0.001 vs sham; † p < 0.01 vs C+sham; ‡ p < 0.001 vs C+sham; *
p < 0.05 effect of LP diet.
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2.3.4. Islet Size Distribution
Islets were grouped into large (>10,000 µm2), medium (5,000-10,000 µm2) and small
(300-5,000 µm2) sizes by measuring mean islet area and normalized to total pancreas
area (mm2). The LP diet did not alter the islet distribution (Table 2.2), and therefore the
change in β-cell mass in LP female mice was not attributed to an increase in new small
islets or small islets becoming large. Additionally, STZ treatment did not alter the
distribution of islet sizes on d7, demonstrating that the reduced β-cell mass associated
with STZ affected all sizes of islets equally (Table 2.2). By d14 C+STZ male, but not female
mice, showed a significant reduction in the number of large islets compared to sham
controls. By d30 there were no longer any differences in islet size distribution for
control-fed animals receiving STZ, but LP female mice showed reduced numbers of islets
of all sizes following STZ (Table 2.2). This shows that the relative deficit in β-cell mass in
these animals shown in Figure 2.1 was due to an overall reduction in the number of
islets, rather than a failure of smaller islets to become large.
2.3.5. Islet Cell Proliferation
The percentage of PCNA positive β- and α-cells was measured to determine the
contribution of replication to the observed changes in islet mass. No significant
differences in β- or α-cell proliferation were observed at d7 between the groups for
either gender (data not shown). On d14 there was a significant increase (p < 0.01) in βand α-cell replication in male C+STZ mice compared to C mice (Figure 2.4a,b). This may
contribute to the 4.5-fold increase in β-cell mass from d7 to 14 and continued expansion
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Table 2.2. The number of small, medium and large sized islets per mm2 of
pancreas.
Small
Male

Female

Medium
Male
Female

Large
Male

Female

Day 7
Control

5.6 ± 0.7

4.5 ± 0.4

1.07 ± 0.23

1.00 ± 0.16

0.63 ± 0.15

0.87 ± 0.09

C+STZ

3.3 ± 0.4

5.6 ± 0.7

0.77 ± 0.16

0.86 ± 0.13

0.47 ± 0.11

0.43 ± 0.08

LP

5.5 ± 0.6

4.7 ± 0.5

1.11 ± 0.15

0.84 ± 0.23

0.46 ± 0.10

0.54 ± 0.15

LP+STZ

4.4 ± 0.4

4.4 ± 0.4

0.63 ± 0.13

0.91 ± 0.36

0.26 ± 0.08

0.27 ± 0.07

2.0 ± 0.3

3.6 ± 0.4

0.29 ± 0.06

0.34 ± 0.06

0.53 ± 0.11

0.33 ± 0.10

Day 14
Control

**

C+STZ

1.6 ± 0.3

2.6 ± 0.3

0.30 ± 0.06

0.49 ± 0.11

0.17 ± 0.04

0.22 ± 0.08

LP

2.1 ± 0.3

3.3 ± 0.4

0.40 ± 0.08

0.49 ± 0.07

0.44 ± 0.05

0.69 ± 0.12

LP+STZ

2.0 ± 0.2

2.9 ± 0.4

0.46 ± 0.09

0.42 ± 0.09

0.36 ± 0.09

0.46 ± 0.09

Control

0.63 ± 0.05

0.75 ± 0.11

0.11 ± 0.02

0.13 ± 0.03

0.12 ± 0.03

0.12 ± 0.03

C+STZ

0.51 ± 0.07

0.83 ± 0.10

0.10 ± 0.03

0.17 ± 0.03

0.12 ± 0.02

0.17 ± 0.03

LP

0.59 ± 0.05

0.93 ± 0.09

0.10 ± 0.02

0.20 ± 0.03

0.16 ± 0.03

0.22 ± 0.03

0.08 ± 0.02

0.06 ± 0.01‡

Day 30

LP+STZ

0.42 ± 0.04

0.48 ± 0.05‡

0.07 ± 0.02

*

0.10 ± 0.02

The number of islets per mm2 of pancreas (± SEM) with a mean area between 300 and
5,000 µm2 (small), between 5,000 and 10,000 µm2 (medium), or >10,000 µm2 (large) in
animals receiving C or LP diet, with or without subsequent administration of STZ at
various ages. Data was analyzed using a 2-way ANOVA with Bonferroni’s post-test (n = 3;
3 sections per pancreas). * p < 0.05 vs LP+sham; ** p < 0.01 vs C+sham; ‡ p < 0.01 vs
LP+sham.
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Figure 2.4. β- and α-cell proliferation.
Percentage of PCNA +ve proliferating β (a,c) and α (b,d) cells at d14 for male (a,b) and
female (c,d) in offspring of control or LP fed mice. White bars = sham, black bars = STZ.
Mean ± SEM; n = 3 animals per group, and 3 sections per pancreas. Data was analyzed
using a 2-way ANOVA with Bonferroni’s post-test. ** p < 0.01 vs C+sham.
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to d30, as well as the increased α-cell mass. However, in female mice there were no
significant changes in β- or α-cell proliferation (Figure 2.4c,d).
2.3.6. Apoptosis for d14 Female Mice
Apoptosis was measured by Tunel assay to determine if reduced rates of apoptosis
in female LP offspring contributed to the observed increased β- and α-cell mass at d14.
However, no significant differences were found for the percentage of apoptotic β- and
α-cells between any groups at d14. (β-cell: C = 0.19 ± 0.09%; C+STZ = 0.32 ± 0.10%; LP =
0.16 ± 0.04%; LP+STZ = 0.24 ± 0.08%; α-cell: C = 0.25 ± 0.09%; C+STZ = 0.32 ± 0.11%; LP
= 0.15 ± 0.06%; LP+STZ = 0.21 ± 0.08%; n = 3; 3 sections per pancreas).
2.3.7. Individual Cell Size for d14 Female Mice
Since cell proliferation rates were unchanged (Figure 2.4c,d) and no change in
apoptosis was found, cell size was examined to determine the relative contribution of
cell hypertrophy to the increased β-cell mass and α-cell mass in d14 female LP mice.
Individual β-cell area was significantly increased (p < 0.01) in the LP group (71.77 ± 3.18
µm2) compared to the C group (61.01 ± 1.41 µm2). This change in the LP group is
associated with an approximate 5.8 fold increase in β-cell mass compared to the C
group. No difference was found for individual α-cell area between C and LP groups at
d14.
2.3.8. PDX-1+/insulin— Islet cells
The offspring were further analyzed by histology to identify a possible precursor cell
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population that might contribute to regeneration of β-cell mass. In C animals between
4% and 8% of islet cells were found to be PDX-1+/insulin— and this did not change with
STZ treatment (Table 2.3; Figure 2.2c-f). However, the abundance of these cells was
significantly increased (p < 0.01) in female LP mice after STZ at d7 and 14. Examining
male mice showed a significant increase (p < 0.05) in PDX-1+/insulin— in LP-fed offspring
at d7, however this difference did not persist to d14 (Table 2.3).
2.3.9. Duct Associated Islet Neogenesis
Small clusters (3-10 cells) associated with ductal structures have been considered an
indication of neogenesis as previously described (24-26)and are depicted in Figure 2.5.
Duct associated clusters were counted and normalized to pancreas area (mm2). On d7,
female C+STZ offspring had a significant increase (p < 0.05) in duct associated islet
clusters compared to the C group. However there was a minor but significant reduction
(p < 0.05) of these neogenic clusters in C+STZ mice at d14, which may suggest an
increase in replication within the small clusters and were therefore outside of the 10 cell
consideration for neogenesis. No changes were observed between the male groups at
either time point studied.
2.3.10. Glucose Homeostasis
Both male STZ-treated groups were relatively hyperglycemic compared with sham
injected mice at days 7, 14 and 30 (Table 2.1), while female STZ treated mice were able
to maintain euglycemia despite changes in β-cell mass. At d42, STZ treatment in male
and female mice led to fasting hyperglycemia (data not shown). At this age an IPGTT was
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Table 2.3. Percentage of PDX-1+/insulin— progenitor cells.
Day 7
Male
Control

3.8 ± 0.6

C+STZ

4.4 ± 0.4

LP
LP+STZ

Day 14
Female

5.6 ± 0.9

#

5.9 ± 0.8

#

Male

Female

4.1 ± 0.4

3.6 ± 0.9

5.9 ± 1.3

5.2 ± 0.3

5.3 ± 1.7

7.8 ± 1.2

2.0 ± 0.6

4.0 ± 1.1

2.9 ± 0.2

10.9 ± 1.6**

4.5 ± 0.8
12.2 ± 1.6

§

The number of PDX-1+/insulin— cells as a percentage of the total PDX-1+ cells (% ± SEM;
n = 3, 3 sections per pancreas) on d7 and 14 for male and female mice receiving C or LP
diet, with or without subsequent administration of STZ. Data was analyzed using a 2-way
ANOVA with Bonferroni’s post-test. # p < 0.05 effect of LP; ** p < 0.01 vs LP+sham; § p <
0.001 vs LP+sham.
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Figure 2.5. Duct associated islet neogenesis.
Micrographs depicting small islets associated with ducts, with insulin stained in red and
glucagon stained in brown (a,b). Magnification bars represent 100 µm. The number of
duct associated islets per mm2 pancreas area at d7 (c,e) and d14 (d,f) for male (c,d) and
female (e,f) in offspring of control or LP fed mice. White bars = sham, black bars = STZ.
Mean ± SEM; n = 3 animals per group, and 3 sections per pancreas. Data was analyzed
using a 2-way ANOVA with Bonferroni’s post-test. * p < 0.05 vs C+sham.
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performed. Blood glucose levels in the C+STZ and LP+STZ groups were elevated over the
time course compared to non-STZ treatment, and did not reach baseline within 90 min.
The area under the curve (AUC) for STZ treated groups was significantly increased (p <
0.05; Figure 2.6a,b insets), indicating a relative impairment of glucose tolerance.
Exposure to LP diet did not impair glucose tolerance at this age.
At d130 fasting hyperglycemia was observed in female STZ treated mice, while no
difference was found between C and LP groups for either gender (Table 2.1). Following
an IPGTT at d130, female STZ, LP and LP+STZ mice displayed glucose intolerance
determined by an elevated AUC (p < 0.05; Figure 2.6d inset). However, the LP male mice
had a comparable glucose response to the C mice during the IPGTT (Figure 2.6c).
2.3.10. Serum and pancreatic insulin
Measurements of serum insulin concentration were made on days 7, 14 and 30.
Despite changes in β-cell mass, serum insulin concentrations were similar between
groups and genders, with d14 mean values listed in Table 2.4. On d14, pancreatic insulin
content was significantly reduced (p < 0.05) in male mice exposed to LP, but not in
females (Table 2.4). STZ-treatment significantly reduced (p < 0.05) insulin content in
females, but the extent of the reduction was greater in animals receiving LP diet. No
change in pancreatic insulin content was observed in males treated with STZ, however,
this may have been more evident after the initial β-cell loss on d7.
2.4. Discussion
The pancreas has the ability to regenerate new β-cells after injury (13; 24; 26),
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Figure 2.6. Intraperitoneal glucose tolerance test.
IPGTTs were performed at d42 (a,b) and 130 (c,d) on male (a,c) and female (b,d)
offspring of C (solid lines) or LP dams (dashed lines), with (open squares) or without
(closed squares) subsequent STZ treatment. Insets represent the corresponding AUC,
where white bars = sham, black bars = STZ. Mean ± SEM; n = 10-13 (a,b); n = 3-5 (c,d).
Data was analyzed using a 2-way ANOVA with Bonferroni’s post-test. * p < 0.05 effect of
STZ treatment (a,b,d insets); § p < 0.05 effect of LP (d, inset).
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Table 2.4. Serum insulin and pancreatic content at day 14.
Serum Insulin
Pancreatic Insulin Content
Concentration (ng/mL)
(ng Insulin/µg DNA)
Male
Female
Male
Female
Control
1.2 ± 0.3
0.9 ± 0.5
17.3 ± 4.7
12.1 ± 2.1
C+STZ
1.4 ± 0.3
0.9 ± 0.3
11.7 ± 3.4
9.2 ± 0.4 §
*
LP
1.2 ± 0.5
0.7 ± 0.3
9.9 ± 2.0
13.2 ± 2.0
*
LP+STZ
0.9 ± 0.3
1.0 ± 0.3
4.6 ± 0.5
6.0 ± 3.0 §
Serum insulin concentration (ng/mL ± SEM; n = 3-5) and pancreatic insulin content (ng
insulin/µg DNA ± SEM; n = 3 ) were measured on d14 for male and female mice receiving
C or LP diet, with or without subsequent administration of STZ. Data was analyzed using
a 2-way ANOVA with Bonferroni’s post-test. * p < 0.05 effect of LP; § p < 0.05 effect of
STZ.

89

however, regeneration after sub-total deletion with a single, high dose of STZ may be
incomplete (13) and this ability decreases with age (15). We used multiple low doses of
STZ to create partial β-cell deletion in young mice that was not accompanied by
lymphocyte infiltration, with the expectation that β-cell mass would largely regenerate.
No significant change in blood glucose levels, or circulating insulin was observed in
female mice following STZ, although there was a decrease in pancreatic insulin content
consistent with β-cell mass loss. Male STZ-treated mice showed elevated blood glucose
levels throughout the study which may have been due initially to a marginally greater
loss of β-cell mass following STZ in males than in females.
Glucose tolerance was impaired in C+STZ females on d42 and β-cell mass was
reduced by d130. This suggests that while β-cell replacement is possible, it is functionally
incomplete, consistent with previous findings in rat (13). Based on sampling at d7 and
14, recovery of β-cell mass by d30 was not due to significant increases in β-cell
proliferation or β-cell hypertrophy, but may be the result of stem/precursor cell
differentiation. A PDX-1+/insulinlow islet cell population was described (27) which were
capable of maturing into insulin expressing cells. Our findings show that 4-8% of islet
cells in C neonatal mice were PDX-1+/insulin—. Additionally, precursor cells within the
ductal tissue may be stimulated to differentiate into new islets as evidenced by the
increased number of small islet clusters associated with the ducts within the female
C+STZ group. Previous studies have observed single insulin+ cells within the ducts or
small clusters of cells budding from the ducts (23-25). These observations are more
qualitative but recently, definitive evidence using lineage tracing of the ductal marker
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carbonic anhydrase II (CA II) demonstrated that ductal cells gave rise to new islets during
regeneration (28).
As in females, β-cell mass was fully replaced by d30 but in males this was attributed
to an increase in β-cell proliferation when sampled at d14. Male C+STZ mice remained
hyperglycemic, which led to overt diabetes in 33% of mice. The gender difference in
blood glucose levels following STZ treatment is consistent with previous findings (29),
which suggest a protective effect of estrogen and an negative impact of testosterone on
blood glucose. Moreover, previous studies in the STZ treated rat, where long term
diabetes develops even with an initial regeneration of β-cells, males develop diabetes
earlier than females (15; 30). However, here we report a novel finding that male and
female mice appear to regenerate β-cell mass by different mechanisms.
This is the first study to describe the effects of LP during gestation on the
development of the endocrine pancreas in the mouse offspring. Protein restriction did
not affect maternal weight gain or food intake, contrary to the findings in rats where
maternal weight gain decreased, even with increased food intake (6; 9). Birth weight
was decreased, as observed previously (6; 31; 32), however a relative overgrowth
compared to C was reported in mice by 3 weeks (31) or 8 months (32), which was not
observed here. β-cell mass was significantly increased in the female offspring on d14,
unlike the findings in rat (6; 9; 11), indicating important species and gender differences.
This could represent a compensatory response to meet the demands of increased
nutrient availability, leading to β-cell hypertrophy, but no increase in pancreatic insulin
content was found. On d14 the β-cell mass in female LP mice was approximately three91

fold greater than in C. Hypertrophy of individual β-cells could account for this, whereas
proliferation and apoptosis were unchanged. Male LP offspring did not show increased
β-cell mass on d14, and had comparable values to control-fed animals on d30. These
gender differences could be related to changes in endocrine hormones. Studies have
shown in the LP-fed rat that maternal plasma levels of prolactin, leptin, estradiol and
progesterone are all altered during gestation (33). These changes may differentially
affect fetal trajectory of β-cell growth and glucose homeostasis later in life.
A study in C57BL/6J mice found that male, but not female mice, showed glucose
intolerance at 8 months of age following exposure to LP in early life (32). In contrast
glucose tolerance at d130 was impaired predominantly in female LP mice in the present
study, although the mouse strains and time course used differed. Our results agree with
the corresponding rat model where LP-fed female rats became glucose intolerant at 130
days of age (12). Research has also shown a strong link between poor human fetal
development during times of famine and glucose intolerance later in life (34). Despite
the compensatory β-cell response shown in LP mice early in life, the long term effects
are consistent with rat and human studies.
The effects of malnutrition during fetal development are transmitted to the F2
generation (35; 36). This may occur as a direct result of a hyperglycemic intrauterine
environment, or potentially through epigenetic mechanisms (37-39). Therefore
understanding the mechanism of fetal programming of glucose homeostasis is critical to
future generations as well.
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We found that LP exposure affected pancreatic endocrine plasticity after STZ.
LP+STZ mice failed to reach an equivalent β-cell mass to that of LP mice, unlike controlfed animals, indicating a reduced capacity for β-cell regeneration. In female animals at
d30 this was associated with a reduced number of islets relative to STZ treatment alone,
but this was not seen in males. Consistent with our observations, other studies have
shown that nutrient deficiency early in life effects tissue plasticity. LP diet during
gestation significantly impaired recovery of male adult rats following ischemiareperfusion (40), while maternal calorie restriction during gestation and lactation
impaired β-cell replacement after STZ (41). Changes in islet morphometry resulting from
prior exposure to LP were not specific to β-cells, as the α-cell mass was also increased at
days 14 and 30 in females. Thus the increased β-cell mass in LP-fed females at d14 is
likely to represent a more general increase in islet mass. In the LP+STZ group, α-cell
mass was significantly reduced versus LP alone by d30. This suggests that the inability of
LP-fed animals to recover β-cell mass following STZ also resulted in a delayed ability to
increase α-cell mass as would normally occur with age, implying that the mechanisms
involved might be common to multiple endocrine cell types.
PDX-1+/insulinlow cells secrete less insulin then PDX-1+/insulin+ cells and over time,
this population has the ability to become PDX-1+/insulin+ without cell replication (27),
perhaps functioning as a strategic reserve. In our model, the proportion of the PDX1+/insulin— islet cells was not altered by LP diet, but was increased following STZ.
Previous studies identified a population of PDX-1+/MAFB+/insulin— cells that contributed
to β-cell regeneration following STZ treatment (18). More recently, pancreas derived
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multipotent precursor cells were identified in the mouse and found to express insulin,
high levels of Ngn3, and Glut2 was expressed at near-absent levels (42). Further
characterization of PDX-1+/insulin— precursor cells will be necessary in future
experiments. Expansion and differentiation of β-cell precursors ex vivo would provide an
excellent source of β-cells for replacement therapy.
These findings may indicate that normal maturational pathways that allow such
cells to differentiate into functional β-cells are impaired by LP exposure, resulting in a
reduced β-cell mass. In addition to a risk for later diabetes, the loss of plasticity may
compromise the female offspring during pregnancy, where a substantial expansion of
maternal β-cell mass normally occurs.
In conclusion, we describe a mouse model in which exposure to a LP diet during
gestation has critical effects on the development of the endocrine pancreas and β-cell
recovery after STZ. We have shown that mouse pancreatic development in a proteindeficient environment was altered to produce morphological changes in islet mass in
early life, and glucose intolerance in females later in life. Additionally, recovery from
STZ-induced injury was impaired by prior LP exposure, whereas C-fed STZ treated
offspring regenerated β-cell mass through replication or precursor differentiation. Our
results therefore suggest that the prior dietary environment is a determinant of
subsequent β-cell plasticity in a mouse model.
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CHAPTER 3:
The Mechanism Underlying the Development of Glucose Intolerance and the Failure of
β-cell Regeneration in Fetal Protein Restricted Mice.

Cox, A.R., Carter, D., Strutt, B., Arany, E.J., Hill, D.J.
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3.1. Introduction
Maintenance of β-cell mass is important to provide adequate blood glucose
regulation. In individuals with type 1 diabetes the β-cell mass is reduced by greater than
90%, while in individuals with type 2 diabetes the β-cell mass is reduced with
progression of disease (1; 2). Stimulation of endogenous regenerative mechanisms to
restore β-cell mass is one strategy that is being actively pursued for β-cell replacement
therapies in diabetes. Promising research in rodent models of β-cell injury has
demonstrated the capacity for β-cell regeneration. For example, administration of the βcell specific toxin, streptozotocin (STZ), in single or multiple doses to neonatal rodents
has been followed by rapid and significant regeneration (3-5). However, in adult animals,
the response is less robust leading to diabetes later in life (6; 7). Collectively, there is
evidence to support both β-cell replication and precursor cell differentiation in the
mechanism of β-cell regeneration (8-11). However, it is imperative to determine which
mechanism will be most beneficial as a therapeutic approach to diabetes.
It is important to consider how environmental factors, such as diet, affect β-cell
development and plasticity. Poor fetal growth and low birth weight are associated with
increased risk of impaired glucose tolerance (12), type 2 diabetes (13) and the metabolic
syndrome (14) in adult life. Previous work has examined the impact of maternal protein
restriction (LP) during fetal life in mice on islet development and long term glucose
homeostasis (Chapter 2). Specifically, offspring of LP fed mice were characterized by a
decreased birth weight and in females, an altered islet mass and an impaired glucose
tolerance in adulthood. Additionally, it was observed that neonatal offspring of LP dams
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subsequently treated with multiple low doses of STZ were unable to regenerate their βcell mass to control levels by d30. In contrast, offspring of control (C) fed dams receiving
STZ regenerated β-cell mass within 30 days. There was a significant increase in islet
neogenesis in female C+STZ mice at d7, while the female LP+STZ mice had an increased
presence of PDX-1+/insulin— precursor cells. A lack of differentiation of this PDX1+/insulin— population into mature β-cells may account for the failure of regeneration.
In addition to identifying the source of new β-cells and the supportive cells
contributing to β-cell regeneration, it is also essential to determine the signalling
mechanism involved. Studies have identified various mitogenic and differentiation
factors associated with β-cell regeneration such as insulin-like growth factor (IGF) -I (15),
glucagon-like peptide-1 (GLP-1) (3), activin A and betacellulin (16) and gastrin and
epidermal growth factor (17). The regenerating-islet derived (Reg) gene family members
are upregulated during β-cell regeneration (18-22). Additionally, Reg genes stimulate βcell replication, likely through the upregulation of cell cycle genes such as cyclin D1
(Ccnd1) and cyclin dependent kinase (Cdk) 4 (19; 23; 24). Furthermore, the Wnt pathway
signals through dishevelled (DVL) and β-catenin (CTNNB1) to upregulate gene expression
of Cdk4 and Ccnd1, leading to an increased proliferation of β-cells (25; 26).
Our first objective is to look at the expression profiles of C and LP fed offspring
following STZ to determine if these or other novel genes may be altered under LP
conditions leading to a failure in β-cell regeneration. Identification of novel factors
capable of stimulating β-cell expansion could provide new therapies for β-cell
replacement. Furthermore, understanding how the intrauterine environment affects β102

cell development could lead to intervention strategies to prevent glucose dysregulation
and type 2 diabetes. Therefore our second objective was to identify signalling pathways
and cellular functions that may be altered by LP exposure in utero based on altered gene
expression profiles.
3.2. Materials and Methods
3.2.1. Animals
Balb/c mice (Charles River Ltd, Montreal, QC, Canada) were housed in a temperature
controlled room with 12 h light:dark cycle. Water and food (Bio-Serv, Frenchtown, NJ,
USA) were given ad libitum. An isocaloric LP diet (8% protein) or control (C; 20% protein)
diet was administered to pregnant mice during gestation as described previously
(Chapter 2). On d 1 through 5, female offspring received injections of either 35 mg/kg
body weight of STZ (Sigma Chemical, St.Louis, MO, USA) in sodium citrate buffer (0.1
mol/L, pH 4.5) or equal volume of the vehicle (sham). Female offspring were divided into
four groups: C = control diet, sham injected; C + STZ = control diet, STZ injected; LP = low
protein diet, sham injected; LP + STZ = low protein diet, STZ injected. On day 7, 14 and
30 female offspring were killed and the pancreas was removed and stored in RNAlater
(Applied Biosystems Canada, Streetsville, ON, Canada) at -80°C.
3.2.2. Islet Isolation
Female offspring were killed on day 7 and islets were isolated by a modified protocol
previously described (27). Briefly, the pancreas was removed and perfused in a petri dish
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with 1 mL of Collagenase type V (1 mg/mL; Sigma) in Hank’s Buffered Salt Solution
(HBSS; Invitrogen Canada Inc., Burlington, ON, Canada). Pancreata from 2-4 female mice
for each litter were perfused and collected in 4-8 mL of HBSS + Collagenase type V and
placed in a 37°C shaking water bath for 30 min. Digested tissue was passed through a 14
gauge needle and washed in HBSS + 5% bovine serum (Invitrogen) by centrifugation.
Islets were separated from acinar and duct cells using a Dextran (MP Biomedicals, Solon,
OH, USA) gradient consisting of 27, 23 and 11% Dextran which was centrifuged for 25
min at 1250 rpm. Islets were collected from the 23-11% boundary and washed in HBSS +
5% serum. Islets were placed in a petri dish with HBSS + 5% serum and picked using an
inverted microscope. Islets for RNA use were stored in RNAprotect (Qiagen, Mississauga,
ON, Canada) at -80°C and islets for protein use were sonicated in lysis buffer and stored
at -80°C.
3.2.3. Microarray Experiments
Total RNA was extracted and purified from whole pancreas of 30 day old female
offspring using the Qiagen column method with the RNeasy Plus Mini kit (Qiagen).
Separate RNA samples were extracted from 3 pancreata per group (C, C+STZ, LP, LP+STZ)
with each sample hybridized to a separate GeneChip (n=3). All GeneChips were
processed at the London Regional Genomics Centre (Robarts Research Institute, London,
Ontario, Canada; http://www.lrgc.ca). RNA quality was assessed using the Agilent 2100
Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) and the RNA 6000 Nano kit
(Caliper Life Sciences, Mountain View, CA, USA) (Appendix 4).
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Biotinylated complimentary RNA (cRNA) was prepared from 10 μg of total RNA as
per the Affymetrix GeneChip Technical Analysis Manual (Affymetrix, Santa Clara, CA,
USA). Double-stranded cDNA was synthesized using SuperScript II (Invitrogen) and
oligo(dT)24 primers. Biotin-labeled cRNA was prepared by cDNA in vitro transcription
using the BioArray High-Yield RNA Transcript Labeling kit (Enzo Biochem, New York, NY,
USA) incorporating biotinylated UTP and CTP. Ten μg of labeled cRNA was hybridized to
Affymetrix Mouse 430 2.0 arrays for 16 h at 45°C as described in the Affymetrix
Technical Analysis Manual (Affymetrix). GeneChips were stained with StreptavidinPhycoerythrin, followed by an antibody solution and a second StreptavidinPhycoerythrin solution, with all liquid handling performed by a GeneChip Fluidics Station
450 (Affymetrix). GeneChips were scanned with the Affymetrix GeneChip Scanner 3000
(Affymetrix).
Probe level data from the .CEL files were analyzed using Partek Genomics Suite v6.5
(Partek, St.Louis, MO, USA). Probes were imported and summarized using RMA and
ANOVA was used to determine fold changes and p-values. Differentially expressed
genes between the four groups were selected based on fold change (≥ 1.5) differences
and a p-value cut-off of 0.05. Gene Ontology (GO) enrichment was performed within
Partek to determine enriched GO terms (molecular functions, biological processes or
cellular components) within a specific list of genes. A Fisher’s exact test was used to
determine significantly enriched GO terms.
3.2.4. Reverse Transcription and Real–Time PCR
Total RNA was extracted from whole pancreas from 7, 14 and 30 day old female
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offspring and from isolated islets of d7 mice with the RNeasy Plus Mini kit (Qiagen). RNA
quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc.) and
the RNA 6000 Nano kit (Caliper Life Sciences) (Appendix 4). RNA from whole pancreas
was treated with DNase (Invitrogen) to remove contaminating DNA and 4 μg were
reverse transcribed (RT) using Superscript III Reverse Transcriptase (Invitrogen) and
random hexamers (Invitrogen). Eight μL of RNA from isolated islets was treated with
DNase (Invitrogen) and then RT using the Superscript Vilo kit (Invitrogen). Primer sets
directed against insulin I, insulin II, glucagon, Reg1, Reg3δ, Ctnnb1, Cdk4, Ccnd1 and the
housekeeping genes 18s and cyclophilin A were designed using NCBI Primer Blast
(http://www.ncbi.nlm.nih.gov/; National Center for Biotechnology Information,
Bethesda, MD, USA) (Table 3.1). Primers were designed to have a melting temperature
~60°C, a product size between 80 and 150 bases, 4-5 base mismatches with similar nontarget sequences, at least 1 near the 3’ end and spanning an exon-exon junction when
possible. Cyclophilin A primer set was designed as previously described (28).
The relative abundance of each RNA transcript was determined by quantitative realtime RT-PCR (qPCR) using the Bio-Rad CFX384 real-time PCR machine (Bio-Rad,
Mississauga, ON, Canada) with SYBR Green (Bio-Rad) for detection of PCR products. Over
a wide range of known cDNA concentrations, all primer sets were demonstrated to have
good linear correlation (slope = −3.32) and equal priming efficiency for an input cDNA
dilution series compared with their cycle threshold (Ct) values (Appendix 5). The relative
abundance of each target compared with the calibrator was determined by comparative
Ct method using 2-ΔΔCt; ΔΔCt is the calibrated Ct value (primer − internal control).
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Table 3.1. Real-time PCR primers utilized
Target
Primer (5’-3’)
Insulin I
Forward: AGCCCCGGGGACCTTCAGAC
Reverse: GCGGGTCGAGGTGGGCCTTA
Insulin II
Forward: ACCATCAGCAAGCAGGAAGCCT
Reverse: GAAGAGCAGGGCCAGCAGGG
Glucagon
Forward: AGCTTGGGCCCAGGACACACT
Reverse: CCAGCTGCCTTGCACCAGCA
Beta catenin Forward: ACGCACCGTCCTTCGTGCTG
Reverse: AGGCGAACGGCATTCTGGGC
Cyclin D1
Forward: GCACCAGCCACACAGCGGTA
Reverse: GATGTGGGCAGGCTGCAGGG
Cdk4
Forward: CCTCTCTAGCTCGCGGCCTGT
Reverse: TTCCTGCGGCGCCATACACC
Reg1
Forward: TCCTGGGCAACTGGGTCTCCT
Reverse: GGGCATCACAGTTGTCATCCTTCCA
Reg3δ
Forward: TCCACGCATCAGCTGTCCCCA
Reverse: AGCCCAGGTCTGTGGTTCCAG
Cyclophilin A Forward: ATGGTCAACCCCACCGTGT
Reverse: TTCTGCTGTCTTTGGAACTTTGTC
18s
Forward: ACGATGCCGACTGGCGATGC
Reverse: CCCACTCCTGGTGGTGCCCT
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Reference no.
NM_008386
NM_008387
NM_008100
NM 007614
NM_007631
NM_009870
NM_009042
NM_013893
NM_008907
NR_003278

3.2.5. Western Blot Analysis
At least 200 islets isolated from 7 day old female mice were sonicated in lysis buffer
containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM phenylmethanesulfonylfuoride,
0.1% Igepal (MP Biomedicals, Solo, OH, USA), 0.1% Aprotinin (Sigma), 14% mini
complete 7x solution (Roche, Mississauga, ON, Canada) in deionized water. Protein
quantification was performed using a micro BCA protein assay kit (Peirce Protein
Researcher, Rockford, IL, USA) according to manufacturer’s instructions. A
representative standard curve is shown in Appendix 3.3. Acetone precipitation was
performed to concentrate the protein samples and was then dissolved in 50 μL of 1x
sample buffer. Protein (≤5 µg) was resolved on a 12% SDS-PAGE gel and transferred to a
nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen). Membranes
were probed with a sheep anti-REG1 antibody (1:200; R&D Systems, Minneapolis, MN,
USA) with a donkey anti-sheep secondary (1:1000; R&D Systems) and then stripped and
probed with a rabbit anti-β-actin antibody (1:5000, Abcam, Cambridge, MA, USA) used
as a loading control with a goat anti-rabbit secondary antibody (1:10,000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Antibody specificity is demonstrated in Appendix 6.
Relative abundance of REG1 was determined by densitometry using GeneSnap v7.09 and
GeneTools v 3.06 software (SynGene, Cambridge, England) and normalized to β-actin.
3.2.6. Pancreatic Insulin, Glucagon and GLP-1 Content
Whole pancreas tissue was collected at d7 from female offspring and snap frozen in
liquid nitrogen and stored at -80°C. Tissue samples (~20 mg) were mechanically
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homogenized in 200 µL of lysis buffer with 2% DPPIV inhibitor (Millipore, Etobicoke, ON,
Canada). Insulin extraction was performed, adding 50 µL of tissue lysates to 150 µL acid
ethanol (165 mM HCL in 75% ethanol). After overnight incubation at 4°C, samples were
centrifuged (2000g) for 5 minutes at 4°C. Insulin was quantified in the supernatant with
a sensitive rat insulin radioimmunoassay (RIA) (Millipore; 100% reactivity to mouse
insulin) and normalized to pancreatic DNA content from the pellet. Assay sensitivity was
0.2 ng/mL. Glucagon content was also measured from tissue lysates using the glucagon
RIA kit (Millipore). Assay sensitivity for glucagon was 20 pg/mL. Pancreas tissue lysates
(100-200 μL) were purified by Sep-Pak C18 (Waters, Milford, MA, USA) as previously
described (29). Ten μL of each sample was dried down using a Savant and then
reconstituted in hydrating buffer included with the RIA kit. Total GLP-1 content was
measured using the GLP-1 (total) RIA kit (Millipore) according to the manufacturer’s
instructions. Assay sensitivity for GLP-1 was 3 pM. A representative standard curve is
shown in Appendix 3.3.
3.2.7. Statistical Analysis
The effects of diet and STZ treatment were analyzed using a two-way ANOVA with a
Bonferroni post-test using GraphPad Prism v5 software (GraphPad Software, La Jolla, Ca,
USA). Statistical analysis of microarray data was performed as detailed above (Methods
3.2.1). All values are means ± SEM and significance level p < 0.05.
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3.3. Results
3.3.1. Microarray Experiments
DNA microarray experiments were performed to identify pancreatic genes involved
in β-cell regeneration following STZ treatment, and in the metabolic deficiencies seen in
female LP offspring. Over 45,000 transcripts were examined on the Mouse 430 2.0 gene
chip. Comparisons were made between groups (ie. C+STZ vs C; LP vs C; LP+STZ vs LP;
LP+STZ vs C+STZ) to create gene lists containing all genes with a significant (p < 0.05)
change in expression of ≥ 1.5 fold (Appendix 7). In the LP offspring 369 transcripts were
significantly reduced (p < 0.05) by ≥ 1.5 fold compared to control-fed animals and 35
transcripts were significantly increased (p < 0.05). The C+STZ group, which were capable
of regeneration of β-cells by day 30 (Chapter 2), had a significantly decreased (p < 0.05)
expression of 60 transcripts, while 18 transcripts were significantly increased (p < 0.05)
by ≥ 1.5 fold compared to the sham injected controls. Only 9 transcripts were
significantly decreased (p < 0.05) in the LP+STZ group compared to LP alone by ≥ 1.5
fold. This suggests that STZ treatment does not have a large additive affect on gene
expression in LP offspring. However, comparing LP+STZ to C+STZ mice, 411 transcripts
were significantly decreased (p < 0.05) and 15 transcripts were significantly increased (p
< 0.05). These represent candidate genes that might be linked to the failure of β-cell
plasticity seen in LP-fed animals following STZ treatment.
3.3.2. GO Enrichment – Islet Function
Gene Ontology (GO) is a bioinformatics initiative to annotate genes based on their
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biological process, molecular function or cellular component. A GO enrichment analysis
can determine significantly shared GO terms within a set of genes (30). The algorithm
attempts to determine whether an observed level of annotation for a group of genes is
significant (p < 0.05) within the context of annotation for all genes within the genome
(30). Using the gene lists created from the microarray data based on a ≥ 1.5 fold change
and a p-value cut off of 0.05, GO enrichment analysis was performed as an indication of
which biological processes, molecular functions or cellular components may be affected
by prior LP exposure and regeneration following STZ. From this analysis specific genes
with the significantly enriched GO term were identified within the data set.
Our first observation was the significant enrichment (p < 0.05) of GO terms such as
glucose transport, protein processing, protein maturation, secretory granule and
hormone activity. Therefore genes encoding for the islet hormones, enzymes for
hormone processing and glucose transporters were identified within the microarray
data (Table 3.2). Both insulin genes and islet amyloid polypeptide were significantly
decreased (p < 0.05) in expression in both the C+STZ and LP groups compared to control,
with a further decrease (p < 0.05) in insulin expression in the LP+STZ group (Table 3.2).
Glucagon and somatostatin were significantly decreased (p < 0.05) in the LP group
compared to control (Table 3.2). Genes involved in glucose transport (Glut2),
gluconeogenesis (G6pc2), and hormone processing (Pc2, Cpe, Scg2) were significantly
decreased (p < 0.05) in the C+STZ and LP groups (Table 3.2). An additive effect of LP and
STZ was not observed, except for insulin I and II genes, which corresponds with the
reduced β-cell mass at this time (Chapter 2).
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Table 3.2. Islet hormones, processing and secretion
Gene
Probeset ID Symbol
Gene Name

C+STZ

LP

LP+STZ

1422447_at

Ins1

insulin I

-4.959*

-2.434*

-4.063#

1422446_x_at

Ins2

insulin II

-3.285*

-2.124*

-3.570#

1425952_a_at

Gcg

glucagon

-1.764

-2.968*

-2.092

1417954_at

Sst

somatostatin

-1.447

-1.812*

-1.54

1423510_at

Iapp

Islet amyloid polypeptide

-5.323*

-3.439*

-4.385

1449067_at

Slc2a2/Glut2 glucose transporter 2

-1.912*

-1.702*

1.894

1448312_at
1423529_at

Pcsk2/Pc2
G6pc2

proprotein convertase 2
glucose-6-phosphatase,
catalytic, 2

-1.678*
-5.254*

-1.648*
-3.687*

-1.52
-3.996

1415949_at

Cpe

carboxypeptidase E

-1.692*

-1.756*

-2.055

1450708_at

Scg2

secretogranin II

-2.024*

-1.795*

-1.795

1423150_at

Scg5

secretogranin V

-1.801

-1.704

-1.760

1418149_at

Chga

chromogranin A

-1.702*

-1.445

-1.698

Represents fold change in expression versus the C group for microarray analysis
performed using total RNA samples from d30 pancreata of female offspring from C- and
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a twoway ANOVA (n = 3). * p < 0.05 vs C+sham; # p < 0.05 vs LP+sham.
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3.3.3. GO Enrichment – β-Cell Regeneration
Regarding β-cell regeneration, GO enrichment analysis of the gene lists comparing
C+STZ to C and LP+STZ to C+STZ revealed that GO terms including regulation of cell
proliferation, G1/S transition checkpoint, tissue regeneration and cell differentiation
were significantly enriched (p < 0.05). Genes encoding known regulators of the cell cycle,
mitogenic factors and transcription factors were investigated in the microarray data
(Table 3.3). Transcripts for cell cycle proteins that may be altered by LP and therefore
affect cell proliferation were examined. Ccnd1 expression was significantly reduced (p <
0.05) in the LP group compared to control, while other genes (Cdk4, Pcna, Ki67) were
not significantly altered (Table 3.3). The proto-oncogene c-Myc was found to be
significantly increased (p < 0.05) in the C+STZ group versus control and also when
compared to the LP+STZ group (Table 3.3). Members of the Wnt signalling pathway
(Ctnnb1, Dvl1) were examined since the pathway was recently shown to stimulate Ccnd1
and c-Myc expression associated with β-cell proliferation (31). However, no significant
expression changes in Ctnnb1 or Dvl1 mRNAs were observed. The regenerating isletderived gene, Reg1, was significantly decreased (p < 0.05) with prior LP exposure, while
Reg3δ was unchanged (Table 3.3). Tmem27, which encodes for a protein that stimulates
β-cell proliferation (32), and was found to be significantly decreased (p < 0.05) in both
C+STZ and LP groups compared to control (Table 3.3). Igf-I was significantly
downregulated (p < 0.05) in the LP and LP+STZ groups compared to the control and STZ
groups, respectively (Table 3.3). However, the expression of insulin receptor substrate 2
(Irs2), the downstream signalling target in the IGF-I and insulin signalling pathways, was
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Table 3.3. Cell cycle genes, mitogenic and transcription factors
Gene
Probeset ID Symbol Gene Name
C+STZ
1448698_at
1422441_x_at
1417947_at
1426817_at
1424942_a_at
1420811_a_at
1450978_at
1415905_at
1448290_at
1424009_at
1435064_a_at
1452014_a_at
1443969_at
1422174_at
1421112_at
1419424_at
1416072_at

Ccnd1
Cdk4
PCNA

cyclin D1
cyclin-dependent kinase 4
proliferating cell nuclear antigen
antigen identified by monoclonal
antibody Ki 67
Mki67
c-Myc
myelocytomatosis oncogene
Ctnnb1
β-catenin
Dvl1
Dishevelled, dsh homolog 1
Reg1
regenerating islet-derived 1
Reg3β
regenerating islet-derived 3 beta
Reg3δ
regenerating islet-derived 3 delta
Tmem27 transmembrane protein 27
Igf-1
insulin-like growth factor 1
Irs2
insulin receptor substrate 2
pancreatic and duodenal
Pdx1
homeobox 1
NK2 transcription factor related,
Nkx2.2
locus 2
Ptf1a
Ptf1a
Cd34
CD34

LP

LP+STZ

-1.080
-1.100
-1.236

-1.099*
-1.060
-1.287

-1.12
-1.180
-1.610

-1.679
1.594*
-1.231
-1.043
-1.159
1.121
-1.080
-1.997*
-1.010
1.111

-1.236
1.175
-1.438
-1.087
-1.441*
-1.551
-1.299
-2.495*
-1.253*
1.181*

-1.624
-1.033†
-1.564
-1.097
-1.559
-1.36
-1.524
-2.078
-1.511†
1.149

-1.237*

-1.183*

-1.212

-1.072
-1.184
-1.413

1.031
-1.677
-1.606*

-1.076#
-1.813
-1.547

Represents fold change in expression versus the control group for microarray analysis
performed using total RNA samples from d30 pancreata of female offspring from C- and
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a twoway ANOVA (n = 3). * p < 0.05 vs C+sham; † p < 0.05 vs C+STZ; # p < 0.05 vs LP+sham.

114

significantly increased (p < 0.05) in LP offspring (Table 3.3). Important β-cell transcription
factors were also significantly altered (p < 0.05); Pdx-1 was decreased in C+STZ and LP
groups, while Nkx2.2 was decreased in the LP+STZ group compared to LP alone (Table
3.3). Also of note was a significant decrease (p < 0.05) in the expression of the
hematopoietic and endothelial progenitor cell marker, Cd34 in LP offspring (Table 3.3).
3.3.4. GO Enrichment – Translation and Cellular Respiration
The GO enrichment data was also analyzed to identify cellular systems affected by
LP exposure that may predispose for the development of altered islet metabolism and
protein synthesis. The gene list comparing the C and LP groups consisted of many GO
terms relating to protein biosynthesis, such as ribosome binding and translation
initiation (Table 3.4). These GO terms were significantly enriched as indicated by the
respective p-value. Furthermore, GO terms relating to cellular respiration, such as the
electron transport chain (ETC) and ATP synthesis coupled proton transport, were
significantly enriched in the gene list comparing the C and LP groups (Table 3.5). This
suggests that LP offspring have significant alterations to transcripts that may have an
important impact on translation and cellular respiration. The gene list comparing fold
change between C+STZ and LP+STZ was also significantly enriched for GO terms relating
to translation and cellular respiration (Table 3.4 and 3.5). A greater percentage of genes
from the C+STZ versus LP+STZ gene list were present within each GO term compared to
the C versus LP list (Table 3.4 and 3.5).
The mitochondria are the site of cellular respiration and the ETC, so transcripts
encoding ETC enzymes were identified as an indication of potential mitochondrial
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Table 3.4. Enrichment of GO terms relating to protein biosynthesis
Function
translation
ribosomal subunit
rRNA binding
translational elongation
translation factor activity,
nucleic acid binding
eukaryotic translation
elongation factor 1 complex
translation regulator activity
translational initiation
ribosome binding
translation elongation factor
activity
translation initiation factor
activity

Type
biological
process
cellular
component
molecular
function
biological
process
molecular
function
cellular
component
molecular
function
biological
process
molecular
function
molecular
function
molecular
function

LP vs Control gene list
% genes # genes
p-value
in group in group

LP+STZ vs C+STZ gene list
% genes # genes
p-value
in group in group

1.00E+00

24.08

59

1.92E-260

32.38

79

1.10E-12

47.62

10

3.38E-62

52.38

11

1.14E-06

30.00

6

4.12E-46

47.37

9

6.69E-04

30.00

3

7.54E-28

50.00

5

1.94E-03

7.29

7

1.27E-07

9.47

9

1.97E-03

50.00

2

4.62E-12

50.00

2

3.05E-03

6.73

7

6.94E-07

8.74

9

1.29E-02

11.11

3

2.26E-10

19.23

5

1.97E-02

16.67

2

9.13E-09

25.00

3

2.05E-02

9.38

3

0.002531

9.38

3

2.43E-02

6.67

4

5.52E-06

10.17

6

Using the microarray data, gene lists were created for significantly altered (p<0.05)
genes in the LP group compared to the C group with ≥ 1.5 fold change and also for the
comparison LP+STZ versus C+STZ. These gene lists were analyzed for GO terms that were
significantly enriched based on a Fisher’s exact test with p < 0.05. The percentage and
number of genes from the gene list out of the total genes for that GO term are listed.
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Table 3.5. Enrichment of GO terms relating to cellular respiration
Function
cytochrome-c oxidase
activity
proton-transporting ATP
synthase complex, coupling
factor F(o)
electron transport chain
proton transport
ATP synthesis coupled
proton transport
NADH dehydrogenase
(ubiquinone) activity
NADH dehydrogenase
(quinone) activity
ATP biosynthetic process
mitochondrial part
oxidation reduction

Type
molecular
function
cellular
component
biological
process
biological
process
biological
process
molecular
function
molecular
function
biological
process
cellular
component
biological
process

LP vs Control gene list
% genes # genes
p-value
in group in group

LP+STZ vs C+STZ gene list
% genes # genes
p-value
in group in group

2.50E-07

37.50

6

2.24E-33

43.75

7

4.72E-07

50.00

5

2.10E-89

90.00

9

1.46E-06

11.46

11

3.76E-61

25.53

24

2.34E-04

12.50

6

4.75E-42

29.17

14

3.14E-04

15.15

5

3.76E-54

39.39

13

3.44E-03

17.65

3

3.62E-16

29.41

5

3.44E-03

17.65

3

3.62E-16

29.41

5

2.00E-01

4.44

2

4.98E-11

15.56

7

1.00E+00

7.08

24

3.71E-47

12.76

43

1.00E+00

2.85

17

1.26E-10

5.56

33

Using the microarray data, gene lists were created for significantly altered genes in the
LP group compared to the C group with ≥ 1.5 fold change and also for the LP+STZ versus
the C+STZ groups. These gene lists were analyzed for GO terms that were significantly
enriched based on a Fisher’s exact test with p < 0.05. The percentage and number of
genes from the gene list out of the total genes for that GO term are listed.
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dysfunction (Table 3.6). Most notably, 23 transcripts related to Complex I of the ETC
were significantly altered (p < 0.05), the majority of which were downregulated in the LP
and/or LP+STZ groups (Table 3.6). ATP synthase (Complex V) is the final step in the ETC
leading to the production of ATP. Twelve transcripts encoding for ATP synthase subunits
were also significantly downregulated in the LP and/or LP+STZ groups (Table 3.6). Similar
observations were also found for transcripts encoding subunits of Complex II, III and IV
(Table 3.6). Decreased expression of ETC enzyme encoding transcripts may result in
mitochondrial dysfunction in LP offspring.
3.3.5. Antioxidant Expression
The mitochondrial respiratory chain is a major site of reactive oxygen species (ROS)
production which can be detrimental to cell function and survival (33; 34). Since the LP
diet had a significant effect on the expression of genes relating to cellular respiration,
genes responsible for ROS scavenging were identified in the microarray (Table 3.7).
Expression of transcripts encoding for the antioxidants glutathione peroxidase (Gpx1,
Gpx3, Gpx4), peroxiredoxin (Prdx1, Prdx2, Prdx4) and glutathione S-transferase (Gstp1,
Mgst1) were significantly decreased (p < 0.05) in the LP group compared to control
(Table 3.7). Similarly, in the LP+STZ group there was a significant decrease (p < 0.05) in
expression of transcripts for antioxidants (Gpx1, Gpx4, Prdx4, Prdx5, Gstk1, Gstm6,
Gstt1) compared to the C+STZ group, while expression of the glutathione S-transferase
members (Gstk1, Gstm6, Gstt1) were further downregulated (p < 0.05) compared to the
LP group (Table 3.7). Interestingly, the expression of the enzyme involved in glutathione
synthesis, glutathione synthetase (Gss), was significantly upregulated (p < 0.05) in the LP
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Table 3.6 Mitochondrial electron transport chain components
Probeset ID
Complex I

Gene
Symbol

1422241_a_at

Ndufa1

1417368_s_at

Ndufa2

1452790_x_at

Ndufa3

1417286_at

Ndufa5

1448427_at

Ndufa6

1428360_x_at

Ndufa7

1423692_at

Ndufa8

1418068_at

Ndufa10

1429708_at

Ndufa11

1430713_s_at

Ndufa13

1448483_a_at

Ndufb2

1416547_at

Ndufb3

1434056_a_at

Ndufb6

1416417_a_at

Ndufb7

1448198_a_at

Ndufb8

1452184_at

Ndufb9

1416056_a_at

Ndufb11

1448284_a_at

Ndufc1

1423737_at

Ndufs3

1433603_at

Ndufs6

1424313_a_at

Ndufs7

1428179_at

Ndufv2

1424628_a_at

Ndufv3

Complex II

1418005_at

Sdhb

Gene Name
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 1
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 2
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 3
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 6 (B14)
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 7 (B14.5a)
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 8
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex 10
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex 11
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 13
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 2
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 3
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 6
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 7
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 8
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 9
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 11
NADH dehydrogenase (ubiquinone) 1,
subcomplex unknown, 1
NADH dehydrogenase (ubiquinone) Fe-S
protein 3
NADH dehydrogenase (ubiquinone) Fe-S
protein 6
NADH dehydrogenase (ubiquinone) Fe-S
protein 7
NADH dehydrogenase (ubiquinone)
flavoprotein 2
NADH dehydrogenase (ubiquinone)
flavoprotein 3
succinate dehydrogenase complex, subunit B,
iron sulfur (Ip)
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C+STZ

LP

LP+STZ

-1.158

-1.568*

-1.94†

-1.069

-1.459*

-1.62†

1.004

-1.340*

-1.64†

-1.024

-1.266*

-1.41†

1.544*

1.096

-1.17†

1.125

-1.123

-1.39†

-1.137

-1.266*

-1.36

1.131*

1.152*

1.15

1.103

-1.220

-1.47†

-1.116

-1.509*

-1.83†

1.009

-1.383*

-1.80†

-1.091

-1.276*

-1.51†#

-1.224

-1.753*

-1.95†

-1.006

-1.314*

-1.49†

-1.215

-1.540*

-1.78†

-1.190

-1.639*

-1.86†

-1.098

-1.611*

-1.850†

1.554

1.110

-1.19†

1.101

-1.138

-1.33†

-1.060

-1.354*

-1.575†

1.044

-1.258

-1.434†

1.095

-1.225

-1.52†

-1.156

-1.499*

-1.83†

-1.079

-1.292

-1.52†

Complex III

1453229_s_at
1448292_at

Uqcrh
Uqcr

ubiquinol-cytochrome c reductase hinge protein
ubiquinol-cytochrome c reductase (6.4kD)
subunit

1.101
1.259

-1.322*
-1.157

-1.582†
-1.43†

1448322_a_at
1415933_a_at
1416902_a_at
1417417_a_at

Cox4i1
Cox5a
Cox5b
Cox6a1

-1.088
-1.164
-1.042
-1.214

-1.538*
-1.636*
-1.396*
-1.697*

-1.758†
-1.73†
-1.612†
-1.83

1416565_at
1434491_a_at
1416970_a_at
1429188_at

Cox6b1
Cox6c
Cox7a2
Cox11

cytochrome c oxidase subunit IV isoform 1
cytochrome c oxidase, subunit Va
cytochrome c oxidase, subunit Vb
cytochrome c oxidase, subunit VIa, polypeptide
1
cytochrome c oxidase, subunit VIb polypeptide 1
cytochrome c oxidase, subunit VIc
cytochrome c oxidase, subunit VIIa 2
COX11 homolog, cytochrome c oxidase
assembly protein (yeast)

-1.082
-1.217
-1.076
-1.137

-1.432*
-1.586*
-1.573*
-1.360*

-1.69†
-2.06†#
-1.98†
-1.497

ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1
ATP synthase, H+ transporting, mitochondrial F1
complex, delta subunit
ATP synthase, H+ transporting, mitochondrial F1
complex, epsilon subunit
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit c2 (subunit 9)
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit c3 (subunit 9)
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit d
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit f
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit f, isoform 2
ATP synthase, H+ transporting, mitochondrial
F1F0 complex, subunit e
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit g
ATP synthase, H+ transporting, mitochondrial F0
complex, subunit s
ATP synthase, H+ transporting, mitochondrial F1
complex, O subunit

-1.087

-1.336

-1.56†

1.374*

1.020

-1.137†

-1.037

-1.467*

-1.791†

1.160

-1.110

-1.34†

-1.004

-1.459*

-1.57†

-1.163

-1.536*

-1.77†

-1.055

-1.503*

-1.87†

1.122

-1.310

-1.675†

-1.112

-1.487*

-1.89†

1.115
-1.120

-1.257
-1.249*

-1.60†
-1.244

1.107

-1.283

-1.52†

Complex IV

Complex V

1416058_s_at

Atp5c1

1423716_s_at

Atp5d

1416567_s_at

Atp5e

1415980_at

Atp5g2

1454661_at

Atp5g3

1423676_at

Atp5h

1416143_at

Atp5j

1416269_at

Atp5j2

1450640_x_at

Atp5k

1448203_at
1417970_at

Atp5l
Atp5s

1416278_a_at

Atp5o

Represents fold change in expression versus the control group for microarray analysis
performed using total RNA samples from d30 pancreata of female offspring from C- and
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a twoway ANOVA (n = 3). * p < 0.05 vs C+sham; † p < 0.05 vs C+STZ; # p < 0.05 vs LP+sham.
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Table 3.7. Genes encoding antioxidants and related proteins
Probeset ID
1460671_at

Gene
Symbol Gene Name
Gpx1
glutathione peroxidase 1

C+STZ
1.048

LP
-1.365*

LP+STZ
-1.594†

1449106_at

Gpx3

glutathione peroxidase 3

-1.191

-1.359*

-1.34

1451695_a_at

Gpx4

glutathione peroxidase 4

-1.160

-1.468*

-1.72†

1441931_x_at

Gss

glutathione synthetase

1.145

1.750*

1.864†

1451124_at
1417634_at

Sod1
Sod3

superoxide dismutase 1, soluble
superoxide dismutase 3,
extracellular

1.028

-1.258*

-1.446†

1.249*

1.219*

1.174

1416000_a_at

Prdx1

peroxiredoxin 1

-1.110

-1.541*

-1.526

1418506_a_at

Prdx2

peroxiredoxin 2

-1.150

-1.322*

-1.43

1416167_at

Prdx4

peroxiredoxin 4

-1.281

-1.696*

-2.022†

1416381_a_at

Prdx5

peroxiredoxin 5

1.050

-1.102

-1.301†

1452823_at

Gstk1

glutathione S-transferase kappa 1

1.024

-1.052

-1.280†#

1422072_a_at

Gstm6

glutathione S-transferase, mu 6

1.014

-1.043

-1.133†#

1449575_a_at

Gstp1

glutathione S-transferase, pi 1

-1.189

-1.550*

-1.682

1418186_at
1415897_a_at

Gstt1
Mgst1

glutathione S-transferase, theta 1
microsomal glutathione Stransferase 1

-1.092

-1.123

-1.35†#

-1.348

-1.559*

-1.91

Represents fold change in expression versus the control group for microarray analysis
performed using total RNA samples from d30 pancreata of female offspring from C- and
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a twoway ANOVA (n = 3). * p < 0.05 vs C+sham; † p < 0.05 vs C+STZ; # p < 0.05 vs LP+sham.
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and LP+STZ groups compared to the C and C+STZ groups, respectively (Table. 3.7).
Transcripts encoding for superoxide dismutase (SOD), which converts superoxide into
hydrogen peroxide and water, were differentially expressed; Sod1 was significantly
downregulated (p < 0.05) in the LP and LP+STZ groups while Sod3 was significantly
upregulated (p < 0.05) in the C+STZ and LP groups (Table 3.7).
3.3.6. Real-Time PCR from Whole Pancreas
Microarray experiments were used to identify candidate genes but this was
followed up with quantitative real-time RT-PCR (qPCR) on d30 pancreatic RNA samples
for more precise measurements of gene expression changes. Day 7 and 14 samples were
also analyzed to look at a time course of changes in expression during β-cell
regeneration. Eight candidate genes were identified for validation. Insulin I, insulin II,
and glucagon were selected on the basis that altered islet mass may impact their gene
expression. Ccnd1 and Cdk4 were also selected as prime regulators of the cell cycle.
Potential regulators of these cell cycle genes, Ctnnb1, Reg1 and Reg3δ, were also
selected as candidates. Gene expression for insulin I and II was significantly increased (p
< 0.05) in C+STZ and LP offspring compared to control at d7, while in LP+STZ mice,
insulin II was significantly greater (p < 0.05) than C+STZ mice (Figure 3.1a,b). By d14,
insulin I gene expression was unaltered between groups, however, insulin II expression
was significantly reduced (p < 0.05) by STZ and LP treatment (Figure 3.1a,b). At d30 both
insulin genes were significantly upregulated (p < 0.05) in the LP offspring compared to
controls, while the LP+STZ group had a significant reduction (p < 0.01) compared to the
untreated LP offspring (Figure 3.1a,b). Glucagon gene expression was significantly
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Figure 3.1. Gene expression changes in whole pancreas following LP diet or STZ
treatment.
Fold change in gene expression compared to d7 C determined by qPCR for the C (white
bars), C+STZ (grey bars), LP (black bars) and LP+STZ (hatched bars) groups at d7, 14 and
30 were calculated using the ΔΔCt method with cyclophilin A used as a reference gene.
(a) insulin I, (b) insulin II, (c) glucagon, (d) Ctnnb1, (e) Ccnd1, (f) Cdk4, (g) Reg1, (h)
Reg3delta (δ). Fold change ± SEM; n = 6/group. Data was analyzed using a 2-way ANOVA
with Bonferroni’s post-test within each time point. * p < 0.05 vs sham; ** p < 0.01 vs
sham; *** p < 0.001 vs sham; # p < 0.05 vs C+sham; ## p < 0.01 vs C+sham, † p < 0.001
vs C+sham; ‡ p < 0.05 vs C+STZ; § p < 0.05 effect of STZ; a p < 0.05 effect of LP; b p < 0.01
effect of LP; c p < 0.001 effect of LP.
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increased (p < 0.01) at d7 in the LP offspring versus the control but no other changes
were observed during the time of study (Figure 3.1c). The expression of Ctnnb1, Ccnd1,
and Cdk4 were all similar at d7, with a significant reduction (p < 0.05) observed for the
C+STZ and LP groups versus control (Figure 3.1d-f). Prior LP exposure had a significant
effect (p < 0.05) increasing expression of Ctnnb1 and Cdk4 at d30, with a similar
significant (p < 0.05) observation for ccnd1 at d14 (Figure 3.1d-f). The regenerating islet
derived gene family members Reg1 and Reg3δ were also measured. Initially Reg1 was
significantly upregulated (p < 0.05) with STZ treatment at d7, while LP exposure had an
effect of significantly lowering (p < 0.05) expression at d14 (Figure 3.1g). For Reg3δ no
changes were observed until d30 at which time prior LP exposure resulted in a
significant increase (p < 0.001) in expression (Figure 3.1h).
3.3.7. Real-Time PCR from Isolated Islets
Aside from the islet hormones, the candidates may be widely expressed throughout
the pancreas, therefore we examined islet specific expression. Reg1 is upregulated in
regenerating islets (18) and in the current study Reg1 expression was increased in whole
pancreas at d7 in STZ treated offspring. Therefore, to determine which candidate genes
may be expressed early on as a driving force for β-cell regeneration, d7 was selected for
analysis of the islet specific changes in expression. Insulin I gene expression was not
significantly altered between groups, however, exposure to the LP diet significantly
reduced (p < 0.01) expression of insulin II (Figure 3.2a,b). Glucagon gene expression was
significantly increased (p < 0.01) in STZ treated groups, regardless of diet (Figure 3.2c).
Similar to our observations in the whole pancreas, Reg1 gene expression
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Figure 3.2. Gene expression changes in isolated islets at d7.
Fold change in gene expression compared to the C group by qPCR in islets isolated at d7
from female offspring of C and LP fed mice with or without subsequent STZ
administration. Expression values were calculated using the ΔΔCt method with 18s used
as a reference gene. (a) insulin I, (b) insulin II, (c) glucagon and (d) Reg1. White bars =
sham, black bars = STZ. Means ± SEM; n = 3-5/group. Data were analyzed using a twoway ANOVA with Bonferroni’s post test. b p < 0.01 effect of LP; * p < 0.05 effect of STZ;
** p < 0.01 effect of STZ.
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was significantly increased (p < 0.01) with STZ treatment and specifically a 5 fold
increase in LP+STZ islets when compared to the LP sham group (Figure 3.2d). The
expression of the other candidate genes, Ctnnb1, Ccnd1, Cdk4 and Reg3δ, were
expressed at low or undetectable levels within the islets (data not shown). These genes
are common to many cell types and therefore the changes observed from whole
pancreatic RNA samples likely represent extra-islet changes in expression.
3.3.8. Western Blot Analysis
Protein lysates were collected from isolated islets at d7 and analyzed to correlate
the observed changes in REG1 gene expression with protein expression. Western blot
analysis demonstrated a reduced presence of REG1 protein expression following STZ in
LP offspring, which significantly differed from the C+STZ (p < 0.01) and LP sham (p <
0.05) groups (Figure 3.3).
3.3.9. Pancreatic Insulin, Glucagon and GLP-1 Content
Analysis by qPCR on isolated islets at d7 indicated significantly decreased expression
of the insulin II gene in LP offspring, while glucagon expression was significantly
increased with STZ treatment. To determine any corresponding changes in protein
expression, pancreatic insulin and glucagon content were determined by RIA. Pancreatic
insulin content was significantly reduced (p < 0.05) with STZ treatment, which is
consistent with a loss of β-cell mass at this time (Figure 3.4a). Despite an upregulation of
the proglucagon gene, no significant differences in glucagon protein content were
observed (Figure 3.4b). This may suggest an increase in other products of the
127

b

Sham
STZ

8

Reg1/ b actin

**
6
4
2

*
0

Control

LP

Figure 3.3. Western blot analysis of Reg1.
REG1 protein expression levels were determined by western blot analysis (a) from
lysates of d7 isolated islets from female mice receiving C or LP diet, with or without
subsequent administration of STZ. The top panel shows REG1 protein levels at 14 kDa
and the lower panel shows β-actin at 42 kDa. (b) Densitometry was performed for
quantification of REG1 and normalized to β-actin levels. White bars = sham; black bars =
STZ. Means ± SEM; n = 3-6. Data were analyzed using a two-way ANOVA with
Bonferroni’s post test. * p < 0.05 vs LP+sham; ** p < 0.01 vs LP+STZ.
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Figure 3.4. Pancreatic insulin, glucagon and GLP-1 content.
Pancreatic (a) insulin, (b) glucagon and (c) total GLP-1 content were measured by
radioimmunoassay on d7 from whole pancreas tissue from female mice receiving C or LP
diet, with or without subsequent administration of STZ. White bars = sham; black bars =
STZ. Means ± SEM; n = 3-6. Data was analyzed using a two-way ANOVA with Bonferroni’s
post test. a p < 0.05 effect of STZ; b p < 0.01 effect of STZ.
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proglucagon gene such as GLP-1. Measurements of pancreatic GLP-1 content indicated a
significant increase (p < 0.05) in animals subsequent to STZ treatment (Figure 3.4c). A
change in the post-translational processing of proglucagon was also supported by a
significantly altered ratio of GLP-1 to glucagon pancreatic content (Figure 3.4d).
3.4. Discussion
Offspring exposed to protein restriction during fetal life have been associated with
low birth weight and long term impairments in glucose tolerance and type 2 diabetes (5;
12; 13; 35). Previously, we have shown that female LP mouse offspring have reduced
body weights at d1, altered islet cell mass at d14 and develop glucose intolerance at
d130 (Chapter 2). Here we used global expression arrays at d30 to identify genes that
may be altered in the pancreas by LP exposure leading to impaired glucose metabolism
in adulthood. Prior LP exposure significantly decreased all islet hormones, as well as the
key transcription factor Pdx-1. Additionally, genes involved in glucose transport, insulin
processing and secretion (Glut2, Pc2, Cpe, Scg2, Chga) were downregulated in LP
offspring. However, the β-cell mass in the LP offspring was similar to the control group
at d30 (Chapter 2). It is possible that altered expression of islet hormones and β-cell
functional genes begins as early as d30, contributing to the later development of glucose
intolerance.
The gene lists comparing LP and C fed offspring demonstrated many significantly
enriched GO terms relating to protein biosynthesis. Loss of expression of genes encoding
translational machinery could limit protein biosynthesis and greatly influence cell
function. The acute demand for insulin secretion during post-prandial states, or in the
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case of hyperinsulinemia, in the presence of insulin resistance, can lead to an imbalance
in protein homeostasis and ER stress (36). However, no changes in expression of genes
relating to ER stress or the unfolded protein response were observed in the microarray.
Furthermore previous observations in LP mice showed no changes in fasting blood
glucose levels, serum insulin concentration or apoptosis (Chapter 2), therefore it is
unclear how these changes impact protein production and cell function.
The LP diet also significantly affected cellular respiration based on GO enrichment
analysis. Cellular respiration is important for converting nutrient substrates into energy
in the form of ATP, but more importantly in the β-cell, ATP generation increases the
ratio of ATP/ADP initiating a cascade of events leading to insulin secretion. β-cells have
an aerobic metabolism at least threefold higher than in most other cell types and may
therefore be more susceptible to nutritional environment (37). Previous microarray
studies from d21.5 fetuses of LP fed rat dams revealed observations that the cellular
respiration pathway was one of the most affected by LP exposure in utero. At this time
they found genes associated with cellular respiration were upregulated. However, at 3
months of age they found that expression of respiratory genes encoding for malate
dehydrogenase, citrate synthase, ATP6 and ND4L were downregulated in LP offspring
(38). This is consistent with the current observations in LP mice, where cellular
respiratory gene expression was largely downregulated at d30. Programming of the fetal
mitochondria has been suggested as a key adaptation for survival in a suboptimal
intrauterine environment (39-42). However, introduction into an optimal environment
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postnatally may ultimately lead to mitochondrial dysfunction underlying the
development of glucose intolerance in adult life.
β-cell gene expression of antioxidants is relatively low and therefore the β-cell is
vulnerable to ROS (43; 44). Mitochondrial function is particularly susceptible to oxidative
damage, leading to decreased mitochondrial ATP synthesis, cellular calcium
dyshomeostasis and induction of mitochondrial permeability transition (45). Specifically
in mouse islets increased ROS production and mitochondrial damage resulted in
decreased glucose stimulated ATP synthesis and deficiencies in insulin secretion (46).
Moreover, mitochondrial dysfunction and ROS production have been shown to play a
role in the development and progression of type 2 diabetes (33; 34; 47). In female LP
offspring reduced expression of many antioxidants was observed in the whole pancreas,
increasing susceptibility to ROS. If these changes are pertinent to the β-cell, along with
the loss of expression of important ETC genes (potential for mitochondrial dysfunction),
may contribute to the development of glucose intolerance at d130 in LP mouse
offspring. While increased rates of apoptosis were not previously observed in LP mice
(Chapter 2), the primary effect of these changes may be a reduced ATP production
leading to decreased insulin secretion in adult life. Further experimentation is required
to determine if gene expression changes related to the microarray analysis relate
specifically to the β-cell and how the changes may produce defects in β-cell function.
While application of the microarray findings to β-cells is intriguing, the effects of LP
on gene expression must account for the whole pancreas. Acinar and duct cells are
important for the production and dispersion of digestive enzymes and the bicarbonate
132

ion. The microarray data suggests a decreased expression of genes relating to protein
synthesis, mitochondrial function and ROS scavenging. Reduced function of these
processes may contribute to cell stress, decreased metabolism, and reduced enzyme
production and secretion. Together this may impact digestion and therefore absorption
of fats and proteins, which may cause downstream metabolic changes.
Additionally, LP programming of the pancreas during fetal life reduces β-cell
plasticity. Previously we demonstrated that LP offspring treated with multiple low doses
of STZ were unable to regenerate and restore β-cell mass to the level of sham injected
mice (Chapter 2). The microarray analysis also examined genes that may be altered by LP
exposure resulting in an inability to regenerate β-cell mass. The insulin genes, as well as
genes involved in glucose transport, insulin processing and secretion (Glut2, Pc2, Cpe,
Scg2, Chga) were downregulated in C+STZ groups. In the C+STZ group β-cell
regeneration was complete by d30 (Chapter 2), therefore decreased expression of these
genes suggests either transcript levels were not restored to control values at this time or
these changes mark an early decline in function preceding glucose intolerance
previously observed at d42 (Chapter 2). Treatment of LP offspring with STZ further
decreased expression of the insulin genes, which is consistent with the reduced β-cell
mass at this time (Chapter 2).
Neonatal growth and β-cell regeneration have been demonstrated to involve the
Wnt/β-catenin pathway (48). The Wnt/β-catenin pathway acts to upregulate the cell
cycle genes Ccnd1 and Cdk4 (25; 31). Through microarray analysis we found that Ccnd1
had a significantly decreased gene expression in LP offspring, while Cdk4 was
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unchanged, and neither gene was altered with STZ treatment. Despite observing
changes in expression for Ctnnb1, Ccnd1 and Cdk4 in whole pancreas by qPCR,
expression within isolated islets was low at d7 and therefore the cell cycle genes are
unlikely to play a role early on during β-cell regeneration.
Members of the Reg gene family have also been shown to play a role in β-cell
regeneration. Reg1 gene expression was increased in regenerating β-cells and is
mitogenic to both ductal and β-cells (18; 19; 49-51). Adjuvant therapy in diabetic NOD
mice and STZ treated C57BL/6 mice induced an increased expression of Reg2, mediating
β-cell regeneration (52). INGAP (mouse REG3δ) stimulates β-cell neogenesis from ductal
cells, increasing β-cell mass and reversing diabetes in STZ treated C57BL/6J mice (20;
53). Further support for the Reg genes as facilitators of β-cell regeneration was observed
from a microarray analysis of 3 month old mice treated with multiple doses of STZ (80
mg/kg) (21). Fifteen days after STZ treatment, gene expression for Reg2, Reg3α, Reg3β,
Reg3δ, and Reg3γ were all increased (21). Additionally, Reg1 expression was significantly
upregulated when quantified by northern blot hybridization (21). In the current study,
our microarray analysis did not suggest any significant differences among the Reg genes
in the C+STZ group. The disparity between these studies could be related to the age of
the mice (3 months vs. 30 days) and the dose of STZ used (80 mg/kg vs. 35 mg/kg).
However, we did observe a significant increase in gene expression with qPCR for Reg1 in
STZ treated mice at d7 in whole pancreas and isolated islets. While other Reg genes
were not measured by qPCR, Reg1 may be the primary target for induction of β-cell
regeneration in neonates.
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Despite a significant increase in Reg1 mRNA in the LP+STZ group, examination of
protein presence suggested a reduction compared to the C+STZ group. A few
possibilities may explain this discrepancy. First, increased protein ubiquitination may
target REG1 for proteasomal degradation or other post-translational modification may
lead to protein instability. Some proteins, such as β-catenin and cyclins, are normally
regulated via the ubiquitin-proteasomal pathway (54; 55), however, it is not known if
REG1 is post-translationally modified under normal circumstances. These changes could
be a general effect of LP exposure, effecting many proteins and therefore cellular
function. Secondly, an increased rate of secretion in an effort to stimulate β-cell
regeneration could impact the measurement of REG1 islet content. Third, gene
expression profiles in LP offspring suggest a potential deficit in protein biosynthesis and
therefore may limit the production of key regulators of β-cell regeneration such as REG1.
An increase in pancreatic GLP-1 content was observed in STZ-treated offspring,
consistent with an increase in proglucagon gene expression and without a significant
change in glucagon content. This suggests an altered processing of the prohormone. To
support this theory, measurements of expression of the PC enzymes should be made at
d7. A decreased expression of Pc2 was observed with the microarray at d30, but Pc1 was
unchanged (data not shown). Similarly, a single injection of STZ to neonatal Wistar rats
led to an increase in GLP-1 content (3). This was associated with α-cell hyperplasia and
regeneration of β-cells (3). Previous research has also shown that in neonatal rats
treated with STZ, administration of exogenous GLP-1 significantly improved β-cell
regeneration, predominantly due to neogenesis of islets (56). However, in 7 day old
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LP+STZ mice, the α-cell mass is reduced and β-cell regeneration fails. This may be
attributed to possible alterations at the level of the GLP-1R or in the downstream
signalling pathway. Although notably GLP-1R expression was unchanged by microarray
analysis at d30 (data not shown). In contrast, STZ treatment of C-fed offspring did result
in β-cell regeneration, while demonstrating a similar increase in GLP-1 content,
suggesting that GLP-1 is an important stimulus for regeneration in the current model.
In conclusion, these results support the role of REG1 and GLP-1 in β-cell
regeneration in C-fed offspring and suggest that reduced REG1 production and/or GLP-1
signalling limits β-cell plasticity in LP-fed offspring. Further investigation is required to
determine the defect in GLP-1 signalling and whether exogenous REG1 can rescue β-cell
regeneration in LP mice. Additionally, the effects of fetal protein restriction appear to
alter gene expression necessary for many cell functions, such as cellular respiration, free
radical scavenging and protein biosynthesis. These alterations may critically impact βcell function leading to the development of glucose intolerance in adulthood.
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CHAPTER 4:
General Discussion and Future Experiments
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This thesis examined the effects of administration of maternal LP diet in a mouse
model on endocrine pancreas development and long term glucose homeostasis in the
offspring. The plasticity of neonatal LP offspring was challenged by depletion of β-cells
with multiple low doses of STZ and the capacity to regenerate was monitored. This was
contrasted with STZ treated C-fed offspring, in which the mechanism of β-cell
regeneration and potential signalling genes involved were investigated.
4.1. The LP Mouse Model
Our objective to compare findings from maternal feeding LP diet in mice with those
previously described in the rat (1-6) was accomplished. We observed a decreased body
weight at d1 in LP-fed offspring compared to C diet, followed by rapid catch up growth
and impaired glucose intolerance in females in adulthood. This is comparable to findings
in the rat (5; 7; 8). However, in the mouse we observed a reduction in α- and β-cell mass
in LP offspring only at d7, while in the rat model β-cell mass was already reduced at birth
(1; 2; 6). The reduction in islet mass at d7 preceded a significant increase at d14 in the
female LP offspring. With respect to the β-cell mass, this increase was attributed mainly
to cell hypertrophy. Therefore there are some species differences regarding the growth
trajectory of the β-cell mass between mouse and rat, but the long term metabolic
outcome remains the same.
Interestingly, gender differences were observed in LP-fed mouse offspring. Female
offspring were glucose intolerant at 130 days of age, as was observed with LP rats (5).
The impairment in female LP rats was likely due to a relative deficiency of β-cell mass
(5). In contrast, female LP mice had no change in β-cell mass at this time, therefore
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pancreatic insulin content and glucose-stimulated insulin secretion (GSIS) in isolated
islets should be measured to determine if there is a functional deficit in the β-cell. The
male LP mice did not demonstrate any changes in glucose tolerance or β-cell mass as
adults. Estrogen levels were not examined in the current study, but alterations may
account for the gender differences observed in LP offspring. Previous research in rats
and mice has shown that estrogens regulate glucose metabolism and tolerance through
increased β-cell insulin content, insulin gene expression, and insulin release (9-11).
Therefore estrogen hormone therapy may be appropriate to restore glucose tolerance
and β-cell function in female LP mice. In contrast, LP male rats were found to have
reduced plasma testosterone levels, which was postulated to contribute to insulin
resistance (5), but in the current studies these parameters were not measured and no
apparent impact on glucose homeostasis was observed in male LP mice. However,
previous studies have determined that in maternal LP rat plasma, levels of prolactin,
leptin, estradiol and progesterone are all altered during gestation (12). These changes
may differentially program fetal trajectory of β-cell growth and glucose homeostasis
later in life. Further studies must be considered to determine whether these hormones
have gender specific effects.
Deficits in glucose tolerance may be the result of reduced islet vascularization
and therefore poor nutrient sensing or insulin delivery to target tissues. Prior LP
exposure was shown to decrease islet vasculature in rats at birth and in neonates
(1; 13). Long term deficits in islet vascularity could potentially contribute to β-cell
dysfunction and glucose intolerance. To address this possibility, vasculature in
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mouse pancreatic sections could be stained for platelet endothelial cell adhesion
marker - 1 (PECAM-1; CD31) in LP neonatal mice to determine if islet vascular loss
plays a role in alterations in endocrine function and growth.
The underlying cause of β-cell dysfunction may result from reduced expression of
genes important for the maintenance of glucose homeostasis such as insulin, Glut2 and
Gck. One of the main regulators of these genes is the transcription factor Pdx-1 (14-17).
A loss of Pdx-1 expression may explain the observed glucose intolerance in LP-fed
female offspring. Recently, Pdx-1 expression was found to be reduced at d14 and 3
months of age in offspring of rats that had undergone a bilateral uterine artery ligation
to induce IUGR (18). While the method of insult differs from the current study, nutrient
deficiency still occurs and these IUGR rat offspring also developed impaired glucose
tolerance (19). The authors proposed that epigenetic silencing of Pdx-1 expression was
responsible for the phenotype. Specifically, isolated islets from fetal, neonatal and adult
offspring were analyzed for alterations in epigenetic modifications at the Pdx-1
promoter (20). Control islets were associated with histone modifications indicative of
open chromatin favouring gene transcription, as well as a lack of DNA methylation of the
Pdx-1 promoter region. In contrast, islets from rats born with IUGR had a progressive
change in epigenetic markings in islet cells from fetal life until 6 months of age. Histone
markers of inactive chromatin were increased along with an increase in DNA
methylation of CpG islands in the Pdx-1 promoter. Progression of these modifications
paralleled the progressive decrease in Pdx-1 expression as glucose homeostasis
deteriorated in IUGR offspring. Based on our microarray analysis at day 30, female LP
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mice have a significant reduction in Pdx-1 expression. Therefore, it is possible that a
similar mechanism is responsible for the impaired glucose tolerance in the current study
with LP-fed mice.
Support has been emerging for the theory that reprogramming of mitochondrial
function is a key adaptation enabling the fetus to survive in a limited energy
environment (21-23). However, these alterations in mitochondrial function can have
deleterious effects in a nutrient-enriched environment postnatally. Previous microarray
studies in 3 month old LP rat offspring found that expression of cellular respiratory
genes were downregulated (24). This is consistent with the current observations in LP
mice, where 31 transcripts encoding for electron transport chain (ETC) enzyme subunits
were significantly altered in the LP group at d30. Similar observations were also found in
insulin target tissues, the liver and skeletal muscle, in microarray experiments conducted
in LP-fed C57Bl/6 mice at birth (25). Genes related to the mitochondria and more
specifically, oxidative phosphorylation, were the most over-represented genes altered in
the liver and skeletal muscle. Furthermore, measurements of oxidative phosphorylation
in the liver and skeletal muscle were reduced in IUGR rats induced by bilateral uterine
artery ligation, demonstrating mitochondrial dysfunction and reduced ATP production
(22; 23). Therefore, not only is the pancreas impacted by the fetal environment, but
programming of the mitochondria is also observed in other organs involved in glucose
homeostasis. Additionally, islets of IUGR rats were shown to have a gradual increase in
ROS production, oxidative stress and impaired ATP production with age (21).
Mitochondrial dysfunction resulted in impaired insulin secretion from isolated islets of
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IUGR rats. Here we have shown a decreased expression of genes encoding enzymes
involved in the mitochondrial transport chain and antioxidant enzymes, which are
important for ATP production and reduction of ROS, respectively. Together these
changes may result in decreased β-cell function and diminished insulin secretion leading
to glucose intolerance at adult age in LP mice. Future studies should measure the rate of
ATP production in isolated islets along with GSIS and the levels of ROS or markers of
oxidative damage.
The mechanism of poor fetal development and the risk for glucose intolerance
requires further investigation. While amino acids are important for fetal and neonatal
growth(26), these effects may be secondary to poor placental development and reduced
amino acid transporters (27). This may result in fetal hypoxia and reduce fetal plasma
amino acid levels, contributing to catabolism and reduced fetal growth. Future studies
should examine whether hormone or amino acid therapy can rescue the effects of LP on
placental development. As well, further analysis is required to determine the β-cell
specific changes in mitochondrial function and protein synthesis and whether epigenetic
changes are involved the pancreatic gene expression changes following LP. Lastly, an
altered diet can influence the gut microbiota and may impact host defence and risk of
metabolic disease (28; 29). Prebiotic administration to LP dams may be viable option for
rescuing the effects of on fetal growth and adult metabolism.
4.2. STZ-Induced Beta Cell Regeneration
In addition to examining the effects of fetal exposure to LP on endocrine pancreas
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development, we examined the capacity for β-cell regeneration in C and LP neonatal
mice. Partial β-cell destruction using multiple low doses of STZ was used to induce a
subsequent regeneration. Following 50-60% loss of β-cell mass, regeneration in both
male and female offspring of C-fed dams was observed by d30. In contrast, the single
dose STZ regimen in rats induces a 90% loss of β-cell volume followed by a recovery to
only 40% of the control values by 3 weeks (30; 31). Additionally, the capacity for
regeneration decreases with increasing age at administration of STZ (31). Therefore the
timing and STZ regimen used influences the degree of regeneration, so it is important to
select the appropriate model for the desired outcome. We used multiple low doses of
STZ in neonates with the expectation of a robust response for regeneration.
Despite regeneration of β-cell mass, male C+STZ mice remained hyperglycemic
throughout the period of study, while female mice maintained euglycemia. However,
recovery was not sustained as functional deficits developed at d42 marked by glucose
intolerance in both genders. We postulated that β-cells that survived following STZ
treatment may have become stressed by the increased metabolic demand and/or newly
regenerated β-cells were not fully mature leading to glucose intolerance at d42. Electron
microscopy could be performed on pancreatic sections at d42 to examine the
ultrastructural changes of the β-cell. Insulin granule number and granule maturity could
be determined to indicate insulin production and β-cell maturity, respectively, possibly
explaining the glucose intolerance observed at d42. Wang et al. noted that β-cells had
slightly uneven granulation in 6-20 week old STZ rats (31). Furthermore, 33% of male
C+STZ mice became overtly diabetic between 60-80 days of age and were sacrificed
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prior to d130. On the other hand, all female C+STZ mice survived to d130, but the β-cell
mass was significantly decreased. Impaired function observed at d42 may have resulted
in continued stress on the β-cell, leading to β-cell apoptosis and loss of β-cell mass by
d130. Although β-cell regeneration does occur following multiple low doses of STZ, this
is not sustained over the long term. This is consistent with previous studies in the STZ
treated rat, where long term diabetes develops even with an initial regeneration of βcells, with males developing diabetes earlier (31; 32). If stimulation of endogenous β-cell
regeneration is to be of therapeutic benefit, newly generated β-cells must be fully
capable of tight glucose regulation and maintain long term survival.
Previous research has also observed gender differences in response to STZ
exposure. It was found that STZ had an increased cytotoxicity in male mice compared to
females, leading to increased plasma glucose levels (33-35). Testosterone treatment in
females was shown to increase plasma glucose levels while castration of male mice led
to a reduction in glucose levels (33). On the other hand, estrogens appear to protect the
β-cell from STZ induced apoptosis (35; 36) which is supported by increased plasma
glucose levels following castration in female STZ treated mice (33). These findings are
consistent with the current results demonstrating that male C+STZ mice were
hyperglycemic throughout the study and became overtly diabetic between 60-80 days of
age, while the females were relatively euglycemic.
4.3. β-cell Regeneration in LP-Fed Offspring
In contrast to C-fed offspring, STZ treatment in neonatal LP offspring resulted in a
failure of β-cell regeneration. After an initial loss of ~50% of β-cell mass, both male and
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female LP+STZ mice had values of β-cell mass that were significantly lower than sham
injected LP mice at all time points measured. Changes in glucose homeostasis were
similar in male and female LP+STZ mice compared to their respective counterparts. The
survival in male LP+STZ mice was lower than in C+STZ mice at 33% versus 67%. These
findings are consistent with a study in which rat dams were 50% calorie restricted (R)
from day 15 of gestation until weaning and the offspring injected with a single dose of
STZ (100 mg/kg) at birth (37). β-cell mass regenerated rapidly by day 7 in STZ treated
rats of C-fed dams, however, the R+STZ rats showed poor regeneration out to day 21.
The observed impairment in β-cell regeneration was attributed to reduced neogenesis,
while β-cell proliferation was preserved. These results suggests two important findings:
1) protein restricted offspring lack the ability to expand β-cell mass which is of concern
under certain physiological conditions, such has pregnancy and obesity, where increased
β-cell mass is necessary to meet the insulin demand and 2) fetal programming may
affect key components of regeneration such as β-cell replication or precursor cell
differentiation, thereby limiting the possibility for therapeutic stimulation of
endogenous β-cell regeneration in diabetes.
4.4. The Mechanism of β-Cell Regeneration
The regeneration of β-cells may involve many components including β-cell
replication and/or precursor cell differentiation, a complex milieu of inflammatory or
growth factor stimuli, the extracellular matrix and supportive endothelial and bone
marrow cells. Examining the source of new β-cells, it was determined that male C+STZ
mice regenerate primarily through β-cell proliferation, while female C+STZ mice showed
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an increase in neogenesis and precursor cell differentiation. Whether the sex hormones
play a role in stimulation of β-cell proliferation or precursor cell differentiation remains
to be determined. Alternatively, β-cell proliferation was found to be increased following
short term in vivo glucose infusion in rats (38) and suggests that hyperglycemia in C+STZ
male mice stimulated β-cell proliferation primary to precursor differentiation. One could
argue that both proliferation and neogenesis occur in hyperglycemic environments
depending on the model (30; 39-41) and therefore glucose levels are unlikely to be the
cause of gender differences in the mechanism of regeneration.
Regeneration of β-cells in female C+STZ mice involved neogenesis and precursor cell
differentiation. A previous study used a lineage tracing model (RIP-CreER;Z/AP) to
specifically tag the insulin expressing cells with human placental alkaline phosphatase
(AP) (42). It was determined that following 70% partial pancreatectomy (Px),
regenerated β-cells were labelled with AP and therefore originated from β-cell
replication and not from stem/precursor cell differentiation (42). Lineage tracing has not
been used in STZ models, except to exclude bone marrow derived cells as a direct source
of insulin producing β-cells (43; 44). RIP-CreER;Z/AP transgenic mice have been
established in our laboratory and will be useful in support of the current study on the
origin of β-cells in STZ induced regeneration. To support the findings that female C+STZ
mice regenerate via neogenesis and precursor cell differentiation we would expect an
increased percentage of β-cells expressing insulin but lacking AP following STZ.
Attempts to characterize a pancreatic stem cell or β-cell precursor in the postnatal
pancreas have proven more difficult. One possible source of precursor cells may be the
152

subpopulation of cells within the islets we observed that expressed PDX-1 but lacked
insulin expression. During embryogenesis early pancreatic precursors are characterized
by PDX-1+/insulin— expression (45). Recently, Szabat et al. identified a population of
PDX-1+/insulinlow cells that convert to PDX-1+/insulin+ without cell division (46),
suggesting a potential precursor population that could be stimulated to increase β-cell
mass. Interestingly, in LP+STZ female mice there was a significantly higher proportion of
PDX-1+/Insulin— cells within the islets. This may represent an increase in the
somatostatin-producing δ-cell population since a subset of δ-cells in the normal
pancreas express Pdx-1 (40). A previous study found that 2 days after STZ treatment
there was a significant increase in the number of somatostatin+/PDX-1+ cells, which was
followed by differentiation to somatostatin+/PDX-1+/Ins+ and an increase in the number
of β-cells 5 days after STZ treatment (40). This leads to three potential explanations for
the observed increase in PDX-1+/Insulin— cells within the islets of LP+STZ mice. First, a
subset of δ-cells expressing PDX-1 represents a reserve pool of β-cell precursors that
proliferate and differentiate following β-cell loss (40). Second, δ-cells in general are βcell precursors and can initiate PDX-1 expression and further differentiate into β-cells.
Lastly, it is possible that the PDX-1+/Insulin— cells are not δ-cells and represent a
precursor population early in the β-cell differentiation pathway as observed during
pancreatic organogenesis. Further characterization of the PDX-1+/Insulin— population
through immunohistochemical staining for somatostatin and markers of β-cell
differentiation (early - NGN3, MAFB; late – MAFA, PAX6) will be important for use of
these putative precursors in therapeutic treatment. Despite the presence of PDX153

1+/Insulin— cells within the islets of LP+STZ mice, a concomitant increase in β-cell mass
did not occur. This may suggest that prior exposure to a LP diet negatively impacts the
differentiation of β-cell precursors during regeneration. These effects could result from a
lack of differentiation signals or epigenetic changes to downstream transcription factors,
NGN3andMAFA, restricting their expression.
The bone marrow compartment is a source of adult stem cells such as endothelial
progenitors (47; 48), mesenchymal cells which are capable of deriving bone, adipose and
cartilage (49) and also cells that can reconstitute the hematopoietic system (50). While
evidence has shown that bone marrow-derived cells do not differentiate into insulinproducing β-cells (51; 52), there has been strong support for the involvement of bone
marrow derived cells in β-cell regeneration (43; 53; 54). The original study found that
transplantation of ckit+ bone marrow-derived cells into STZ treated mice resulted in
improved glycemia, increased β-cell survival, insulin production, islet cell proliferation
and differentiation of donor derived cells into CD31+ endothelial cells (43). More
recently, endogenous bone marrow-derived cells were found to home to the injured
pancreas following STZ treatment and contributed to intra-islet angiogenesis leading to
β-cell regeneration (44). It is possible that LP fetal programming may alter the ability of
endogenous bone marrow cells to migrate to the injured pancreas and/or differentiate
into supportive vasculature leading to a failure of β-cell regeneration in LP+STZ mice. A
study examining LP rats found attenuated colony formation, proliferation, and
differentiation of bone marrow stromal cells in the offspring and that this may
contribute to delayed skeletal maturity with a delay in osteoblast activity (55). Other
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compartments of the bone marrow, such as the endothelial progenitors, may also be
altered by the LP diet and therefore limit the ability to support β-cell regeneration.
Endogenous bone marrow-derived stem cells can be tracked in vivo using a
transgenic mouse line (Vav-iCre; R26R-eYFP) that marks all hematopoietic lineage cells
with enhanced yellow fluorescent protein (YFP) (44). This transgenic mouse line could be
used to determine the impact of fetal protein restriction on migration and
differentiation of bone marrow-derived cells in the injured pancreas. Migration could be
measured by cell counts of YFP+ cells within the STZ pancreas, with and without prior
exposure to LP. Additionally, the number of YFP+/CD31+ cells would provide an
indication of the differentiation capability of bone marrow-derived cells in LP+STZ mice.
Alterations in either migration or differentiation may underlie the failure of regeneration
in LP+STZ mice. Rescue experiments could be performed in which YFP+ hematopoietic
cells from control donors can be transplanted into LP+STZ wild type recipients. β-cell
mass would be measured to determine the outcome of regeneration.
Bone marrow-derived cells and revascularization of the islets may provide a milieu
of growth factors and stimuli for regeneration of β-cells, however, other sources of
regenerative signals must also be considered. Recently one study suggested that β-cells
undergoing apoptosis may release factors that stimulate proliferation in nearby β-cells
(56). This was found to occur through the release of microparticles from apoptosing βcells, which stimulated increased expression of the PSP/reg (Reg1) and insulin genes and
increased proliferation (56). This may suggest that following STZ treatment, β-cells
undergoing apoptosis signal to nearby β-cells, stimulating proliferation in an attempt to
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increase β-cell mass. Alternatively, an inflammatory signal following STZ damage may
stimulate β-cell regeneration. While infiltrating leukocytes and overwhelming
inflammation were not observed in the current study, previously both human and
mouse islets were shown to increase interleukin-6 (IL-6) release in vitro in response to
metabolic stresses such as elevated glucose (57). Increasing local IL-6 levels may have
paracrine/autocrine effects related to β-cell regeneration. Interestingly, functional IL-6
response elements have been identified in the Reg1 promoter (58; 59). Furthermore,
Reg1 was found to be upregulated during β-cell regeneration (60; 61). These studies
suggest that microparticles or inflammatory signals such as IL-6 may be key stimulators
of regeneration acting through Reg1 to promote β-cell proliferation.
We used microarray analysis to identify candidate genes and signalling pathways as
putative regeneration signals. Members of the Reg family (Reg1, Reg3δ) and the Wnt
signalling pathway (Ctnnb1), as well as their downstream target genes, cyclin D1 (Ccnd1)
and Cdk4, were chosen as viable candidates. As described above, Reg1 has been
suggested to play a role in β-cell regeneration (60; 61), as well as other Reg genes, such
as INGAP (Reg3δ), Reg2, Reg3α (62-64). Signalling through β-catenin (CTNNB1) has also
been demonstrated to increase β-cell mass (65; 66). While whole pancreas analysis by
qPCR revealed differential expression of the candidate genes at d7, 14 and 30, islet
specific expression of Reg3δ, Ctnnb1, Ccnd1 and Cdk4 was quite low or undetermined
when sampled at d7. Islet specific expression of Reg1 mRNA was significantly increased
in LP+STZ islets. β-cell regeneration however failed in LP+STZ islets suggesting that the
islets attempted to stimulate regeneration through increased Reg1 expression.
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However, western blot analysis indicated a reduced protein level for REG1 in LP+STZ
islets may be the cause of failed β-cell regeneration. In contrast, the C-fed offspring
increased REG1 protein levels following STZ treatment which could account for β-cell
regeneration.
Given the significant increase in Reg1 mRNA expression, it was expected that
protein expression would also be elevated in LP+STZ islets. However, the reverse was
found. One possible explanation is that the protein is short lived due to a posttranslational modification targeting REG1 for degradation. Ubiquitination is a posttranslational modification in which the small highly conserved protein ubiquitin is
attached to substrate proteins via an enzymatic cascade, leading to a polyubiquitin
chain, and then the substrate is quickly captured and degraded by the 26S proteasome
(67). It is not known whether REG1 is susceptible to post-translational modifications,
however these events could represent a general effect of prior LP-feeding or a
regulatory mechanism to prevent high levels of growth factor expression, such as REG1.
Ubiquitin ligases recognize specific phosphorylated forms of the substrate (68),
therefore another consideration is the upregulation of protein kinases leading to
differential phosphorylation of REG1 post-translationally, ubiquitination and subsequent
proteasome degradation. The use of inhibitors of the proteasome, such as derivatives of
calpain inhibitors (68; 69), would establish the involvement of the ubiquitin-proteasome
pathway in Reg1 degradation. A second explanation for the low levels of REG1 in LP+STZ
islets would be alterations in protein biosynthesis. Based on microarray data from
pancreatic samples at d30, we observed a large number of genes, mostly
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downregulated, in LP offspring, suggesting a reduced capacity for or a dysfunction of
protein biosynthesis. In addition to protein formation, proper protein folding is required
for structure and function. REG1 contains 6 cysteines residues, suggesting the presence
of intramolecular disulfide bonds (70). Improper folding of REG1 could also lead to
degradation. Lastly, the demand for signalling molecules to stimulate β-cell regeneration
in LP+STZ mice would be elevated, as indicated by increased Reg1 mRNA levels, so
potentially REG1 is secreted at an increased rate and therefore islet content of REG1 is
reduced. To examine this possibility, isolated islets from all four groups can be cultured
in the presence of IL-6 and dexamethasone (59) or gastrin (71) to stimulate Reg1
expression, followed by measurements of REG1 secretion in the media and then
compared to the islet content.
In addition to looking at the microarray for candidate genes for β-cell regeneration,
we also followed up with the islet hormones. In particular, proglucagon gene expression
was found to be significantly upregulated with STZ treatment. However, pancreatic
glucagon content was unchanged compared to the sham injected group. Since glucagon
is a product of a prohormone, we considered the possibility of alternative processing
leading to increased production of glucagon-like peptide-1 (GLP-1) and found an
increased GLP-1 content in STZ treated offspring. In the intestinal L cell, proglucagon is
processed by prohormone convertase (PC) 1/3 to GLP-1, GLP-2 and glicentin, while the
α-cells primarily express PC2 and convert proglucagon into glucagon (72; 73). GLP-1 is
released from the intestinal L cells in response to nutrient ingestion to stimulate
glucose-dependent insulin secretion and inhibits gastric emptying and glucagon
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secretion (74; 75). GLP-1 also increases pancreatic insulin content and mRNA expression
of insulin, Glut2 and Gck (76; 77). Additionally, GLP-1 has been identified as a β-cell
survival factor, as GLP-1 signalling has been demonstrated to decrease apoptosis in STZ
treated mice and other models of diabetes (78-80).
Interestingly, observations suggest that GLP-1 acts as a trophic factor for β-cells.
Proliferation of β-cells has been shown both in vitro using the Ins1 cell line (81; 82) and
in vivo (39; 83-85). Studies also suggest that GLP-1 or GLP-1 receptor (GLP-1R) agonists
stimulate islet neogenesis in STZ treated or Px rats (39; 86). GLP-1R knockout mice had a
reduced capacity for β-cell regeneration following Px, suggesting a role for endogenous
GLP-1 in regeneration (87). Furthermore, STZ treated rats had an increase in GLP-1
content 8 days after STZ treatment which may be associated with precursor cell
differentiation and/or α-cell transdifferentiation (41). The potential of increasing local
GLP-1 would be a great advantage for β-cell regeneration and this may result from
alternative processing of the proglucagon hormone in α-cells as suggested previously
(41).
In the current study, the α-cell mass was unchanged in C+STZ mice, but proglucagon
mRNA was highly expressed and with an increased ratio of GLP-1 to glucagon content,
suggests a relative increased GLP-1 production following STZ. Therefore GLP-1 may play
a role in β-cell regeneration in C+STZ mice. The α-cell mass was reduced with prior LPfeeding, however the expression of the proglucagon gene was increased following STZ,
indicating that on a per α-cell basis there was a further increase in proglucagon gene
expression. Furthermore, the GLP-1/glucagon content ratio was increased, suggesting
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that prohormone processing further increases the GLP-1 product. Considering GLP-1
content was increased in LP+STZ mice but regeneration failed, there may be a defect in
the downstream signalling cascade. Moreover, GLP-1 has been shown to initiate PDX-1
expression in ducts, β-cells and undifferentiated precursors (83; 88-91). It is tempting to
speculate that GLP-1 signalling may increase PDX-1 expression in intra-islet precursor
cells, consistent with the increased presence of PDX-1+/insulin— cells in the LP+STZ
pancreas. However, further differentiation of PDX-1+/insulin— cells into mature β-cells
appears to be blocked given the reduced β-cell mass in LP+STZ mice.
Future experiments should examine isolated islets from LP offspring to determine
whether the defect in GLP-1 signalling occurs at the level of the receptor (measure
mRNA and protein levels) or the downstream targets. GLP-1 signalling through the GLP1R has been demonstrated to involve PI3k, AKT, MAPK and PKCζ (92-94). Western blot
analysis could be used to measure activation of downstream targets following GLP-1
treatment of islets from all four groups. Additionally, insulin content, GSIS and
proliferation can be measured following GLP-1 administration.
4.5. Limitations and Further Consideration
Immunohistological analysis of pancreatic tissues has long been the gold standard
for quantifying changes in islet mass. However, histology is a static measurement and
may not represent the true dynamics within the pancreas. Furthermore, antibody
specificity and quality vary and make consistent staining and analysis difficult. The need
for in vivo imaging of the β-cell has never been greater. This would allow for real-time
quantification of β-cell mass and would greatly benefit human studies. Currently the
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only evidence that can be obtained from humans is post-mortem analysis. Imaging β-cell
mass would allow for improved identification of β-cell loss and disease progression, as
well as monitoring survival of islet transplants. Magnetic resonance imaging (MRI) of
supraparamagnetic iron oxide labelled islets detected as few as 200 labelled islets
transplanted under the rat kidney capsule (95). In a similar study, labelled human islets
were transplanted into the portal vein of the mouse liver and the progressive loss of islet
mass was detected in real time using MRI (96). Another study used positron emission
tomography (PET) to image islets transplanted under the kidney capsule transfected
with a thymidine kinase that allows for retention of the contrast agent [18F]FHBG (97).
Islets had a strong PET signal within the kidney capsule and during peak response of a
glucose tolerance test, the PET signal was directly correlated with the peak insulin
response to glucose, showing that it was proportional to the insulin secretory capacity of
transplanted islets (97).
Another important consideration for immunohistochemical analysis of β-cell
regeneration is the use of lineage tracing models. Many studies over the years have
postulated the origin of new β-cells based on transcription factor and other marker gene
expression, as well as co-localization of heterogeneous cell markers. For example,
proliferation of α-cells and demonstration of co-localization of glucagon with PDX-1 or
GLUT2 during β-cell regeneration shows strong evidence for α- to β-cell
transdifferentiation (41). However, definitive evidence for this theory was demonstrated
by Thorel et al. (98) using lineage tracing to label the α-cells, which resulted in
regenerated β-cells also containing the label.
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Ultimately therapeutic interventions must be applicable to humans. However, it is
more feasible to use non-human primates and rodents for disease modelling. Careful
reflection must be used when translating observations from animal models to humans.
In humans, islet maturation is complete at birth, while in rodents this occurs by weaning
(99). For proper comparisons to be made with humans, extension of the LP diet until
weaning may be required. In adult humans there are approximately 0.05 replicating βcells per islet within typical histological sections (100), in contrast with mice at 1 year
which have ~0.50 replicating β-cells per islet (101). The greater capacity for β-cell
replication in mice is further evidenced by the tenfold increase in β-cell mass in response
to insulin resistance in obesity (101), while in humans long term morbid obesity seems
to result in only ~50% increase in β-cell mass (100). Nevertheless, it remains that
humans are capable of β-cell proliferation, even in older individuals with long-standing
type 1 diabetes (102), and neogenesis has also been suggested to occur (reviewed in
(103)). However, observations of islet neogenesis are largely based on associations of
single hormone positive cells within the ductal epithelium or small clusters that appear
to be “budding” from ducts. Again, lineage tracing is required, which cannot be
performed in humans, and in mice there is a lack of consensus for a true ductal marker
(SOX9 (104), HNF1β (105), CA II (106)).
While there is hope for endogenous β-cell regeneration, in the setting of type I
diabetes there is a requirement for immune suppression to prevent attack on newly
generated β-cells. In clinical trials, treatment with anti-CD3 antisera delayed progression
of diabetes through immune suppression in recent onset individuals (107). Current
162

immunosuppressant therapies in patients receiving islet transplantation have produced
many side effects (108). Additionally, immunosuppressive drugs may reduce β-cell
function, graft survival and proliferation (109-111). Therefore, the best treatment for
type 1 diabetes must combine a supply of functional β-cells sufficient to maintain proper
glucose regulation with an immunosuppressant regime without toxic side effects to the
individual or newly generated β-cells. Immune suppression is not required in type 2
diabetes and therefore endogenous regeneration may be more readily applied to type 2
diabetes to overcome the reduced β-cell function and mass.
4.6. Concluding Remarks
This study has established a mouse model for further study of mechanisms
underlying nutritional insults, such as LP, during fetal development and the increased
risk for impaired glucose tolerance in adulthood. This mouse model has the advantage of
using transgenic mice in future studies, over the well established LP rat model.
Additionally, results from the current study suggest that LP programming of
mitochondrial function may increase the susceptibility to pancreatic cell dysfunction.
Further consequences of the LP model include a reduced capacity for β-cell regeneration
following STZ induced β-cell loss. The ability to stimulate β-cell regeneration is a complex
prospect and based on the current study, may be dependent on the environmental
influences during fetal development. Moreover, these findings implicate a limited ability
to adapt to pathophysiological changes requiring increased β-cell mass such as in obesity
and pregnancy. In contrast, C-fed offspring demonstrated a significant capacity for β-cell
regeneration, which may involve β-cell replication or duct associated islet neogenesis
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and suggests that GLP-1 and/or REG1 may act to stimulate β-cell growth in the multiple
low dose STZ neonatal mouse model (Figure 4.1). Further studies are required to
determine how GLP-1 signalling is affected in LP offspring and whether this deficit can be
overcome to improve β-cell plasticity to prevent long term impairments in low birth
weight offspring. In conclusion, this study has provided a model that sheds light onto the
effects of LP exposure in utero on β-cell growth and development and the potential role
of GLP-1 and Reg1 following β-cell injury.
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Figure 4.1. Summary of β-cell plasticity in female offspring.
Following multiple low dose STZ treatment of female offspring from C-fed and LPfed dams, β-cell mass was reduced on d7 to 51% and 45% in C+STZ and LP+STZ mice,
respectively. (a) In C+STZ female offspring, protein levels from isolated islet for Reg1 and
pancreatic GLP-1 content were significantly increased at d7. Duct associated islet
neogenesis was increased at d7 and an islet progenitor population expressing Pdx+ but
lacking insulin was observed at d7 and 14. We postulate that increased levels of Reg1
(- -) and/or GLP-1 (—) may stimulate differentiation of ductal or islet progenitors leading
to regeneration of β-cell mass by d30. (b) On d7 and d14 there was a sginficantly
increased presence of islet progenitors but no increase in duct associated islet
neogenesis. GLP-1 content was increased at d7, but protein levels for Reg1 were
reduced. We hypothesize that in LP+STZ female mice, reduced progenitor cell
differentiation occurs as a result of a lack of Reg1 (- -) protein levels and/or the
downstream signalling pathway of GLP-1 (—) has been altered due to prior LP exposure,
leading to a failure in β-cell regeneration.
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Appendix
Appendix 1.1. Animal protocol approval
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Appendix 2. Immunohistochemistry Control Experiments
Appendix 2.1. Control staining for insulin and glucagon
Immunohistochemical staining was performed as described in the methods section
(Chapter 2.2) for insulin (a, b) and glucagon (c, d) with the omission of the primary
antibody (a, c) or the secondary antibody (b, d) to demonstrate specificity of the
reaction. Immunoadsorption with each primary antibody has been performed
previously. Primary antibodies used were rabbit anti-insulin and mouse anti-glucagon.
Magnification bar = 100 μm.
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Appendix 2.2. Control staining for insulin, glucagon and PCNA
Immunohistochemical staining was performed as described in the methods section
(Chapter 2.2) for insulin (a, b), glucagon (c, d) and PCNA (e, f) with the omission of the
primary antibody (a, c, e) or the secondary antibody (b, d, f) to demonstrate specificity
of the reaction. Primary antibodies used were guinea pig anti-insulin, rabbit antiglucagon and mouse anti-PCNA. Magnification bar = 100 μm.
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Appendix 2.3. Control stain for insulin and Pdx-1
Immunofluorescent staining was performed as described in the methods section
(Chapter 2.2). DAPI (a, c) nuclear stain was used to localize the islet. Omission of the
primary antibody for insulin (b) and Pdx-1 (d) was performed to demonstrate the
specificity of the reaction. Primary antibodies used were mouse anti-insulin and rabbit
anti-Pdx-1. Magnification bar = 250 μm.
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Appendix 3. Standard Curves
Appendix 3.1. ELISA standard curve
An ELISA was performed on serum samples to measure the insulin concentration at d7,
14 and 30 as described in the methods section (Chapter 2.2). A representative standard
curve from one experiment is shown here. Concentration on the x-axis is measured in
ng/mL.
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Appendix 3.2. BCA assay standard curve
The protein concentration of cell lysates from whole pancreas tissue used in RIA
experiments and lysates from isolated islets used in western blot analysis was quantified
using a micro BCA assay kit as described in the methods section (Chapter 3.2). A
representative standard curve from one experiment is shown here. Concentration on
the x-axis is measured in μg/mL.
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Appendix 3.3. RIA standard curve
Radioimmunoassays (RIA) were performed on whole pancreas lysates to measure
pancreatic content for insulin, glucagon and GLP-1 as described in the methods section
(Chapter 3.2). A representative standard curve from one experiment is shown here, with
radioactivity measured in counts per min on the y-axis.
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Appendix 4.1. RNA integrity
RNA samples extracted from whole pancreas tissue and isolated islets were sent to the
London Regional Genomics Center for qualitative analysis using the Agilent 2100
Bioanalyzer. Samples with an RNA Integrity Number (RIN) of at least 6 (a) were
considered acceptable for use in microarray and real-time PCR experiments. Panel b is
an example of a sample with a maximal RIN of 10 and the reference ladder is shown in
panel c. Images show the electropherogram on the left with the fluorescence labelled on
the y-axis and time on the x-axis. On the right is the gel-like image with 2 dark bands
corresponding to the 18s and 28s ribosomal bands. Quality of RNA samples were also
confirmed by spectophotometry. Samples were considered acceptable with an
absorbance ratio for the 260/280 values of 1.7-2.2.
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Appendix 5. Primer Validation
Appendix 5.1. RT-PCR experiments indicating appropriate size of expected products
RT-PCR was performed to confirm that each primer amplified the expected product at
the expected base pair size. Insulin I (134 bp), insulin II (90 bp), glucagon (147 bp), beta
catenin (117 bp), cyclin D1 (129 bp), Cdk4 (87 bp), Reg1 (103 bp), Reg3d (83 bp), 18s
(145 bp), cyclophilin A (102 bp). A previously tested primer set targeting a gene
encoding a cytoskeletal protein (known as 15/16) was used as a positive control (+Cnt;
200 bp). A negative control (-Cnt) consisted of a PCR reaction containing all reagents,
insulin I primers and ultra pure water substituted for cDNA.
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Appendix 5.2. Primer efficiency curves
Real-time RT-PCR was performed for each primer using a dilution series of input cDNA.
The log of the input cDNA was plotted against the threshold cycle (Ct) and the equation
for the line of best fit was determined. The slope of the curve indicates the efficiency of
the primer, with 100% efficiency equal to -3.32. Primer efficiencies were: insulin I –
111%, insulin II – 106%, glucagon – 98%, beta catenin – 102%, cyclin D1 – 76%, Cdk4 –
98%, Reg1 – 104%, Reg3δ – 98%, 18s – 90%, cyclophilin A – 106%. All primers were
determined to have a suitable efficiency for further experimental use. Primers evaluated
included insulin I, insulin II, glucagon, β-catenin, cyclin D1, Cdk4, Reg1, Reg3δ, 18s and
cyclophilin A.
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-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

Beta Catenin

33
31
29

y = -3.28x + 29.98

Ct

27
25
23
21
-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

Cyclin D1

37
35
33
Ct

y = -4.06x + 35.15

31
29
27
-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

Cdk4

35
33
Ct

31

y = -3.38x + 34.03

29
27
25
-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

188

Reg1

25
23
21

y = -3.24x + 22.33

Ct

19
17
15
13
-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

Reg3d

31
29
Ct

27
y = -3.17x + 28.58

25
23
21
-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

18s

19
17
15
Ct

y = -3.59x + 16.66

13
11
9
-0.5

0

0.5
1
1.5
Log cDNA input

2

2.5

Cyclophilin A

28
27

y = -3.182x + 29.58

Ct

26
25
24
23
-0.5

0

0.5

1
1.5
Log cDNA input

2

2.5
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Appendix 6.1. Specificity of Reg1 antibody in western blot analysis
Western blot analysis was performed using protein lysates from cells of the rat
insulinoma cell line, Ins1, freshly isolated islets and whole pancreas tissue. (a)
Immunoblotting for beta actin (42 kDa) was observed in all 3 samples. (b) Reg1 (14 kDa)
protein was expressed in islets and pancreas samples but not in the cell line Ins1, as
expected, showing specificity of the Reg1 antibody.
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Appendix 7. Microarray Data
Appendix 7.1. Significantly altered genes in the C+STZ group compared to the C+sham
group
Differentially expressed genes between the four groups were selected based on a pvalue cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference
from the C+sham group. A 2-way ANOVA was performed with a Student Newman-Keuls
post test.
Gene Symbol

Gene Title

Iapp
G6pc2
Iapp
Ins1
Iapp
Ins2
Iapp
Mat2a
Mat2a
Mat2a
Mat2a
Neat1
Sfi1
Scg2
Tmem27
--Sfrs7
Tuba1b
Slc2a2
Mat2a
Nelf
Pcsk2
Mat2a

islet amyloid polypeptide
glucose-6-phosphatase, catalytic, 2
islet amyloid polypeptide
insulin I
islet amyloid polypeptide
insulin II
islet amyloid polypeptide
methionine adenosyltransferase II, alpha
methionine adenosyltransferase II, alpha
methionine adenosyltransferase II, alpha
methionine adenosyltransferase II, alpha
nuclear paraspeckle assembly transcript 1 (non-protein coding)
Sfi1 homolog, spindle assembly associated (yeast)
secretogranin II
transmembrane protein 27
--splicing factor, arginine/serine-rich 7
tubulin, alpha 1B
solute carrier family 2 (facilitated glucose transporter), member 2
methionine adenosyltransferase II, alpha
nasal embryonic LHRH factor
proprotein convertase subtilisin/kexin type 2
methionine adenosyltransferase II, alpha
solute carrier family 25 (mitochondrial carrier, adenine nucleotide
translocator
hexosaminidase B
heterogeneous nuclear ribonucleoprotein D-like
peptidylprolyl isomerase C
cyclin D1
suppressor of cytokine signaling 3
chromogranin A
cytotoxic granule-associated RNA binding protein 1
proprotein convertase subtilisin/kexin type 2
insulinoma-associated 1
transformation related protein 53 binding protein 1
neurexophilin 2
coiled-coil domain containing 34
hook homolog 1 (Drosophila)

Slc25a4
Hexb
Hnrpdl
Ppic
Ccnd1
Socs3
Chga
Tia1
Pcsk2
Insm1
Trp53bp1
Nxph2
Ccdc34
Hook1

p-value
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Fold
change

0.002
0.001
0.005
0.001
0.004
0.002
0.003
0.029
0.036
0.029
0.032
0.004
0.022
0.026
0.020
0.001
0.047
0.021
0.004
0.041
0.009
0.015
0.023

-5.32
-5.25
-5.02
-4.96
-3.79
-3.29
-3.29
-3.12
-2.84
-2.78
-2.78
-2.33
-2.11
-2.02
-2.00
-1.99
-1.99
-1.91
-1.91
-1.88
-1.84
-1.83
-1.83

0.020
0.030
0.006
0.035
0.048
0.020
0.026
0.046
0.005
0.008
0.036
0.032
0.028
0.009

-1.78
-1.76
-1.75
-1.72
-1.72
-1.71
-1.70
-1.69
-1.68
-1.67
-1.66
-1.66
-1.66
-1.65

D0H4S114
Hells
Pnn
Tmem57
Dnaja1
Nfkbiz
Ddx5
Luc7l2
Gm6159/Hnrnpr
Shcbp1
Cdca8
Pisd/Pisd-ps1/Pisd-ps3
Sf3b1
Papss2
Zfp799
LOC632664/Ptprg
Sfpq
Tmem107
Rab11fip2
5830433M19Rik
6720475J19Rik
BC088983
Pycard
Actb
Tsc22d3
Gm7120
Ndufa6
Ndufc1
9130219A07Rik
Myc
Gm10094/Sap18
Slc19a2
Gm12844/Rhoa
AI646023
Slc19a2
Snd1
Sdf2l1
Pim3
--1200015M12Rik/1200016E2
4Rik/A130040M12Rik/
E430024C06Rik
1810009J06Rik/Gm2663

DNA segment, human D4S114
helicase, lymphoid specific
pinin
transmembrane protein 57
DnaJ (Hsp40) homolog, subfamily A, member 1
nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, ze
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
LUC7-like 2 (S. cerevisiae)
predicted gene 6159/heterogeneous nuclear ribonucleoprotein R
Shc SH2-domain binding protein 1
cell division cycle associated 8
phosphatidylserine decarboxylase/phosphatidylserine decarboxylase,
pseudogene
splicing factor 3b, subunit 1
3'-phosphoadenosine 5'-phosphosulfate synthase 2
zinc finger protein 799
similar to protein tyrosine phosphatase, receptor type, G/protein
tyrosine phosphatse
splicing factor proline/glutamine rich (polypyrimidine tract binding
protein associated
transmembrane protein 107
RAB11 family interacting protein 2 (class I)
RIKEN cDNA 5830433M19 gene
RIKEN cDNA 6720475J19 gene
cDNA sequence BC088983
PYD and CARD domain containing
actin, beta
TSC22 domain family, member 3
predicted gene 7120
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14)
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1
RIKEN cDNA 9130219A07 gene
myelocytomatosis oncogene
predicted gene 10094/Sin3-associated polypeptide 18
solute carrier family 19 (thiamine transporter), member 2
predicted gene 12844/ras homolog gene family, member A
expressed sequence AI646023
solute carrier family 19 (thiamine transporter), member 2
staphylococcal nuclease and tudor domain containing 1
stromal cell-derived factor 2-like 1
proviral integration site 3
--RIKEN cDNA 1200015M12 gene/RIKEN cDNA 1200016E24 gene/RIKEN
cDNA A130040
RIKEN cDNA 1810009J06 gene/predicted gene 2663
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0.024
0.044
0.032
0.010
0.041

-1.65
-1.64
-1.64
-1.63
-1.62

0.018
0.048
0.026
0.041
0.026
0.048

-1.61
-1.61
-1.60
-1.59
-1.57
-1.56

0.025
0.020
0.001
0.010

-1.56
-1.56
-1.56
-1.55

0.050

-1.54

0.022
0.006
0.038
0.041
0.012
0.029
0.018
0.008
0.049
0.022
0.034
0.028
0.028
0.033
0.033
0.029
0.042
0.044
0.012
0.035
0.044
0.010
0.046

-1.54
-1.53
-1.53
-1.53
-1.51
-1.51
-1.50
1.52
1.53
1.54
1.54
1.55
1.56
1.59
1.62
1.66
1.69
1.89
1.94
2.20
2.27
2.29
2.35

0.049
0.032

3.49
3.62

Appendix 7.2. Significantly altered genes in the LP+sham group compared to the
C+sham group
Differentially expressed genes between the four groups were selected based on a pvalue cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference
from the C+sham group. A 2-way ANOVA was performed with a Student Newman-Keuls
post test.
Gene Symbol

Gene Title

Iapp
G6pc2
Iapp
Iapp
Gcg
Iapp
Mat2a
Mat2a
Mat2a
Mat2a
Tmem27
Hba-a1/Hba-a2
Ins1
Mat2a
Hbb-b1/Hbb-b2
Sfrs7
Tuba1b
Ins2
Tubb2a
Ddx17
Vim
Rpl13a/Zfp526
Snhg1

islet amyloid polypeptide
glucose-6-phosphatase, catalytic, 2
islet amyloid polypeptide
islet amyloid polypeptide
glucagon
islet amyloid polypeptide
methionine adenosyltransferase II, alpha
methionine adenosyltransferase II, alpha
methionine adenosyltransferase II, alpha
methionine adenosyltransferase II, alpha
transmembrane protein 27
hemoglobin alpha, adult chain 1/hemoglobin alpha, adult chain 2
insulin I
methionine adenosyltransferase II, alpha
hemoglobin, beta adult major chain/hemoglobin, beta adult minor chain
splicing factor, arginine/serine-rich 7
tubulin, alpha 1B
insulin II
tubulin, beta 2A
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
vimentin
ribosomal protein L13A/zinc finger protein 526
small nucleolar RNA host gene (non-protein coding) 1
similar to RAN, member RAS oncogene family/RAN, member RAS
oncogene family
similar to RAN, member RAS oncogene family/similar to RAN, member
RAS oncogene family

LOC100045999/Ran
LOC100045999/
LOC640204/Ran
Gm10164/Gm10223/
Gm10268/Gm10362/
Gm4329/Gm6133/Hk1/
LOC100048040/Rpl17
--Ankrd10
Vim
Sh3bgrl
--Rps18
Rpl13a
Rps12
1110067D22Rik

p-value

ribosomal protein L17 pseudogene/ribosomal protein L17
pseudogene/predicted
--ankyrin repeat domain 10
vimentin
SH3-binding domain glutamic acid-rich protein like
--ribosomal protein S18
ribosomal protein L13A
ribosomal protein S12
RIKEN cDNA 1110067D22 gene

193

Fold
change

0.007
0.001
0.006
0.005
0.017
0.003
0.024
0.021
0.020
0.023
0.003
0.040
0.011
0.029
0.013
0.014
0.006
0.014
0.017
0.026
0.025
0.003
0.041

-3.75
-3.69
-3.44
-3.17
-2.97
-2.95
-2.93
-2.90
-2.72
-2.70
-2.50
-2.45
-2.43
-2.40
-2.38
-2.29
-2.16
-2.12
-2.06
-2.05
-2.05
-2.03
-2.00

0.020

-1.96

0.023

-1.95

0.003
0.001
0.005
0.019
0.006
0.001
0.009
0.004
0.006
0.031

-1.94
-1.92
-1.91
-1.90
-1.89
-1.86
-1.86
-1.85
-1.85
-1.84

Gm8203/H2afz
D0H4S114
LOC100045999/Ran
Rpl9
Nme2
Ndufb9
Mat2a
Marcks
3300001P08Rik
LOC100045999/Ran
Sst
Ppib
Aplnr
Rpl34
Col3a1
Tia1
Gm9844/LOC100048142/
Tmsb10
Scg2
Rpl22
Gm10241/Gm13430/
Gm13690/ LOC100046167/
Sumo2
Rps27l
Sfi1
Gm1821/ Gm8441/
LOC218963/ Ubb
Rps21
Hint1
Mat2a
Gm10257/ Gm8524/ H3f3a/
H3f3c/ LOC100045490
H2afz
Rps21
Gm10164/ Gm10223/
Gm10294/ LOC100041933/
LOC100046300/
LOC100047874/ Rpl17
Cpe/ LOC100046434
1810073G21Rik
Gm10117/ Gm7206/
Gm9822/ Rpl9
Rps21
Ndufb6
Polr3k
Hax1
Sdpr
Tmem204
Rnaset2a/ Rnaset2b
Rps27l
Rpl22l1
Tuba1a
Ddx5
Eif3i
Gm10164/ Gm10223/
Gm10294/ LOC100041933/
LOC100046300/ Rpl17

predicted gene 8203/H2A histone family, member Z
DNA segment, human D4S114
similar to RAN, member RAS oncogene family/RAN, member RAS
oncogene family
Ribosomal protein L9
non-metastatic cells 2, protein (NM23B) expressed in
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9
methionine adenosyltransferase II, alpha
myristoylated alanine rich protein kinase C substrate
RIKEN cDNA 3300001P08 gene
similar to RAN, member RAS oncogene family/RAN, member RAS
oncogene family
somatostatin
peptidylprolyl isomerase B
apelin receptor
ribosomal protein L34
collagen, type III, alpha 1
cytotoxic granule-associated RNA binding protein 1
predicted gene 9844/similar to thymosin, beta 10/thymosin, beta 10
secretogranin II
ribosomal protein L22
predicted gene 10241/ predicted gene 13430/ predicted gene 13690/
similar
ribosomal protein S27-like
Sfi1 homolog, spindle assembly associated (yeast)
predicted gene 1821/ predicted gene 8441/ ubiquitin pseudogene/
ubiquitin
ribosomal protein S21
histidine triad nucleotide binding protein 1
methionine adenosyltransferase II, alpha
predicted gene 10257/ predicted gene 8524/ H3 histone, family 3A/ H3
hi
H2A histone family, member Z
ribosomal protein S21

0.009
0.006

-1.84
-1.84

0.033
0.009
0.006
0.006
0.032
0.001
0.004

-1.84
-1.83
-1.83
-1.83
-1.83
-1.82
-1.81

0.020
0.017
0.025
0.010
0.013
0.038
0.019

-1.81
-1.81
-1.81
-1.80
-1.80
-1.80
-1.80

0.010
0.036
0.004

-1.80
-1.79
-1.79

0.007
0.017
0.039

-1.79
-1.79
-1.79

0.005
0.007
0.011
0.019

-1.78
-1.77
-1.77
-1.77

0.004
0.016
0.007

-1.76
-1.76
-1.76

ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/
predicted
carboxypeptidase E/ similar to carboxypeptidase E
RIKEN cDNA 1810073G21 gene
ribosomal protein L9 pseudogene/ predicted gene 7206/ ribosomal
protein L9
ribosomal protein S21
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6
polymerase (RNA) III (DNA directed) polypeptide K
HCLS1 associated X-1
serum deprivation response
transmembrane protein 204
ribonuclease T2A/ ribonuclease T2B
ribosomal protein S27-like
ribosomal protein L22 like 1
tubulin, alpha 1A
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
eukaryotic translation initiation factor 3, subunit I

0.006
0.028
0.039

-1.76
-1.76
-1.76

0.006
0.019
0.006
0.049
0.006
0.002
0.003
0.005
0.015
0.011
0.011
0.016
0.006

-1.76
-1.75
-1.75
-1.74
-1.74
-1.74
-1.74
-1.74
-1.73
-1.73
-1.73
-1.73
-1.73

ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/
predicted

0.010

-1.72
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Gm15500/ Rpl5
Gm15365/ Tomm20
Rpl26
D030056L22Rik
Chchd2/ LOC100045688
Rps10
Chac2
Rps21
Nfkbiz
Sfpq
Tra2b
--Trp53bp1
Rpl35
Ogt
Slc2a2
Ywhab
Cox6a1
Cnn3/ LOC100047856
Prdx4
Rpl13a
Gm10027/ Gm10260/ Rps18
Cav1
Gm6722/ H2afz
Dnpep
Atp5f1
Cox6b1
Sepp1
Rpl35
Rps11
Dbi
Gm11263/ Gm13654/
Gm14138/ Gm6476/
Gm8779/ LOC100043734/
LOC236932/ LOC639593/
Rps6
Rps8
Rps24
Prss3
Ppic
--Atp5h
Gm2962/ Uqcrb
Morf4l1
Sdpr
Gm6948/ Gm8942/
LOC677113/ Rps24
--Gm15451/ Rpl10a
Fam96a
Rpl34

predicted gene 15500/ ribosomal protein L5
predicted gene 15365/ translocase of outer mitochondrial membrane
20 homolog
ribosomal protein L26
RIKEN cDNA D030056L22 gene
coiled-coil-helix-coiled-coil-helix domain containing 2/ similar to coiledcoil
ribosomal protein S10
ChaC, cation transport regulator homolog 2 (E. coli)
ribosomal protein S21
nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, ze
splicing factor proline/glutamine rich (polypyrimidine tract binding
protein associated)
transformer 2 beta homolog (Drosophila)
--transformation related protein 53 binding protein 1
ribosomal protein L35
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-Nacetylglucosamine:polyp
solute carrier family 2 (facilitated glucose transporter), member 2
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation
protein, beta pol
cytochrome c oxidase, subunit VI a, polypeptide 1
calponin 3, acidic/ similar to calponin 3, acidic
peroxiredoxin 4
ribosomal protein L13A
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal
protein
caveolin 1, caveolae protein
predicted gene 6722/ H2A histone family, member Z
aspartyl aminopeptidase
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b,
isoform 1
cytochrome c oxidase, subunit VIb polypeptide 1
selenoprotein P, plasma, 1
ribosomal protein L35
ribosomal protein S11
diazepam binding inhibitor

predicted gene 11263/ predicted gene 13654/ 40S ribosomal protein S6
(Phos
ribosomal protein S8
ribosomal protein S24
protease, serine, 3
peptidylprolyl isomerase C
--ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d
predicted gene 2962/ ubiquinol-cytochrome c reductase binding protein
mortality factor 4 like 1
serum deprivation response
ribosomal protein S24 pseudogene/ predicted gene 8942/ similar to
ribosomal
--ribosomal protein L10a pseudogene/ ribosomal protein L10A
family with sequence similarity 96, member A
ribosomal protein L34
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0.007

-1.72

0.035
0.012
0.001

-1.72
-1.72
-1.72

0.010
0.006
0.032
0.009

-1.71
-1.71
-1.71
-1.71

0.006

-1.71

0.005
0.033
0.001
0.019
0.009

-1.71
-1.71
-1.71
-1.71
-1.71

0.027
0.006

-1.70
-1.70

0.040
0.026
0.038
0.013
0.006

-1.70
-1.70
-1.70
-1.70
-1.69

0.019
0.007
0.041
0.025

-1.69
-1.69
-1.69
-1.69

0.010
0.006
0.006
0.010
0.008
0.011

-1.69
-1.69
-1.69
-1.69
-1.69
-1.68

0.033
0.006
0.008
0.005
0.026
0.021
0.003
0.034
0.005
0.046

-1.68
-1.68
-1.68
-1.68
-1.68
-1.68
-1.68
-1.68
-1.68
-1.68

0.016
0.001
0.010
0.003
0.017

-1.68
-1.68
-1.67
-1.67
-1.67

Psma7
Rpl3
Ero1l/ Gm10191/ Gm13004/
Gm16382/ Gm7689/
Gm9401/ LOC638399/
LOC675018/ Rpl31
Rps5
Pcsk2
Rps14
Emp1
Ero1l/ Rpl31
Sec61b
Gm5805/ Rps14
Prdx1
Ggh
Romo1
Oaz1
Rpl13a
Pcsk2
Cald1
Rps3
Eif4g2
Btf3
Qdpr
Gm10071/ Gm12918/
Gm15710/ Gm5075/
Gm9026/ LOC674921/ Rpl13
Gm11263/ Gm13654/
LOC100043734/ LOC236932/
Rps6
Tmsb4x
Macrod2
Atp5k
Ndufb9
Eif5a
Gm9354/ LOC100042019/
Rps27a
Cox5a
Tsc22d1
Gm10213/ Gm10247/
Gm10296/ Gm15434/ Ino80/
LOC100046034/
mCG_133520/ Rpl35a
Anxa2
--Gm10119/ Gm9000/ Rps3a
Tmem208
Rpl35
Dnpep
Tpm4
Rps10
Rpl19
Rps24
Rpl15
Actb
Rpsa
Sec11c
Gm10443/ LOC100044740/
Rps28

proteasome (prosome, macropain) subunit, alpha type 7
ribosomal protein L3

0.014
0.008

-1.67
-1.67

ERO1-like (S. cerevisiae)/ predicted gene 10191/ predicted gene 13004/
ribosomal protein S5
proprotein convertase subtilisin/kexin type 2
ribosomal protein S14
epithelial membrane protein 1
ERO1-like (S. cerevisiae)/ ribosomal protein L31
Sec61 beta subunit
predicted gene 5805/ ribosomal protein S14
peroxiredoxin 1
gamma-glutamyl hydrolase
reactive oxygen species modulator 1
ornithine decarboxylase antizyme 1
ribosomal protein L13A
proprotein convertase subtilisin/kexin type 2
caldesmon 1
ribosomal protein S3
eukaryotic translation initiation factor 4, gamma 2
basic transcription factor 3
quinoid dihydropteridine reductase

0.008
0.012
0.020
0.007
0.016
0.009
0.013
0.008
0.015
0.025
0.013
0.021
0.007
0.003
0.002
0.009
0.032
0.016
0.010

-1.67
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.64
-1.64
-1.64

predicted gene 10071/ predicted gene 12918/ predicted gene 15710/
predicted

0.015

-1.64

0.011
0.010
0.004
0.020
0.010
0.040

-1.64
-1.64
-1.64
-1.64
-1.64
-1.64

0.006
0.012
0.050

-1.64
-1.64
-1.64

0.011
0.019
0.013
0.022
0.009
0.014
0.048
0.010
0.011
0.013
0.014
0.012
0.039
0.008
0.010

-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62

0.008

-1.62

predicted gene 11263/ predicted gene 13654/ similar to ribosomal
protein S
thymosin, beta 4, X chromosome
MACRO domain containing 2
ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9
eukaryotic translation initiation factor 5A
predicted gene 9354/ similar to fusion protein: ubiquitin (bases
43_513); rib
cytochrome c oxidase, subunit Va
TSC22 domain family, member 1
ribosomal protein L35a pseudogene/ predicted gene 10247/ ribosomal
protein
annexin A2
--predicted gene 10119/ predicted gene 9000/ ribosomal protein S3A
transmembrane protein 208
ribosomal protein L35
aspartyl aminopeptidase
tropomyosin 4
ribosomal protein S10
ribosomal protein L19
ribosomal protein S24
ribosomal protein L15
actin, beta
ribosomal protein SA
SEC11 homolog C (S. cerevisiae)
predicted gene 10443/ similar to ribosomal protein S28/ ribosomal
protein
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Hnrnpa2b1
Rpl39
Myeov2
Hnrpdl
Eef1b2
Gm13654/ Rps6
Nxph2
Myadm
Tsc22d1
Prdx1
Rps24
Prdx4
Fabp4
EG436523/ Gm10334/ Prss1/
Prss3
Rpl7a
Tomm20
Ndufb11
1110003E01Rik
Morf4l1
Rps4x
1810027O10Rik
Matr3
Cd34
Eif1
Gt(ROSA)26Sor
Serf2
Sep-07
EG668525
Prdx1
Gm13654/ Rps6
Col4a1
Vamp3
Eif2s2
Gng10
Gm10443/ Rps28
Tomm20
Gm10191/ Gm16382/
Gm7689/ LOC638399/
LOC675018/ Rpl31
Nfe2l2
Hnrnph1
Ppia
Gm11793/ Hnrnpf
Rps8
Ndufab1
Lrpap1
Rps7
Igfbp4
Myeov2
Hexb
Rpl14
Atp5j2
Rpl14
Gm4076
Gm10269/ Gm4342/ Rpl35
Cox6c
Itm2b

heterogeneous nuclear ribonucleoprotein A2/B1
ribosomal protein L39
myeloma overexpressed 2
heterogeneous nuclear ribonucleoprotein D-like
eukaryotic translation elongation factor 1 beta 2
predicted gene 13654/ ribosomal protein S6
neurexophilin 2
myeloid-associated differentiation marker
TSC22 domain family, member 1
peroxiredoxin 1
ribosomal protein S24
peroxiredoxin 4
fatty acid binding protein 4, adipocyte
predicted gene, EG436523/ predicted gene 10334/ protease, serine, 1
(trypsin)
ribosomal protein L7A
translocase of outer mitochondrial membrane 20 homolog (yeast)
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11
RIKEN cDNA 1110003E01 gene
mortality factor 4 like 1
ribosomal protein S4, X-linked
RIKEN cDNA 1810027O10 gene
matrin 3
CD34 antigen
eukaryotic translation initiation factor 1
gene trap ROSA 26, Philippe Soriano
small EDRK-rich factor 2
septin 7
Predicted gene, EG668525
peroxiredoxin 1
predicted gene 13654/ ribosomal protein S6
collagen, type IV, alpha 1
vesicle-associated membrane protein 3
eukaryotic translation initiation factor 2, subunit 2 (beta)
guanine nucleotide binding protein (G protein), gamma 10
predicted gene 10443/ ribosomal protein S28
translocase of outer mitochondrial membrane 20 homolog (yeast)
predicted gene 10191/ ribosomal protein L31 pseudogene/ predicted
gene 768
nuclear factor, erythroid derived 2, like 2
heterogeneous nuclear ribonucleoprotein H1
peptidylprolyl isomerase A
predicted gene 11793/ heterogeneous nuclear ribonucleoprotein F
ribosomal protein S8
NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1
low density lipoprotein receptor-related protein associated protein 1
ribosomal protein S7
insulin-like growth factor binding protein 4
myeloma overexpressed 2
hexosaminidase B
ribosomal protein L14
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f,
isoform 2
ribosomal protein L14
predicted gene 4076
predicted gene 10269/ predicted gene 4342/ ribosomal protein L35
cytochrome c oxidase, subunit VIc
integral membrane protein 2B
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0.016
0.011
0.006
0.008
0.009
0.005
0.026
0.001
0.013
0.018
0.014
0.020
0.024

-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.61
-1.61
-1.61
-1.61
-1.61

0.003
0.007
0.049
0.006
0.014
0.006
0.020
0.010
0.042
0.023
0.013
0.015
0.006
0.009
0.009
0.014
0.009
0.034
0.000
0.049
0.042
0.013
0.043

-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60

0.011
0.004
0.025
0.043
0.019
0.016
0.011
0.037
0.018
0.010
0.030
0.042
0.013

-1.60
-1.60
-1.60
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59

0.029
0.020
0.027
0.013
0.002
0.011

-1.59
-1.59
-1.59
-1.59
-1.59
-1.59

H47
Reep5
Tff2
Rpl10
Gm10027/ Gm10260/ Rps18
Zzz3
Eif3i
Glrx3
Pisd/ Pisd-ps1/ Pisd-ps3
Hnrpdl
Gm10079/ LOC100047501/
Rps16
Kpna2
--Serf2
Gm10063/ Gm12334/
Gm5462/ Gm7567/ Gm9153/
LOC676277/ Rps12
Cox7a2
Ptn
--Tmem107
Rpl7
Ndufa1
Sfrs11
P4hb
1810028F09Rik
--Arl1
H47
9430020K01Rik
Gm13819/Gm2423/ Ywhaq
--1110028C15Rik
Mrpl13
Akr1a4
Polr1d
Brp44
Rpl21
Mgst1
Gm11793/Hnrnpf
4933421E11Rik
Neat1
Xbp1
--Serpini2
Epas1
Gm10443/Rps28
LOC100046668/Rps23
Psmb4
Hnrnph1
Gm12270/Gm15483/
Gm6573/Gm6834/
LOC100044992/Rps13
---

histocompatibility 47
receptor accessory protein 5
trefoil factor 2 (spasmolytic protein 1)
ribosomal protein 10
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal
protein
zinc finger, ZZ domain containing 3
eukaryotic translation initiation factor 3, subunit I
glutaredoxin 3
phosphatidylserine decarboxylase/phosphatidylserine decarboxylase,
pseudogene
heterogeneous nuclear ribonucleoprotein D-like
ribosomal protein S16 pseudogene/ ribosomal protein S16 pseudogene/
riboso
karyopherin (importin) alpha 2
--small EDRK-rich factor 2
predicted gene 10063/ predicted gene 12334/ ribosomal protein S12
pseudoge
cytochrome c oxidase, subunit VIIa 2
pleiotrophin
--transmembrane protein 107
ribosomal protein L7
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1
splicing factor, arginine/serine-rich 11
prolyl 4-hydroxylase, beta polypeptide
RIKEN cDNA 1810028F09 gene
--ADP-ribosylation factor-like 1
histocompatibility 47
RIKEN cDNA 9430020K01 gene
predicted gene 13819/ predicted gene 2423/ tyrosine 3monooxygenase/trypto
--RIKEN cDNA 1110028C15 gene
mitochondrial ribosomal protein L13
aldo-keto reductase family 1, member A4 (aldehyde reductase)
polymerase (RNA) I polypeptide D
brain protein 44
ribosomal protein L21
microsomal glutathione S-transferase 1
predicted gene 11793/heterogeneous nuclear ribonucleoprotein F
RIKEN cDNA 4933421E11 gene
nuclear paraspeckle assembly transcript 1 (non-protein coding)
X-box binding protein 1
--serine (or cysteine) peptidase inhibitor, clade I, member 2
endothelial PAS domain protein 1
predicted gene 10443/ribosomal protein S28
similar to yeast ribosomal protein S28 homologue/ribosomal protein
S23
proteasome (prosome, macropain) subunit, beta type 4
Heterogeneous nuclear ribonucleoprotein H1
predicted gene 12270/predicted gene 15483/ribosomal protein S13
pseudogene
---
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0.021
0.024
0.007
0.006

-1.58
-1.58
-1.58
-1.58

0.015
0.010
0.013
0.008

-1.58
-1.58
-1.58
-1.58

0.014
0.006

-1.58
-1.58

0.012
0.037
0.004
0.009

-1.58
-1.58
-1.57
-1.57

0.009
0.020
0.023
0.015
0.002
0.022
0.019
0.023
0.027
0.049
0.018
0.013
0.010
0.000

-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.56

0.010
0.011
0.015
0.003
0.042
0.003
0.020
0.021
0.018
0.017
0.010
0.046
0.013
0.019
0.033
0.046
0.017

-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56

0.013
0.013
0.027

-1.55
-1.55
-1.55

0.010
0.001

-1.55
-1.55

Gnb2l1
Chfr
Gm5963/Rps21
Uba2
Rps27l
Rpl14
S100a11
Gstp1
Gm6573/Gm6834/
LOC100044992/Rps13
Rpl18
Sypl
Rpl35
--Vamp3
Pdia2
Rps15a
Marcks
Serf2
Eef1g/LOC100047986
--Krtcap2
Prdx1
Ythdc1
Fbxo22
Ndufb8
Sparc
Rpl13
Gm13020/Gm7379/Rpl38
Cox4i1
Atp6v0b
Rpl7
Rpl6
Gdi2
Atp5h
Gm3244/Ndufb4
Dbi
Gja1
Dynlt3
Rpl23a
Tmed10
Ccdc72
Gja1
Ndufb11
Rgs5
Cnn3/LOC100047856
Cst3
Mff
Rps10
Igf1
Rps20
--Acat1
Acat1
Gm11599/Gm11687/
Gm12091/Gm12366/

guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1
checkpoint with forkhead and ring finger domains
predicted gene 5963/ribosomal protein S21
ubiquitin-like modifier activating enzyme 2
ribosomal protein S27-like
ribosomal protein L14
S100 calcium binding protein A11 (calgizzarin)
glutathione S-transferase, pi 1
ribosomal protein S13 pseudogene/predicted gene 6834/similar to
ribosomal S13
ribosomal protein L18
synaptophysin-like protein
ribosomal protein L35
--vesicle-associated membrane protein 3
protein disulfide isomerase associated 2
ribosomal protein S15A
myristoylated alanine rich protein kinase C substrate
small EDRK-rich factor 2
eukaryotic translation elongation factor 1 gamma/similar to eukaryotic
translation
--keratinocyte associated protein 2
peroxiredoxin 1
YTH domain containing 1
F-box protein 22
NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8
secreted acidic cysteine rich glycoprotein
ribosomal protein L13
ribosomal protein L38 pseudogene/ribosomal protein L38
pseudogene/ribosomal
cytochrome c oxidase subunit IV isoform 1
ATPase, H+ transporting, lysosomal V0 subunit B
ribosomal protein L7
ribosomal protein L6
guanosine diphosphate (GDP) dissociation inhibitor 2
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d
predicted gene 3244/NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 4
diazepam binding inhibitor
gap junction protein, alpha 1
dynein light chain Tctex-type 3
ribosomal protein L23a
transmembrane emp24-like trafficking protein 10 (yeast)
coiled-coil domain containing 72
gap junction protein, alpha 1
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11
regulator of G-protein signaling 5
calponin 3, acidic/similar to calponin 3, acidic
cystatin C
mitochondrial fission factor
ribosomal protein S10
insulin-like growth factor 1
ribosomal protein S20
--acetyl-Coenzyme A acetyltransferase 1
acetyl-Coenzyme A acetyltransferase 1
predicted gene 11599/predicted gene 11687/predicted gene 12091/40S
R
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0.029
0.010
0.031
0.003
0.029
0.015
0.019
0.018

-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.55

0.024
0.022
0.009
0.007
0.026
0.003
0.016
0.045
0.011
0.010

-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.54
-1.54

0.048
0.009
0.034
0.035
0.020
0.016
0.014
0.046
0.017

-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54

0.021
0.035
0.006
0.033
0.026
0.017
0.008

-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54

0.010
0.013
0.004
0.017
0.021
0.041
0.036
0.012
0.014
0.010
0.018
0.017
0.001
0.022
0.045
0.015
0.001
0.024
0.050

-1.54
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.53
-1.52
-1.52
-1.52

0.030

-1.52

Gm12922/Gm14583/
Gm16408/Gm4968/
Gm5921/Gm6139/
Gm6266/Gm6359/
Gm6433/Gm7143/
Gm8225/Gm8235/
Gm8520/LOC100048354/
LOC634916/LOC639606/Rps2
Ddx5
Rpl26
Insm1
Psmd6
Aqp1
Gm6159/Hnrnpr
--Nelf
Gm13611/ LOC100048508/
Rpl36
Prpf4b
Dnaja1
Naca
Ndufs8
Gm11263/Gm12242/
Gm13654/Gm14138/
Gm16406/Gm4796/
Gm6476/Gm9143/
LOC100043734/
LOC236932/LOC623245/
LOC639593/Rps6
Wbp5
Basp1/LOC100045716
Jtb
Rpl14
Ndufa13
Rpl36al
Sumo1
Yif1a
Rpl27
Gm1821/Ubb
--Gm6301/Rpl27
2810422J05Rik/Gm11808
/Uba52
Rps17
Gm10045/Gm10155/
Gm10163/Gm10240/
Gm12411/Gm13653/
Gm14648/Gm16376/
Gm5495/LOC100042767/
LOC100047019/
LOC100047314/
LOC676590/Rpl21
Atp5j
Rplp0
Cxcr7
--Marcks
B230219D22Rik

DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
ribosomal protein L26
insulinoma-associated 1
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6
aquaporin 1
predicted gene 6159/heterogeneous nuclear ribonucleoprotein R
--nasal embryonic LHRH factor

0.050
0.041
0.012
0.013
0.003
0.041
0.008
0.030

-1.52
-1.52
-1.52
-1.52
-1.52
-1.52
-1.52
-1.52

predicted gene 13611/similar to Rpl36 protein/ribosomal protein L36
PRP4 pre-mRNA processing factor 4 homolog B (yeast)
DnaJ (Hsp40) homolog, subfamily A, member 1
nascent polypeptide-associated complex alpha polypeptide
NADH dehydrogenase (ubiquinone) Fe-S protein 8

0.024
0.001
0.046
0.025
0.012

-1.52
-1.51
-1.51
-1.51
-1.51

0.013
0.037

-1.51
-1.51

predicted gene 11263/predicted gene 12242/predicted gene 13654/40S
r
WW domain binding protein 5
brain abundant, membrane attached signal protein 1/similar to 22 kDa
neuronal
jumping translocation breakpoint
ribosomal protein L14
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13
ribosomal protein L36A-like
SMT3 suppressor of mif two 3 homolog 1 (yeast)
Yip1 interacting factor homolog A (S. cerevisiae)
ribosomal protein L27
predicted gene 1821/ubiquitin B
--ribosomal protein L27 pseudogene/ribosomal protein L27
RIKEN cDNA 2810422J05 gene/predicted gene 11808/ubiquitin A-52
residue r
ribosomal protein S17

0.001
0.041
0.028
0.012
0.025
0.026
0.010
0.024
0.027
0.010
0.043

-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.50
-1.50
-1.50
-1.50
-1.50

0.013
0.044

-1.50
-1.50

predicted gene 10045/predicted gene 10155/predicted gene
10163/predicted
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F
ribosomal protein, large, P0
chemokine (C-X-C motif) receptor 7
--myristoylated alanine rich protein kinase C substrate
RIKEN cDNA B230219D22 gene

0.032
0.024
0.043
0.017
0.019
0.011
0.044

-1.50
-1.50
-1.50
-1.50
-1.50
-1.50
-1.50
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Gtpbp2
Scrt2
Zfand2a
Ceacam1
Pcca
Samhd1
Ncam1
Pttg1
St3gal6
Gm2380
--Gdap2
Rab6b
Rnasek
Itih4
Tnrc6a
--Gm5620/Gm7172/
LOC100045728/Tuba1a
/Tuba1c
Ddx5
Stap2
Hdac11
Gss
Fcgr2b
Klra21
Car7
1110002E22Rik
Slc5a9
Opa3
Ang2
Ptgr2
Actr1a
Hoxa5
Armc8
Duxbl
Vat1
D13Ertd787e

GTP binding protein 2
scratch homolog 2, zinc finger protein (Drosophila)
zinc finger, AN1-type domain 2A
carcinoembryonic antigen-related cell adhesion molecule 1
propionyl-Coenzyme A carboxylase, alpha polypeptide
SAM domain and HD domain, 1
neural cell adhesion molecule 1
pituitary tumor-transforming gene 1
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
predicted gene 2380
--ganglioside-induced differentiation-associated-protein 2
RAB6B, member RAS oncogene family
ribonuclease, RNase K
inter alpha-trypsin inhibitor, heavy chain 4
trinucleotide repeat containing 6a
---

0.002
0.021
0.020
0.001
0.009
0.014
0.005
0.009
0.004
0.029
0.034
0.026
0.001
0.003
0.017
0.022
0.029

-1.50
1.50
1.51
1.51
1.51
1.53
1.53
1.53
1.54
1.54
1.54
1.55
1.56
1.57
1.58
1.61
1.62

predicted gene 5620/predicted gene 7172/similar to tubulin, alpha 1/
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5
signal transducing adaptor family member 2
histone deacetylase 11
glutathione synthetase
Fc receptor, IgG, low affinity IIb
killer cell lectin-like receptor subfamily A, member 21
carbonic anhydrase 7
RIKEN cDNA 1110002E22 gene
solute carrier family 5 (sodium/glucose cotransporter), member 9
optic atrophy 3 (human)
angiogenin, ribonuclease A family, member 2
prostaglandin reductase 2
ARP1 actin-related protein 1 homolog A, centractin alpha (yeast)
homeo box A5
armadillo repeat containing 8
double homeobox B-like
vesicle amine transport protein 1 homolog (T californica)
DNA segment, Chr 13, ERATO Doi 787, expressed

0.000
0.008
0.002
0.014
0.003
0.016
0.007
0.010
0.013
0.005
0.003
0.012
0.011
0.010
0.004
0.002
0.002
0.002
0.006

1.63
1.63
1.65
1.66
1.75
1.81
1.84
1.86
1.89
1.93
1.94
1.94
1.95
2.02
2.24
2.26
2.43
2.50
2.67
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Appendix 7.3. Significantly altered genes in the LP+STZ group compared to the C+STZ
group
Differentially expressed genes between the four groups were selected based on a pvalue cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference
from the C+STZ group. A 2-way ANOVA was performed with a Student Newman-Keuls
post test.
Gene Symbol

Gene Title

Sgk1
D4Wsu53e
Pim3
--Errfi1
Nupr1
Rps27
Gm7285/ Rps7
Gm4076
Dbi
Mtm1
Gm13611/ Gm4604/
LOC100048508/ Rpl36
Slc19a2
Gm4149/ Rpl37a
Dbi
---

serum/glucocorticoid regulated kinase 1
DNA segment, Chr 4, Wayne State University 53, expressed
proviral integration site 3
--ERBB receptor feedback inhibitor 1
nuclear protein 1
ribosomal protein S27
predicted gene 7285/ ribosomal protein S7
predicted gene 4076
diazepam binding inhibitor
X-linked myotubular myopathy gene 1
predicted gene 13611/ predicted gene 4604/ similar to Rpl36 protein/
ribosomal L36
solute carrier family 19 (thiamine transporter), member 2
predicted gene 4149/ ribosomal protein L37a
diazepam binding inhibitor
--ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f,
isoform 2
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously
expressed (fox)
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1
predicted gene 10269/ predicted gene 4342/ ribosomal protein L35
predicted gene 3244/ NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 4
ribosomal protein S9

Atp5j2
Fau/ Gm9843
Ndufc1
Gm10269/ Gm4342/ Rpl35
Gm3244/ Ndufb4
Rps9
Gm13611/ LOC100048508/
Rpl36
Rplp2
Ndufa7
Dbi
Cox7a2
Gm13611/ Gm4604/
LOC100048508/ Rpl36
Gm10079/ Rps16
Nupr1
Ndufb2
--Ube2d3
Ndufa6

p-value

predicted gene 13611/ similar to Rpl36 protein/ ribosomal protein L36
ribosomal protein, large P2
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a)
diazepam binding inhibitor
cytochrome c oxidase, subunit VIIa 2
predicted gene 13611/ predicted gene 4604/ similar to Rpl36 protein/
ribosomal protein L36
ribosomal protein S16 pseudogene/ ribosomal protein S16
nuclear protein 1
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2
--ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast)
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14)
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Fold
change

0.039
0.023
0.009
0.012
0.037
0.012
0.016
0.027
0.009
0.007
0.002

-3.03
-2.63
-2.33
-2.18
-2.11
-2.05
-1.98
-1.95
-1.93
-1.92
-1.91

0.006
0.015
0.013
0.003
0.024

-1.90
-1.90
-1.90
-1.89
-1.89

0.021

-1.88

0.028
0.006
0.005

-1.88
-1.85
-1.85

0.008
0.008

-1.85
-1.85

0.007
0.010
0.007
0.017
0.009

-1.85
-1.85
-1.84
-1.84
-1.84

0.013
0.011
0.011
0.003
0.001
0.047
0.009

-1.83
-1.83
-1.82
-1.81
-1.81
-1.81
-1.80

Gm3362/ Rpl23a
Uqcr
Cox6b1
Rpl35
Rps17
Atp5l
Klk1b5
Atp5j
Rpl35
Atp5j2
Gm14303/ Rps29
Rpl34
Ndufa4
Tmed11
Ccnl2
Uqcrq
Rpl35
Rps21
Rpl26
Rpl23a
Uqcrh
Rpl32
Rpl12
Sepw1
Gm10213/ Gm10247/
Gm10296/ Gm15434/ Ino80/
LOC100046034/
mCG_133520/ Rpl35a
--Rps7
Gm11353/ Gm14289/
Gm15501/ Gm6998/
LOC100042180/
LOC100048094/ Rps8
Rps15
LOC100046223/ Rps15
Rpl37a
Rps10
Rpl9
Ssr4
Hist1h2bc/ Hist1h2be/
Hist1h2bl/ Hist1h2bm/
Hist1h2bp/ LOC100046213/
LOC665622/ RP23-38E20.1
Atp5e
Gm10709/ Gm12447/
Gm12704/ Gm13841/
Gm5561/ Gm6344/ Gm8088/
Rpl29
Dad1
Rpl34
Dbi
Edf1
Hist1h2bc
Bsg
Rps11
Itm2b

predicted gene 3362/ ribosomal protein L23a
ubiquinol-cytochrome c reductase (6.4kD) subunit
cytochrome c oxidase, subunit VIb polypeptide 1
ribosomal protein L35
ribosomal protein S17
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g
kallikrein 1-related peptidase b5
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F
ribosomal protein L35
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f,
isoform 2
predicted gene 14303/ ribosomal protein S29
ribosomal protein L34
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4
transmembrane emp24 protein transport domain containing
cyclin L2
ubiquinol-cytochrome c reductase, complex III subunit VII
ribosomal protein L35
ribosomal protein S21
ribosomal protein L26
ribosomal protein L23a
ubiquinol-cytochrome c reductase hinge protein
ribosomal protein L32
ribosomal protein L12
selenoprotein W, muscle 1

0.011
0.010
0.007
0.010
0.019
0.007
0.046
0.009
0.011

-1.80
-1.80
-1.79
-1.79
-1.78
-1.78
-1.78
-1.78
-1.78

0.019
0.012
0.018
0.038
0.046
0.038
0.011
0.013
0.014
0.017
0.010
0.004
0.014
0.014
0.010

-1.77
-1.77
-1.77
-1.77
-1.76
-1.76
-1.75
-1.75
-1.75
-1.75
-1.75
-1.74
-1.74
-1.74
-1.74

ribosomal protein L35a pseudogene/ predicted gene 10247/ ribosomal
protein
--ribosomal protein S7

0.011
0.002
0.027

-1.74
-1.74
-1.74

predicted gene 11353/ ribosomal protein S8 (Rps8) pseudogene/
predicted gene
ribosomal protein S15
similar to insulinoma protein (rig)/ ribosomal protein S15
ribosomal protein L37a
ribosomal protein S10
Ribosomal protein L9
signal sequence receptor, delta

0.021
0.011
0.008
0.024
0.013
0.023
0.014

-1.74
-1.74
-1.73
-1.73
-1.73
-1.73
-1.73

0.041

-1.73

0.007

-1.73

0.017
0.025
0.029
0.016
0.032
0.016
0.045
0.011
0.017

-1.73
-1.72
-1.72
-1.72
-1.72
-1.72
-1.72
-1.71
-1.71

histone cluster 1, H2bc/ histone cluster 1, H2be/ histone cluster 1, H2bl
ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon
subunit
predicted gene 10709/ predicted gene 12447/ predicted gene 12704/
predicted
defender against cell death 1
ribosomal protein L34
diazepam binding inhibitor
endothelial differentiation-related factor 1
histone cluster 1, H2bc
basigin
ribosomal protein S11
integral membrane protein 2B
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Gm6948/ Gm8942/
LOC677113/ Rps24
Ndufb6
Cox6c
Gm6301/ Rpl27
Gm6573/ Gm6834/
LOC100044992/ Rps13
Rabac1
Rpl23
Atp5k
Gm10027/ Gm10260/ Rps18
Atp5k
--Gm10709/ Gm12508/
Gm13841/ Gm5561/
Gm6344/ Rpl29
Txn1
Rpl22
Reep5
Eif4a2
Cox6a1/ Gm7795
Cox6c
Rpl14
LOC100046668/ Rps23
Gm10027/ Gm10260/ Rps18
Ndufb11
Rps17
Tmed6
Rps19
Atp5o/ LOC100047429
Gm3244/ Ndufb4
Gm12967/ Gm4468/ Rpl37
Ndufa1
Gm10051/ Gm15435/ Rpl28
Eif3k
Atp2c2
2810422J05Rik/ Gm11808/
Uba52
Rps24
Hist1h2ad/ Hist1h2an/
Hist2h2aa1/ Hist2h2aa2/
Hist2h2ac/ Hist2h3c1
Rpl14
Gpx1
Naca
Rps27l
Rps25
Gm10164/ Gm10223/
Gm10294/ LOC100041933/
LOC100046300/ Rpl17
--2010107H07Rik
Ndufb2

ribosomal protein S24 pseudogene/ predicted gene 8942/ similar to
ribosomal
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6
cytochrome c oxidase, subunit VIc
ribosomal protein L27 pseudogene/ ribosomal protein L27
ribosomal protein S13 pseudogene/ predicted gene 6834/ similar to
ribosomal
Rab acceptor 1 (prenylated)
ribosomal protein L23
ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal
protein
ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e
---

0.022
0.011
0.004
0.023

-1.71
-1.71
-1.71
-1.71

0.016
0.010
0.018
0.014

-1.71
-1.70
-1.70
-1.70

0.030
0.015
0.005

-1.70
-1.70
-1.70

0.023
0.018
0.010
0.022
0.042
0.012
0.002
0.016

-1.70
-1.69
-1.69
-1.69
-1.69
-1.69
-1.69
-1.69

0.010

-1.69

0.014
0.007
0.028
0.010
0.009

-1.69
-1.68
-1.68
-1.68
-1.68

0.018

-1.68

0.007
0.031
0.016

-1.68
-1.68
-1.68

0.016
0.014
0.001

-1.68
-1.68
-1.67

0.015
0.017

-1.67
-1.67

histone cluster 1, H2ad/ histone cluster 1, H2an/ histone cluster 2,
H2aa1
ribosomal protein L14
glutathione peroxidase 1
nascent polypeptide-associated complex alpha polypeptide
ribosomal protein S27-like
ribosomal protein S25

0.005
0.020
0.011
0.026
0.024
0.013

-1.67
-1.67
-1.67
-1.67
-1.67
-1.67

ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/
predicted
--RIKEN cDNA 2010107H07 gene
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2

0.021
0.006
0.014
0.003

-1.67
-1.67
-1.67
-1.67

predicted gene 10709/ predicted gene 12508/ predicted gene 13841/
predicted
thioredoxin 1
ribosomal protein L22
receptor accessory protein 5
eukaryotic translation initiation factor 4A2
cytochrome c oxidase, subunit VI a, polypeptide 1/ predicted gene 7795
cytochrome c oxidase, subunit VIc
ribosomal protein L14
similar to yeast ribosomal protein S28 homologue/ ribosomal protein
S23
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal
protein
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11
ribosomal protein S17
transmembrane emp24 protein transport domain containing 6
ribosomal protein S19
ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit/
similar to
predicted gene 3244/ NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 4
predicted gene 12967/ predicted gene 4468/ ribosomal protein L37
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1
predicted gene 10051/ ribosomal protein L28 pseudogene/ ribosomal
protein
eukaryotic translation initiation factor 3, subunit K
ATPase, Ca++ transporting, type 2C, member 2
RIKEN cDNA 2810422J05 gene/ predicted gene 11808/ ubiquitin A-52
residue r
ribosomal protein S24
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Rpl41
Snrpd3
Gm14303/ Rps29
Ndufv2
Atp5h
Rpl18a
Ftl1
Reep5
Ndufa3
Eif5a
Rpl19
Rpl15
Gm2614/ Rps17
Rps17
Rpl14
Pfdn5
Rpl11
Gm10164/ Gm10223/
Gm10268/ Gm10362/
Gm4329/ Gm6133/ Hk1/
LOC100048040/ Rpl17
Map1lc3b
Gm10071/ Gm12918/
Gm15710/ Rpl13
Oaz1
Rpl35
Cst3
Rpl13a/ Zfp526
Slc19a2
--Rps3
2310016E02Rik
Myc
Ndufs8
Ndufs8
Ndufa3
Rps24
Krtcap2
Psmb10
Gm11425/ Gm4957/
Gm5962/ Gm6285/ Gm6336/
Gm7117/ LOC546695/
LOC630855/ LOC639477/
Rpl12
Gm10709/ Gm13841/
Gm5561/ Gm6344/ Rpl29
Rpl13a
Qdpr
Gm10709/ Gm13841/
Gm3550/ Gm6344/ Rpl29
Rps10
Rps18
Ggh
Ndufs8
Gm10117/ Gm7206/
Gm9822/ Rpl9
--1110002B05Rik
Stk24

ribosomal protein L41
small nuclear ribonucleoprotein D3
predicted gene 14303/ ribosomal protein S29
NADH dehydrogenase (ubiquinone) flavoprotein 2
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d
ribosomal protein L18A
ferritin light chain 1
receptor accessory protein 5
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
eukaryotic translation initiation factor 5A
ribosomal protein L19
ribosomal protein L15
predicted gene 2614/ ribosomal protein S17
ribosomal protein S17
ribosomal protein L14
prefoldin 5
ribosomal protein L11
ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/
predic
microtubule-associated protein 1 light chain 3 beta
predicted gene 10071/ predicted gene 12918/ predicted gene 15710/
ribos
ornithine decarboxylase antizyme 1
ribosomal protein L35
cystatin C
ribosomal protein L13A/ zinc finger protein 526
solute carrier family 19 (thiamine transporter), member 2
--ribosomal protein S3
RIKEN cDNA 2310016E02 gene
myelocytomatosis oncogene
NADH dehydrogenase (ubiquinone) Fe-S protein 8
NADH dehydrogenase (ubiquinone) Fe-S protein 8
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3
ribosomal protein S24
keratinocyte associated protein 2
proteasome (prosome, macropain) subunit, beta type 10

predicted gene 11425/ ribosomal protein L12 pseudogene/ predicted
gene 596
predicted gene 10709/ predicted gene 13841/ predicted gene 5561/
predic
ribosomal protein L13A
quinoid dihydropteridine reductase
predicted gene 10709/ predicted gene 13841/ predicted gene 3550/
predic
ribosomal protein S10
ribosomal protein S18
gamma-glutamyl hydrolase
NADH dehydrogenase (ubiquinone) Fe-S protein 8
ribosomal protein L9 pseudogene/ predicted gene 7206/ ribosomal
protein L9
--RIKEN cDNA 1110002B05 gene
serine/threonine kinase 24 (STE20 homolog, yeast)
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0.005
0.020
0.023
0.014
0.007
0.016
0.022
0.006
0.013
0.038
0.018
0.017
0.020
0.030
0.014
0.010
0.019

-1.67
-1.67
-1.67
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.66
-1.65

0.020
0.006

-1.65
-1.65

0.025
0.032
0.006
0.013
0.026
0.031
0.013
0.015
0.010
0.025
0.008
0.041
0.009
0.019
0.030
0.005

-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.65
-1.64
-1.64
-1.64
-1.64

0.011

-1.64

0.025
0.017
0.037

-1.64
-1.64
-1.64

0.030
0.017
0.038
0.040
0.008

-1.64
-1.64
-1.64
-1.64
-1.64

0.017
0.027
0.009
0.044

-1.64
-1.64
-1.64
-1.64

Tbca
Gm10335/ Rpl23a
Ndufa13
Sec61b
Gal
Gm10045/ Gm10155/
Gm10163/ Gm10240/
Gm12411/ Gm13653/
Gm14648/ Gm16376/
Gm5495/ LOC100042767/
LOC100047019/
LOC100047314/ LOC676590/
Rpl21
Cox7a2
Sec61g
LOC100048449/ Rpl18
Eif3i
Rpl37
Fabp4
Hnrnpa1
Rps10
Ifitm2
Erp27
Prss3
Rpl22l1
Gm9385/ Rpl24
Gm13020/ Gm7379/ Rpl38
Gm10164/ Gm10223/
Gm10294/ LOC100041933/
LOC100046300/
LOC100047874/ Rpl17
Rps21
Rpl21
Rps14
Rps5
--Ndufa11
Rpl14
Gm15451/ Rpl10a
--1810005K13Rik
Gstm2
Cox4i1
--Rpsa
Ufm1
Rps8
Rps24
Rps26
Chchd10
Gm10335/ Gm3940/
Gm5384/ Gm7413/ Gm8158/
LOC100042058/ Rpl23a
Akr1a4
Atp5k
Rps15a
Rps8
Fabp4

tubulin cofactor A
predicted gene 10335/ ribosomal protein L23a
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13
Sec61 beta subunit
galanin

0.021
0.013
0.009
0.024
0.012

-1.64
-1.64
-1.64
-1.64
-1.64

0.023
0.019
0.039
0.032
0.016
0.034
0.018
0.035
0.019
0.038
0.009
0.011
0.030
0.017

-1.64
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63
-1.63

0.020

-1.63

ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/
predicted
ribosomal protein S21
ribosomal protein L21
ribosomal protein S14
ribosomal protein S5
--NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11
ribosomal protein L14
ribosomal protein L10a pseudogene/ ribosomal protein L10A
--RIKEN cDNA 1810005K13 gene
glutathione S-transferase, mu 2
cytochrome c oxidase subunit IV isoform 1
--ribosomal protein SA
ubiquitin-fold modifier 1
ribosomal protein S8
ribosomal protein S24
ribosomal protein S26
coiled-coil-helix-coiled-coil-helix domain containing 10

0.021
0.024
0.024
0.014
0.025
0.028
0.014
0.017
0.022
0.024
0.029
0.022
0.035
0.007
0.014
0.049
0.015
0.020
0.032
0.007

-1.63
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.62
-1.61
-1.61
-1.61
-1.61
-1.61

predicted gene 10335/ predicted gene 3940/ predicted gene 5384/
predicted
aldo-keto reductase family 1, member A4 (aldehyde reductase)
ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e
ribosomal protein S15A
ribosomal protein S8
fatty acid binding protein 4, adipocyte

0.024
0.050
0.037
0.049
0.024
0.038

-1.61
-1.61
-1.61
-1.61
-1.61
-1.61

predicted gene 10045/ predicted gene 10155/ predicted gene 10163/
predicted
cytochrome c oxidase, subunit VIIa 2
SEC61, gamma subunit
similar to ribosomal protein L18/ ribosomal protein L18
eukaryotic translation initiation factor 3, subunit I
ribosomal protein L37
fatty acid binding protein 4, adipocyte
heterogeneous nuclear ribonucleoprotein A1
ribosomal protein S10
interferon induced transmembrane protein 2
endoplasmic reticulum protein 27
protease, serine, 3
ribosomal protein L22 like 1
predicted gene 9385/ ribosomal protein L24
ribosomal protein L38 pseudogene/ ribosomal protein L38 pseudogene/
riboso
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Gm10119/ Gm9000/ Rps3a
Eif1
1810046J19Rik
Gm13654/ Rps6
Rpl39
Rpl7
--Rpl27a
Rplp1
Cstb
Mettl7a1
Spint2
Ero1l/ Gm10191/ Gm13004/
Gm16382/ Gm7689/
Gm9401/ LOC638399/
LOC675018/ Rpl31
Qdpr
Gm10191/ Gm16382/
Gm7689/ LOC638399/
LOC675018/ Rpl31
Jtb
Lgals1
Gm2614/ Gm5215/ Gm7780/
LOC674335/ Rps17
Tmed3
Rplp0
Rpl18
Ndufb6
Rpl13a
Hint1
Rpl7a
Atp5f1
--Rpl7
Tmem208
Eef1d
--Ero1l/ Rpl31
Btbd3
Eif3h
Pfdn5
Rps7
Ndufb9
Romo1
Eef1b2
Gnb2l1
Rhoa
Nme2
Ndufv3
2810422J05Rik/ Gm11808/
Uba52
Chchd2/ LOC100045688/
Scand3
5730427N09Rik
Rpl36al
Gm10443/ Rps28
Gm10063/ Gm12334/

predicted gene 10119/ predicted gene 9000/ ribosomal protein S3A
eukaryotic translation initiation factor 1
RIKEN cDNA 1810046J19 gene
predicted gene 13654/ ribosomal protein S6
ribosomal protein L39
ribosomal protein L7
--ribosomal protein L27A
ribosomal protein, large, P1
cystatin B
methyltransferase like 7A1
serine protease inhibitor, Kunitz type 2

0.039
0.026
0.012
0.014
0.019
0.035
0.046
0.018
0.019
0.011
0.031
0.047

-1.61
-1.61
-1.61
-1.61
-1.61
-1.61
-1.60
-1.60
-1.60
-1.60
-1.60
-1.60

ERO1-like (S. cerevisiae)/ predicted gene 10191/ predicted gene 13004/
quinoid dihydropteridine reductase

0.019
0.021

-1.60
-1.60

0.017
0.039
0.015

-1.60
-1.60
-1.60

0.023
0.027
0.039
0.027
0.024
0.010
0.042
0.013

-1.60
-1.60
-1.60
-1.60
-1.60
-1.59
-1.59
-1.59

0.027
0.042
0.030
0.018

-1.59
-1.59
-1.59
-1.59

0.014
0.002
0.022
0.043
0.014
0.002
0.030
0.031
0.030
0.018
0.038
0.028
0.033
0.012

-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.59
-1.58
-1.58
-1.58
-1.58
-1.58

0.013

-1.58

0.032
0.003
0.025
0.023
0.015

-1.58
-1.58
-1.58
-1.58
-1.58

predicted gene 10191/ ribosomal protein L31 pseudogene/ predicted
gene 768
jumping translocation breakpoint
lectin, galactose binding, soluble 1
predicted gene 2614/ predicted gene 5215/ predicted gene 7780/
hypothetical
transmembrane emp24 domain containing 3
ribosomal protein, large, P0
ribosomal protein L18
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6
ribosomal protein L13A
histidine triad nucleotide binding protein 1
ribosomal protein L7A
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b,
isoform 1
--ribosomal protein L7
transmembrane protein 208
eukaryotic translation elongation factor 1 delta (guanine nucleotide
exchange protein)
--ERO1-like (S. cerevisiae)/ ribosomal protein L31
BTB (POZ) domain containing 3
eukaryotic translation initiation factor 3, subunit H
prefoldin 5
ribosomal protein S7
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9
reactive oxygen species modulator 1
eukaryotic translation elongation factor 1 beta 2
guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1
ras homolog gene family, member A
non-metastatic cells 2, protein (NM23B) expressed in
NADH dehydrogenase (ubiquinone) flavoprotein 3
RIKEN cDNA 2810422J05 gene/ predicted gene 11808/ ubiquitin A-52
residue r
coiled-coil-helix-coiled-coil-helix domain containing 2/ similar to coiledcoil
RIKEN cDNA 5730427N09 gene
ribosomal protein L36A-like
predicted gene 10443/ ribosomal protein S28
predicted gene 10063/ predicted gene 12334/ ribosomal protein S12
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Gm5462/ Gm7567/ Gm9153/
LOC676277/ Rps12
Gabarapl1
Rpl18
Prdx4
Gm10079/ LOC100047501/
Rps16
Lcmt1
Mrpl52
Atp5g1/ Gm10039
LOC100047839/ Tomm6
Ndufb11
Rpl13
Rps10
Ube2b
Serf2
Gng5
Higd2a
Ftl1/ Ftl2/ Gm10116
--LOC100044627/ Rpl23
Atp5g3
Hbxip
Cox5b
Gm11263/ Gm13654/
LOC100043734/ LOC236932/
Rps6
Naca
Kdelr1
Rpl23
Atp5d
Ndufb9
Rpl13a
Cox6b1
Hnrpdl
Ndufc1
H2afj
Gm10443/ Rps28
Nid1
Ndufa7
--Gm10071/ Gm12918/
Gm15710/ Gm5075/
Gm9026/ LOC674921/ Rpl13
Ndufb5
Gm10241/ Gm13430/
Gm13690/ LOC100046167/
Sumo2
Gm15500/ Rpl5
Btf3
Gnmt
Myeov2
Atp5g2

pseudogene
gamma-aminobutyric acid (GABA) A receptor-associated protein-like 1
ribosomal protein L18
peroxiredoxin 4
ribosomal protein S16 pseudogene/ ribosomal protein S16 pseudogene/
ribosomal
leucine carboxyl methyltransferase 1
mitochondrial ribosomal protein L52
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c
(subunit 9),
hypothetical protein LOC100047839/ translocase of outer mitochondrial
membrane
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11
ribosomal protein L13
ribosomal protein S10
ubiquitin-conjugating enzyme E2B, RAD6 homology (S. cerevisiae)
small EDRK-rich factor 2
guanine nucleotide binding protein (G protein), gamma 5
HIG1 domain family, member 2A
ferritin light chain 1/ ferritin light chain 2/ ferritin light chain 1
pseudogene
--similar to HL23 ribosomal protein/ ribosomal protein L23
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c
(subunit 9),
hepatitis B virus x interacting protein
cytochrome c oxidase, subunit Vb

0.010
0.013
0.038

-1.58
-1.58
-1.58

0.019
0.012
0.024

-1.58
-1.58
-1.58

0.049

-1.58

0.037
0.013
0.022
0.022
0.043
0.015
0.031
0.002

-1.58
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57
-1.57

0.039
0.005
0.021

-1.57
-1.57
-1.57

0.036
0.028
0.013

-1.57
-1.57
-1.56

predicted gene 11263/ predicted gene 13654/ similar to ribosomal
protein S
nascent polypeptide-associated complex alpha polypeptide
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention
receptor 1
ribosomal protein L23
ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9
ribosomal protein L13A
cytochrome c oxidase, subunit VIb polypeptide 1
heterogeneous nuclear ribonucleoprotein D-like
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1
H2A histone family, member J
predicted gene 10443/ ribosomal protein S28
nidogen 1
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a)
---

0.027
0.029

-1.56
-1.56

0.020
0.030
0.015
0.025
0.021
0.005
0.012
0.024
0.003
0.026
0.017
0.006
0.011

-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56
-1.56

predicted gene 10071/ predicted gene 12918/ predicted gene 15710/
predicted
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5

0.037
0.040

-1.56
-1.56

0.038
0.028
0.007
0.043
0.015

-1.56
-1.56
-1.56
-1.56
-1.56

0.007

-1.55

predicted gene 10241/ predicted gene 13430/ predicted gene 13690/
similar
predicted gene 15500/ ribosomal protein L5
basic transcription factor 3
glycine N-methyltransferase
myeloma overexpressed 2
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c
(subunit 9),
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Gm9786/ Oaz1
Gm3379/ Gm4892/ Gm7476/
Rpl10
Gm13654/ Rps6
--1110003E01Rik
Gm5805/ Rps14
Gabarap
Ptpla
Rpl6
Rala
Hamp2
Cox5b
Ndufa7
Gm14303/ Rps29
Cml1
Fkbp2
Mrps28
1110003E01Rik
Gm11970/ Gm12936/
Gm6525/ Gm8001/ Gm8697/
Rpl36a
Gm10080/ Gm5526/
Gm8894/ Myl6
Gcat
Bag1
Rpl27
Ccdc56
Ube2d1
Creg1
Tff2
Rgs5
--Zfand6
Gabarapl2
Gm6573/ LOC100044992/
Rps13
Mid1ip1
Rps12
Gm9354/ LOC100042019/
Rps27a
Fth1
Gm11599/ Gm11687/
Gm12091/ Gm12366/
Gm12922/ Gm14583/
Gm16408/ Gm4968/
Gm5921/ Gm6139/ Gm6266/
Gm6359/ Gm6433/ Gm7143/
Gm8225/ Gm8235/ Gm8520/
LOC100048354/ LOC634916/
LOC639606/ Rps2
Rps21
Mt1
Sec62
Gm12270/ Gm15483/
Gm6573/ Gm6834/
LOC100044992/ Rps13

ornithine decarboxylase antizyme 1 pseudogene/ ornithine
decarboxylase antizy
predicted gene 3379/ ribosomal protein 10 pseudogene/ 60S ribosomal
protein
predicted gene 13654/ ribosomal protein S6
--RIKEN cDNA 1110003E01 gene
predicted gene 5805/ ribosomal protein S14
gamma-aminobutyric acid receptor associated protein
protein tyrosine phosphatase-like (proline instead of catalytic arginine),
member
ribosomal protein L6
v-ral simian leukemia viral oncogene homolog A (ras related)
hepcidin antimicrobial peptide 2
cytochrome c oxidase, subunit Vb
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a)
predicted gene 14303/ ribosomal protein S29
camello-like 1
FK506 binding protein 2
mitochondrial ribosomal protein S28
RIKEN cDNA 1110003E01 gene

0.024

-1.55

0.035
0.013
0.033
0.031
0.025
0.025

-1.55
-1.55
-1.55
-1.55
-1.55
-1.55

0.028
0.038
0.019
0.004
0.011
0.018
0.015
0.010
0.045
0.017
0.024

-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.55
-1.54
-1.54
-1.54

0.026

-1.54

0.007
0.024
0.043
0.022
0.015
0.014
0.004
0.017
0.016
0.033
0.029
0.037

-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54

predicted gene 11970/ predicted gene 12936/ predicted gene 6525/
predicted
predicted gene 10080/ predicted gene 5526/ predicted gene 8894/
myosin,
glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A ligase)
BCL2-associated athanogene 1
ribosomal protein L27
coiled-coil domain containing 56
ubiquitin-conjugating enzyme E2D 1, UBC4/5 homolog (yeast)
cellular repressor of E1A-stimulated genes 1
trefoil factor 2 (spasmolytic protein 1)
regulator of G-protein signaling 5
--zinc finger, AN1-type domain 6
gamma-aminobutyric acid (GABA) A receptor-associated protein-like 2
ribosomal protein S13 pseudogene/ similar to ribosomal protein S13/
ribosomal
Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish))
ribosomal protein S12
predicted gene 9354/ similar to fusion protein: ubiquitin (bases 43_513);
rib
ferritin heavy chain 1

0.024
0.026
0.043

-1.53
-1.53
-1.53

0.021
0.028

-1.53
-1.53

predicted gene 11599/ predicted gene 11687/ predicted gene 12091/
40S R
ribosomal protein S21
metallothionein 1
SEC62 homolog (S. cerevisiae)

0.043
0.039
0.010
0.036

-1.53
-1.53
-1.53
-1.53

predicted gene 12270/ predicted gene 15483/ ribosomal protein S13
pseudogene

0.020

-1.53
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EG436523/ Gm10334/ Prss1/
Prss3
--Serf2
Ndufab1
Sod1
LOC100046344/ Nme1
Rpl8
Atp6v1f
Dynlt1/ Dynlt1-ps1/
LOC100040563
Cox5b
Cops6
Chchd3
Rpl30
Eif3i
Rpl27
--Rpl7
1810026B05Rik
Prelid1
Atp5h
Gm10257/ Gm8524/ H3f3a/
H3f3c/ LOC100045490
1810010K12Rik
Creg1
Serf2
Lamp2
Spink3
Ndufa2
Cox8a
Ndufs5
--H47
Sepx1
H2-D1
Lamp1
Tm2d2
Eif1
Tecr
Mff
Cox5b
--Fam96a
Hsbp1
Rpl13a
Ndufv2
Sec11c
Rps20
1810027O10Rik
Mrps24
Eif5
Acat1
Atp6v0b
Rpl10
Tceb2
---

predicted gene, EG436523/ predicted gene 10334/ protease, serine, 1
(tryps
--small EDRK-rich factor 2
NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1
superoxide dismutase 1, soluble
similar to Nucleoside diphosphate kinase A (NDK A) (NDP kinase A)
(Tumor metastasis)
ribosomal protein L8
ATPase, H+ transporting, lysosomal V1 subunit F
dynein light chain Tctex-type 1/ dynein light chain Tctex-type 1,
pseudogene
cytochrome c oxidase, subunit Vb
COP9 (constitutive photomorphogenic) homolog, subunit 6 (Arabidopsis
thaliana)
coiled-coil-helix-coiled-coil-helix domain containing 3
ribosomal protein L30
eukaryotic translation initiation factor 3, subunit I
ribosomal protein L27
--ribosomal protein L7
RIKEN cDNA 1810026B05 gene
PRELI domain containing 1
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d
predicted gene 10257/ predicted gene 8524/ H3 histone, family 3A/ H3
hi
RIKEN cDNA 1810010K12 gene
cellular repressor of E1A-stimulated genes 1
small EDRK-rich factor 2
lysosomal-associated membrane protein 2
serine peptidase inhibitor, Kazal type 3
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2
cytochrome c oxidase, subunit VIIIa
NADH dehydrogenase (ubiquinone) Fe-S protein 5
--histocompatibility 47
selenoprotein X 1
histocompatibility 2, D region locus 1
lysosomal-associated membrane protein 1
TM2 domain containing 2
eukaryotic translation initiation factor 1
trans-2,3-enoyl-CoA reductase
mitochondrial fission factor
cytochrome c oxidase, subunit Vb
--family with sequence similarity 96, member A
heat shock factor binding protein 1
ribosomal protein L13A
NADH dehydrogenase (ubiquinone) flavoprotein 2
SEC11 homolog C (S. cerevisiae)
ribosomal protein S20
RIKEN cDNA 1810027O10 gene
mitochondrial ribosomal protein S24
eukaryotic translation initiation factor 5
acetyl-Coenzyme A acetyltransferase 1
ATPase, H+ transporting, lysosomal V0 subunit B
ribosomal protein 10
transcription elongation factor B (SIII), polypeptide 2
---
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0.010
0.001
0.018
0.025
0.024

-1.53
-1.53
-1.53
-1.53
-1.53

0.050
0.030
0.019

-1.53
-1.53
-1.53

0.010
0.007

-1.53
-1.53

0.037
0.036
0.049
0.029
0.034
0.014
0.036
0.007
0.044
0.014

-1.53
-1.53
-1.53
-1.53
-1.52
-1.52
-1.52
-1.52
-1.52
-1.52

0.030
0.038
0.026
0.019
0.014
0.014
0.018
0.023
0.044
0.034
0.049
0.013
0.043
0.020
0.021
0.037
0.027
0.002
0.009
0.017
0.015
0.023
0.031
0.022
0.031
0.032
0.031
0.008
0.049
0.041
0.013
0.019
0.025
0.026

-1.52
-1.52
-1.52
-1.52
-1.52
-1.52
-1.52
-1.52
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.51
-1.50
-1.50
-1.50
-1.50

Gm10443/ LOC100044740/
Rps28
H47
Rap1b
Ddost
Mdh1
RP23-195K8.6
Lat2
Txn1
Kcnh3
Dpp6
Klra21
Gss
Mgea5
N6amt2
Hoxa5
Duxbl
Armc8
Ptgr2
Pvr
Opa3
D13Ertd787e

predicted gene 10443/ similar to ribosomal protein S28/ ribosomal
protein
histocompatibility 47
RAS related protein 1b
dolichyl-di-phosphooligosaccharide-protein glycotransferase
malate dehydrogenase 1, NAD (soluble)
hypothetical protein LOC622404
Linker for activation of T cells family, member 2
thioredoxin 1
potassium voltage-gated channel, subfamily H (eag-related), member 3
dipeptidylpeptidase 6
killer cell lectin-like receptor subfamily A, member 21
glutathione synthetase
meningioma expressed antigen 5 (hyaluronidase)
N-6 adenine-specific DNA methyltransferase 2 (putative)
homeo box A5
double homeobox B-like
armadillo repeat containing 8
prostaglandin reductase 2
poliovirus receptor
optic atrophy 3 (human)
DNA segment, Chr 13, ERATO Doi 787, expressed
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0.027
0.024
0.013
0.045
0.041
0.001
0.023
0.042
0.038
0.015
0.034
0.010
0.001
0.015
0.044
0.035
0.018
0.033
0.018
0.005
0.040

-1.50
-1.50
-1.50
-1.50
-1.50
-1.50
1.51
1.53
1.57
1.59
1.61
1.63
1.64
1.65
1.70
1.74
1.75
1.78
1.91
1.96
2.05

Appendix 7.4. Significantly altered genes in the LP+STZ group compared to the
LP+sham group
Differentially expressed genes between the four groups were selected based on a pvalue cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference
from the LP+sham group. A 2-way ANOVA was performed with a Student Newman-Keuls
post test.

Gene Symbol
Clk1

Gene Title
CDC-like kinase 1
nuclear paraspeckle assembly transcript 1
Neat1
(non-protein coding)
Rab24
RAB24, member RAS oncogene family
Nupr1
nuclear protein 1
Mettl7a1
methyltransferase like 7A1
Ankrd24
ankyrin repeat domain 24
1810005K13Rik RIKEN cDNA 1810005K13 gene
Nupr1
nuclear protein 1
1810010K12Rik RIKEN cDNA 1810010K12 gene
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Fold
p-value
change
0.014
-1.72
0.023
0.019
0.031
0.027
0.046
0.033
0.035
0.028

-1.70
-1.67
-1.67
-1.54
-1.52
-1.51
-1.51
-1.50

Appendix 8.1. Copyright release form
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